0000950170-22-021509.txt : 20221103 0000950170-22-021509.hdr.sgml : 20221103 20221103064109 ACCESSION NUMBER: 0000950170-22-021509 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Annexon, Inc. CENTRAL INDEX KEY: 0001528115 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 275414423 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39402 FILM NUMBER: 221356057 BUSINESS ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (650)-822-5500 MAIL ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 10-Q 1 annx-20220930.htm 10-Q 10-Q
--12-310001528115Q3false0001528115annx:SponsoredResearchAgreementMember2021-01-012021-09-300001528115us-gaap:IndemnificationGuaranteeMember2022-09-3000015281152022-07-012022-09-300001528115us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2021-12-310001528115us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001528115annx:UnvestedRestrictedStockUnitsOutstandingMember2022-09-3000015281152022-01-012022-09-300001528115us-gaap:AdditionalPaidInCapitalMember2022-03-310001528115us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-09-300001528115annx:LaboratoryEquipmentMember2022-09-300001528115us-gaap:EmployeeStockOptionMember2022-09-300001528115us-gaap:RetainedEarningsMember2022-06-3000015281152021-04-012021-06-300001528115us-gaap:RetainedEarningsMember2021-01-012021-03-310001528115srt:MinimumMemberannx:PrefundedWarrantMember2022-07-112022-07-110001528115us-gaap:CommonStockMember2022-04-012022-06-3000015281152022-06-300001528115us-gaap:LeaseholdImprovementsMember2021-12-310001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001528115us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001528115annx:TwoZeroTwoOneAtTheMarketProgramMember2021-12-310001528115us-gaap:AdditionalPaidInCapitalMember2021-03-310001528115us-gaap:CommonStockMember2022-01-012022-03-310001528115us-gaap:CommonStockMember2021-06-300001528115srt:MaximumMember2022-01-012022-09-300001528115us-gaap:WarrantMember2022-01-012022-09-3000015281152022-03-310001528115srt:MinimumMemberannx:IncentiveStockOptionsAndNonstatutoryStockOptionsMember2022-01-012022-09-300001528115us-gaap:PrivatePlacementMember2022-09-300001528115srt:MaximumMember2021-07-012021-09-300001528115us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2021-12-3100015281152022-01-012022-03-310001528115us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001528115annx:SponsoredResearchAgreementMemberus-gaap:ResearchAndDevelopmentArrangementMember2019-03-310001528115us-gaap:AdditionalPaidInCapitalMember2021-12-310001528115srt:MinimumMember2021-01-012021-09-300001528115us-gaap:WarrantMember2022-07-110001528115us-gaap:CommonStockMember2022-07-012022-09-300001528115annx:EmployeeStockPurchasePlanMember2021-07-012021-09-300001528115annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember2021-12-310001528115annx:ComputerEquipmentAndSoftwareMember2022-09-300001528115srt:MinimumMember2021-07-012021-09-300001528115us-gaap:CommonStockMember2021-03-310001528115us-gaap:RetainedEarningsMember2022-03-310001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001528115annx:SponsoredResearchAgreementMember2019-03-012019-03-310001528115us-gaap:CommonStockMember2021-09-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001528115us-gaap:AdditionalPaidInCapitalMember2022-09-300001528115us-gaap:CommonStockMember2021-04-012021-06-3000015281152021-06-300001528115us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-12-310001528115us-gaap:CommonStockMember2021-07-012021-09-300001528115us-gaap:LeaseholdImprovementsMember2022-09-3000015281152020-12-310001528115us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-09-300001528115us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001528115us-gaap:PrivatePlacementMember2022-07-012022-07-310001528115us-gaap:WarrantMembersrt:MaximumMember2022-07-112022-07-1100015281152021-01-012021-12-310001528115us-gaap:WarrantMembersrt:MinimumMember2022-07-112022-07-110001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001528115us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100015281152022-09-300001528115us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-3000015281152021-07-012021-09-300001528115annx:EmployeeStockPurchasePlanMember2022-01-012022-09-300001528115annx:TwoZeroTwoOneAtTheMarketProgramMemberannx:SalesAgreementWithCowenAndCompanyLLCMember2021-08-012021-08-310001528115us-gaap:EmployeeStockOptionMember2021-12-310001528115us-gaap:WarrantMember2022-07-112022-07-110001528115annx:PrefundedWarrantMember2022-10-280001528115us-gaap:RetainedEarningsMember2022-01-012022-03-310001528115annx:TwoZeroTwoOneAtTheMarketProgramMember2022-09-300001528115us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001528115annx:ComputerEquipmentAndSoftwareMember2021-12-310001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001528115annx:PreFundedWarrantsMember2022-09-300001528115annx:PrefundedWarrantMember2022-09-300001528115us-gaap:EmployeeStockOptionMember2022-01-012022-09-3000015281152021-11-012021-11-010001528115us-gaap:RetainedEarningsMember2021-04-012021-06-300001528115us-gaap:RetainedEarningsMember2021-12-310001528115us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2021-12-310001528115srt:MaximumMember2021-01-012021-09-300001528115annx:EmploymentInducementIncentivePlanMember2022-07-310001528115us-gaap:CommonStockMember2022-10-280001528115annx:EmployeeStockPurchasePlanMember2021-01-012021-09-300001528115us-gaap:EmployeeStockMember2021-01-012021-09-300001528115us-gaap:AdditionalPaidInCapitalMember2021-09-300001528115annx:PrefundedWarrantMember2022-07-112022-07-110001528115annx:SponsoredResearchAgreementMember2022-01-012022-09-300001528115us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001528115us-gaap:WarrantMember2022-09-300001528115us-gaap:FurnitureAndFixturesMember2021-12-310001528115us-gaap:PrivatePlacementMember2022-07-112022-07-110001528115us-gaap:RestrictedStockUnitsRSUMember2022-09-300001528115annx:EmployeeStockPurchasePlanMember2022-07-012022-09-300001528115us-gaap:CommonStockMember2021-01-012021-03-310001528115us-gaap:RetainedEarningsMember2021-07-012021-09-300001528115annx:BrisbaneCaliforniaMember2022-01-012022-09-300001528115us-gaap:EmployeeStockOptionMember2022-09-300001528115us-gaap:RetainedEarningsMember2021-03-310001528115annx:StanfordAgreementmemberMemberus-gaap:ResearchAndDevelopmentArrangementMember2011-11-012011-11-300001528115us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001528115us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-3000015281152022-04-012022-06-300001528115us-gaap:RetainedEarningsMember2022-09-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001528115us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001528115us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001528115annx:EmployeeStockPurchasePlanMember2022-09-300001528115us-gaap:AdditionalPaidInCapitalMember2020-12-310001528115annx:TwoZeroTwoOneAtTheMarketProgramMemberannx:SalesAgreementWithCowenAndCompanyLLCMember2021-08-310001528115us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001528115us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001528115us-gaap:AdditionalPaidInCapitalMember2021-06-300001528115us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001528115us-gaap:RetainedEarningsMember2022-04-012022-06-300001528115annx:EmploymentInducementAwardPlanMember2022-09-300001528115srt:MinimumMember2022-01-012022-09-300001528115us-gaap:CommonStockMember2022-06-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001528115us-gaap:RetainedEarningsMember2021-09-300001528115us-gaap:FurnitureAndFixturesMember2022-09-300001528115us-gaap:CommonStockMember2021-12-310001528115annx:BrisbaneCaliforniaMember2022-09-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001528115us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001528115us-gaap:CommonStockMember2020-12-310001528115annx:CommonWarrantsMember2022-09-300001528115us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryBondSecuritiesMember2022-09-300001528115annx:LaboratoryEquipmentMember2021-12-310001528115us-gaap:RetainedEarningsMember2020-12-310001528115srt:MaximumMember2022-07-012022-09-300001528115srt:MinimumMember2022-07-012022-09-3000015281152021-01-012021-09-3000015281152021-01-012021-03-310001528115annx:UnvestedRestrictedStockUnitsOutstandingMember2021-12-3100015281152022-07-112022-07-110001528115annx:StanfordAgreementmemberMemberus-gaap:ResearchAndDevelopmentArrangementMember2022-01-012022-09-3000015281152021-03-310001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001528115us-gaap:RetainedEarningsMember2021-06-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001528115us-gaap:CommonStockMember2022-03-3100015281152021-12-310001528115annx:EmploymentInducementIncentivePlanMember2022-09-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001528115annx:EmployeeStockPurchasePlanMember2021-12-310001528115us-gaap:EmployeeStockMember2022-01-012022-09-300001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001528115srt:MaximumMemberannx:PrefundedWarrantMember2022-07-110001528115us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001528115us-gaap:CommonStockMember2022-09-300001528115us-gaap:AdditionalPaidInCapitalMember2022-06-300001528115us-gaap:RetainedEarningsMember2022-07-012022-09-300001528115us-gaap:WarrantMembersrt:MaximumMember2022-07-1100015281152021-09-300001528115us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001528115annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember2022-09-300001528115us-gaap:AccountingStandardsUpdate202006Member2022-09-30xbrli:pureannx:Claimiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-39402

 

ANNEXON, INC.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

 

27-5414423

(State or other jurisdiction

of incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

1400 Sierra Point Parkway, Bldg C, Suite 200

Brisbane, California 94005

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (650) 822-5500

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ANNX

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ NO ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ NO ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

 

Accelerated filer

 

 

 

 

 

 

 

 

Non-accelerated filer

 

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

 

 

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO

The number of shares of the Registrant’s Common Stock outstanding as of October 28, 2022 was 47,630,393. This number does not include 24,696,206 shares of Common Stock issuable upon the exercise of pre-funded warrants (which are immediately exercisable at an exercise price of $0.001 per share of Common Stock, subject to beneficial ownership limitations) sold in the Registrant’s private placement on July 11, 2022. See Note 6—Stockholders’ Equity to the Registrant’s unaudited condensed consolidated financial statements.

 

 


 

Table of Contents

 

 

 

 

Page

 

 

PART I—FINANCIAL INFORMATION

 

Item 1.

 

Financial Statements

 

 

 

Condensed Consolidated Balance Sheets

3

 

 

Condensed Consolidated Statements of Operations

4

 

 

Condensed Consolidated Statements of Comprehensive Loss

5

 

 

Condensed Consolidated Statements of Stockholders’ Equity

6

 

 

Condensed Consolidated Statements of Cash Flows

8

 

 

Notes to Condensed Consolidated Financial Statements

9

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

28

Item 4.

 

Controls and Procedures

28

 

 

 

 

 

 

PART II—OTHER INFORMATION

 

Item 1.

 

Legal Proceedings

30

Item 1A.

 

Risk Factors

30

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

73

Item 3.

 

Defaults Upon Senior Securities

73

Item 4.

 

Mine Safety Disclosures

73

Item 5.

 

Other Information

73

Item 6.

 

Exhibits

74

SIGNATURES

76

 

In this Quarterly Report on Form 10-Q, “we,” “our,” “us,” “Annexon” and the “Company” refer to Annexon, Inc. and its consolidated subsidiary. Annexon, Annexon, Inc., the Annexon logo and other trade names, trademarks or service marks of Annexon are the property of Annexon, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

2


 

ANNEXON, INC.

Condensed Consolidated Balance Sheets

(in thousands)

 

 

 

September 30,
2022

 

 

December 31,
2021

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

210,658

 

 

$

74,843

 

Short-term investments

 

 

58,861

 

 

 

167,872

 

Prepaid expenses and other current assets

 

 

5,258

 

 

 

4,978

 

Total current assets

 

 

274,777

 

 

 

247,693

 

Restricted cash

 

 

1,032

 

 

 

1,166

 

Property and equipment, net

 

 

17,093

 

 

 

17,848

 

Operating lease right-of-use assets

 

 

19,616

 

 

 

20,333

 

Other non-current assets

 

 

204

 

 

 

 

Total assets

 

$

312,722

 

 

$

287,040

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

6,921

 

 

$

11,153

 

Accrued liabilities

 

 

11,323

 

 

 

9,250

 

Operating lease liabilities, current

 

 

1,806

 

 

 

1,202

 

Other current liabilities

 

 

170

 

 

 

139

 

Total current liabilities

 

 

20,220

 

 

 

21,744

 

Operating lease liabilities, non-current

 

 

31,900

 

 

 

33,387

 

Total liabilities

 

 

52,120

 

 

 

55,131

 

Commitments and contingencies (Note 5)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock

 

 

48

 

 

 

39

 

Additional paid-in capital

 

 

664,839

 

 

 

528,365

 

Accumulated other comprehensive loss

 

 

(406

)

 

 

(180

)

Accumulated deficit

 

 

(403,879

)

 

 

(296,315

)

Total stockholders’ equity

 

 

260,602

 

 

 

231,909

 

Total liabilities and stockholders’ equity

 

$

312,722

 

 

$

287,040

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

3


 

ANNEXON, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

27,862

 

 

$

27,581

 

 

$

83,966

 

 

$

72,849

 

General and administrative

 

 

8,207

 

 

 

8,099

 

 

 

24,938

 

 

 

20,406

 

Total operating expenses

 

 

36,069

 

 

 

35,680

 

 

 

108,904

 

 

 

93,255

 

Loss from operations

 

 

(36,069

)

 

 

(35,680

)

 

 

(108,904

)

 

 

(93,255

)

Interest and other income, net

 

 

1,015

 

 

 

82

 

 

 

1,340

 

 

 

303

 

Net loss

 

 

(35,054

)

 

 

(35,598

)

 

 

(107,564

)

 

 

(92,952

)

Net loss attributable to common stockholders

 

$

(35,054

)

 

$

(35,598

)

 

$

(107,564

)

 

$

(92,952

)

Net loss per share attributable to common stockholders, basic
   and diluted

 

$

(0.51

)

 

$

(0.93

)

 

$

(2.21

)

 

$

(2.43

)

Weighted-average shares used in computing net loss per share
   attributable to common stockholders, basic and diluted

 

 

68,652,859

 

 

 

38,341,110

 

 

 

48,710,433

 

 

 

38,261,359

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

4


 

ANNEXON, INC.

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

(Unaudited)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net loss

 

$

(35,054

)

 

$

(35,598

)

 

$

(107,564

)

 

$

(92,952

)

Other comprehensive gain (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

 

(4

)

 

 

(3

)

 

 

(7

)

 

 

(5

)

Unrealized gain (loss) on available-for-sale securities

 

 

37

 

 

 

(7

)

 

 

(219

)

 

 

7

 

Comprehensive loss

 

$

(35,021

)

 

$

(35,608

)

 

$

(107,790

)

 

$

(92,950

)

 

See accompanying notes to unaudited condensed consolidated financial statements.

5


 

ANNEXON, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

(Unaudited)

 

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Cost

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances as of December 31, 2021

 

 

38,560,854

 

 

$

39

 

 

$

528,365

 

 

$

(180

)

 

$

(296,315

)

 

$

231,909

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,252

 

 

 

 

 

 

 

 

 

4,252

 

Stock option exercises

 

 

2,711

 

 

 

 

 

 

19

 

 

 

 

 

 

 

 

 

19

 

Foreign currency translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

3

 

 

 

 

 

 

3

 

Unrealized loss on available-for-sale
  securities

 

 

 

 

 

 

 

 

 

 

 

(196

)

 

 

 

 

 

(196

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(35,373

)

 

 

(35,373

)

Balances as of March 31, 2022

 

 

38,563,565

 

 

 

39

 

 

 

532,636

 

 

 

(373

)

 

 

(331,688

)

 

 

200,614

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,520

 

 

 

 

 

 

 

 

 

4,520

 

Issuance of common stock per
  Employee Stock Purchase Plan
  purchase

 

 

40,341

 

 

 

 

 

 

113

 

 

 

 

 

 

 

 

 

113

 

Foreign currency translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

(6

)

 

 

 

 

 

(6

)

Unrealized loss on available-for-sale
  securities

 

 

 

 

 

 

 

 

 

 

 

(60

)

 

 

 

 

 

(60

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(37,137

)

 

 

(37,137

)

Balances as of June 30, 2022

 

 

38,603,906

 

 

 

39

 

 

 

537,269

 

 

 

(439

)

 

 

(368,825

)

 

 

168,044

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,911

 

 

 

 

 

 

 

 

 

4,911

 

Stock option exercises

 

 

8,763

 

 

 

 

 

 

45

 

 

 

 

 

 

 

 

 

45

 

Issuance of common stock, pre-funded
  warrants and common warrants, net of
  issuance costs (related party amount of
  $
9,500)

 

 

9,013,834

 

 

 

9

 

 

 

122,614

 

 

 

 

 

 

 

 

 

122,623

 

Foreign currency translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

(4

)

 

 

 

 

 

(4

)

Unrealized gain on available-for-sale
  securities

 

 

 

 

 

 

 

 

 

 

 

37

 

 

 

 

 

 

37

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(35,054

)

 

 

(35,054

)

Balances as of September 30, 2022

 

 

47,626,503

 

 

$

48

 

 

$

664,839

 

 

$

(406

)

 

$

(403,879

)

 

$

260,602

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

6


 

ANNEXON, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

(Unaudited)

 

 

 

Common Stock

 

 

Additional
Paid-In

 

 

Accumulated Other
Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Cost

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances as of December 31, 2020

 

 

38,157,618

 

 

$

38

 

 

$

510,309

 

 

$

(77

)

 

$

(165,992

)

 

$

344,278

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,962

 

 

 

 

 

 

 

 

 

2,962

 

Stock option exercises

 

 

74,930

 

 

 

 

 

 

268

 

 

 

 

 

 

 

 

 

268

 

Foreign currency translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

(1

)

Unrealized loss on available-for-sale
  securities

 

 

 

 

 

 

 

 

 

 

 

(25

)

 

 

 

 

 

(25

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(26,060

)

 

 

(26,060

)

Balances as of March 31, 2021

 

 

38,232,548

 

 

 

38

 

 

 

513,539

 

 

 

(103

)

 

 

(192,052

)

 

 

321,422

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,517

 

 

 

 

 

 

 

 

 

4,517

 

Stock option exercises

 

 

82,805

 

 

 

 

 

 

534

 

 

 

 

 

 

 

 

 

534

 

Issuance of common stock per
  Employee Stock Purchase Plan
  purchase

 

 

6,759

 

 

 

 

 

 

118

 

 

 

 

 

 

 

 

 

118

 

Foreign currency translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

(1

)

Unrealized gain on available-for-sale
  securities

 

 

 

 

 

 

 

 

 

 

 

39

 

 

 

 

 

 

39

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(31,294

)

 

 

(31,294

)

Balances as of June 30, 2021

 

 

38,322,112

 

 

 

38

 

 

 

518,708

 

 

 

(65

)

 

 

(223,346

)

 

 

295,335

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,428

 

 

 

 

 

 

 

 

 

4,428

 

Stock option exercises

 

 

47,986

 

 

 

 

 

 

322

 

 

 

 

 

 

 

 

 

322

 

Foreign currency translation
  adjustment

 

 

 

 

 

 

 

 

 

 

 

(3

)

 

 

 

 

 

(3

)

Unrealized loss on available-for-sale
  securities

 

 

 

 

 

 

 

 

 

 

 

(7

)

 

 

 

 

 

(7

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(35,598

)

 

 

(35,598

)

Balances as of September 30, 2021

 

 

38,370,098

 

 

$

38

 

 

$

523,458

 

 

$

(75

)

 

$

(258,944

)

 

$

264,477

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

7


 

ANNEXON, INC.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

 

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

Operating activities:

 

 

 

 

 

 

Net loss

 

$

(107,564

)

 

$

(92,952

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

1,576

 

 

 

1,635

 

Accretion of discount on available-for-sale securities

 

 

490

 

 

 

934

 

Stock-based compensation

 

 

13,683

 

 

 

11,907

 

Reduction in the carrying amount of right-of-use assets

 

 

717

 

 

 

926

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(280

)

 

 

(1,765

)

Other non-current assets

 

 

(204

)

 

 

 

Accounts payable

 

 

(777

)

 

 

874

 

Accrued liabilities

 

 

4,041

 

 

 

181

 

Operating lease liabilities

 

 

(883

)

 

 

471

 

Other current liabilities

 

 

31

 

 

 

 

Net cash used in operating activities

 

 

(89,170

)

 

 

(77,789

)

Investing activities:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(6,244

)

 

 

(799

)

Purchases of available-for-sale securities

 

 

(46,364

)

 

 

(191,122

)

Proceeds from sale of available-for-sale-securities

 

 

 

 

 

7,988

 

Proceeds from maturities of available-for-sale securities

 

 

154,666

 

 

 

62,000

 

Net cash provided by (used in) investing activities

 

 

102,058

 

 

 

(121,933

)

Financing activities:

 

 

 

 

 

 

Proceeds from the exercise common stock options

 

 

64

 

 

 

1,124

 

Proceeds from employee stock plan purchases

 

 

113

 

 

 

118

 

Proceeds from the issuance of common stock, pre-funded warrants and common warrants

 

 

120,976

 

 

 

 

Proceeds from the issuance of common stock, pre-funded warrants and common warrants -
  related party

 

 

9,500

 

 

 

 

Payment of issuance costs related to the issuance of common stock, pre-funded warrants and
  common warrants

 

 

(7,853

)

 

 

 

Deferred offering costs payment related to the 2021 ATM program

 

 

 

 

 

(395

)

Net cash provided by financing activities

 

 

122,800

 

 

 

847

 

Increase (decrease) in cash, cash equivalents and restricted cash

 

 

135,688

 

 

 

(198,875

)

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

(7

)

 

 

(5

)

Cash, cash equivalents and restricted cash

 

 

 

 

 

 

Beginning of period

 

 

76,009

 

 

 

268,565

 

End of period

 

$

211,690

 

 

$

69,685

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

 

Cash paid for amounts included in the measurement of lease liability

 

$

3,028

 

 

$

996

 

Non-cash investing and financing activities:

 

 

 

 

 

 

Purchases of property and equipment included in accounts payable and accrued liabilities

 

$

118

 

 

$

372

 

Deferred offering costs included in accrued liabilities

 

$

 

 

$

198

 

Right-of-use assets obtained in exchange for lease liability

 

$

 

 

$

21,084

 

Construction-in-progress obtained in exchange for tenant improvement allowance from lessors

 

$

 

 

$

10,748

 

 

 

See accompanying notes to unaudited condensed consolidated financial statements.

8


 

ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

1. Organization

Annexon, Inc., or the Company, is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. The Company is located in Brisbane, California and was incorporated in Delaware in March 2011.

The Company’s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, or the Subsidiary, is a proprietary limited company incorporated in 2016 and domiciled in Australia. The Subsidiary is also engaged in research and development activities in support of its parent company.

Liquidity

Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of September 30, 2022, had an accumulated deficit of $403.9 million and cash and cash equivalents and short-term investments of $269.5 million.

The Company has historically funded its operations through the issuance of shares of its redeemable convertible preferred stock and common stock. On July 11, 2022, the Company closed a private placement of shares of common stock, pre-funded warrants and common warrants, or Private Placement, which resulted in net proceeds of approximately $122.6 million, after deducting placement agent fees and other expenses. Based on projected activities, management projects that cash on hand is sufficient to support operations for at least the next 12 months following issuance of these condensed consolidated financial statements. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and applicable rules and regulations of the SEC regarding interim financial reporting.

The condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations, comprehensive loss, stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows for the interim period presented. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to fair value of investments, useful lives for property and equipment, incremental borrowing rate used in lease accounting, stock options, income taxes and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.

9


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Principles of Consolidation

The condensed consolidated financial statements include the operations of Annexon, Inc. and its wholly-owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds, are stated at fair value.

Restricted cash as of September 30, 2022 relates to the letters of credit established for the Company’s office leases.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Cash

 

$

570

 

 

$

734

 

Cash equivalents

 

 

210,088

 

 

 

74,109

 

Cash and cash equivalents

 

 

210,658

 

 

 

74,843

 

Restricted cash

 

 

1,032

 

 

 

1,166

 

Cash, cash equivalents and restricted cash

 

$

211,690

 

 

$

76,009

 

Short-Term Investments

Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.

The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.

The cost of investments sold is based on the specific-identification method. Interest on available-for-sale debt securities is included in interest and other income (expense), net.

Warrants

Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company’s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.

10


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Research and Development Expense

Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company’s product candidates.

Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company’s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company’s behalf; (iii) contract manufacturing costs to produce clinical trial materials; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation); (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.

Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.

The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company’s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees, non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employee directors on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.

The Company grants certain employees performance-based stock options. For awards that include performance conditions, no compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service inception date would be recognized.

Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes option pricing model and recognized as expense on a straight-line basis (for all but performance-based awards for which the accelerated method is used) over the requisite service period, which is the vesting period.

Determining the appropriate fair value model and related assumptions requires judgment, including estimating the fair value of the underlying common stock, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.

11


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company’s cash and cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits. Management believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity's Own Equity (Subtopic 815-40)” (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU 2020-06 effective as of January 1, 2022. The adoption of ASU 2020-06 did not have an impact on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material impact on its financial position or results of operations.

3. Fair Value Measurements

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

On a recurring basis, the Company measures certain financial assets and liabilities at fair value. The following tables summarize the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

 

September 30, 2022

 

 

 

Valuation
Hierarchy

 

Amortized
Cost

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

210,088

 

 

$

 

 

$

 

 

$

210,088

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

Level 2

 

 

23,825

 

 

 

 

 

 

(100

)

 

 

23,725

 

Government bonds

 

Level 2

 

 

35,354

 

 

 

 

 

 

(218

)

 

 

35,136

 

Total assets

 

 

 

$

269,267

 

 

$

 

 

$

(318

)

 

$

268,949

 

 

12


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

 

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Cost

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

74,109

 

 

$

 

 

$

 

 

$

74,109

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

Level 2

 

 

85,352

 

 

 

 

 

 

(27

)

 

 

85,325

 

Corporate bonds

 

Level 2

 

 

48,814

 

 

 

 

 

 

(24

)

 

 

48,790

 

Government bonds

 

Level 2

 

 

33,809

 

 

 

 

 

 

(52

)

 

 

33,757

 

Total assets

 

 

 

$

242,084

 

 

$

 

 

$

(103

)

 

$

241,981

 

 

For the three and nine months ended September 30, 2022 and 2021, the Company recognized no material realized gains or losses on financial instruments.

4. Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Prepaid research and development costs

 

$

3,562

 

 

$

3,002

 

Prepaid insurance

 

 

1,243

 

 

 

1,282

 

Other prepaid expenses

 

 

396

 

 

 

231

 

Other current assets

 

 

57

 

 

 

463

 

Total prepaid expenses and other current assets

 

$

5,258

 

 

$

4,978

 

Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Leasehold improvements

 

$

17,179

 

 

$

16,594

 

Laboratory equipment

 

 

1,552

 

 

 

1,353

 

Furniture and fixtures

 

 

682

 

 

 

649

 

Computer equipment and software

 

 

33

 

 

 

41

 

Total property and equipment, gross

 

 

19,446

 

 

 

18,637

 

Less: accumulated depreciation

 

 

(2,353

)

 

 

(789

)

Total property and equipment, net

 

$

17,093

 

 

$

17,848

 

 

The Company recognized depreciation for property and equipment of $0.5 million and $0.6 million for the three months ended September 30, 2022 and 2021, respectively, and $1.6 million and $1.6 million for the nine months ended September 30, 2022 and 2021, respectively.

13


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Accrued research and development expenses

 

$

7,054

 

 

$

2,404

 

Accrued compensation

 

 

3,792

 

 

 

3,573

 

Accrued professional services

 

 

313

 

 

 

1,274

 

Accrued construction costs

 

 

 

 

 

1,917

 

Other accrued expenses

 

 

164

 

 

 

82

 

Total accrued liabilities

 

$

11,323

 

 

$

9,250

 

 

5. Commitments and Contingencies

Leases

The Company leases its offices and laboratory in Brisbane, California, or the Brisbane Lease, under a ten-year noncancelable lease agreement that ends in October 2031 with a ten-year renewable option. In November 2021, the Company subleased unoccupied space for two years starting from December 2021 for aggregate sublease payments of $3.4 million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company’s sublease income was $0.4 million and $1.2 million for the three and nine months ended September 30, 2022, respectively.

As of September 30, 2022, the operating lease right-of-use assets were $19.6 million and lease liabilities were $33.7 million on the condensed consolidated balance sheet. The weighted-average remaining lease term is 9.1 years.

The weighted-average incremental borrowing rate used to measure the operating lease liability is 8.4%.

Operating lease costs were $0.5 million and $1.1 million for the three months ended September 30, 2022 and 2021, respectively, and $1.5 million and $2.0 million for the nine months ended September 30, 2022 and 2021, respectively. Variable lease payments were $0.1 million and $36,000 for the three months ended September 30, 2022 and 2021, respectively, and $0.7 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively.

Future minimum lease payments and related lease liabilities as of September 30, 2022, were as follows:

 

 

 

(in thousands)

 

2022 (remaining three months)

 

$

1,175

 

2023

 

 

4,742

 

2024

 

 

4,907

 

2025

 

 

5,079

 

2026 and thereafter

 

 

32,833

 

Total undiscounted lease payments

 

 

48,736

 

Less: Imputed interest

 

 

(15,030

)

Total

 

$

33,706

 

License and Other Agreements

In November 2011, the Company entered into an exclusive licensing agreement, or the Stanford Agreement, with The Board of Trustees of the Leland Stanford Junior University, or Stanford, whereby the Company was granted an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights, or the Licensed Patents, to make, use, offer for sale, sell, import and otherwise commercialize products covered by the Licensed Patents for human or animal diseases, disorders or conditions. Under the Stanford Agreement, the Company made an upfront payment and is obligated to pay Stanford annual license maintenance fees, potential future milestone payments totaling up to $0.5 million, and royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed products. The Company did not achieve any milestones or make any milestone payments for the three and nine months ended September 30, 2022 and 2021.

14


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

In December 2016, the Company entered into a sponsored research agreement, with a not-for-profit entity to perform research on multiple sclerosis. The sponsored research agreement was amended in March 2019, or as amended, the Sponsored Research Agreement. Under the terms of the Sponsored Research Agreement, the Company may receive up to $0.7 million in funding. If within 15 years of the end of the Sponsored Research Agreement, the Company files a marketing authorization application for a product treating multiple sclerosis, the Company will be obligated to pay milestone payments up to four times the amounts received under the Sponsored Research Agreement. The Company has received $0.6 million in funding to date, which was recorded as other income. The Company recognized no income during the nine months ended September 30, 2022 and $0.1 million in income during the nine months ended September 30, 2021.

Guarantees and Indemnifications

In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2022, the Company did not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.

6. Stockholders’ Equity

Private Placement

On July 11, 2022, the Company sold in a private placement an aggregate of 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of its common stock and accompanying common warrants to purchase up to 8,427,508 shares of its common stock. The offering price per share and accompanying common warrant was $3.87125 per share and the offering price per pre-funded warrant and accompanying common warrant was $3.87025 per share, which equals the per share offering price for the shares of common stock less the $0.001 exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $5.806875 per share and expire on June 30, 2025.

An entity related to one of the Company’s directors participated in the Private Placement and purchased 2,453,988 shares of common stock and accompanying common warrants to purchase up to an additional 613,497 shares of common stock for an aggregate price of approximately $9.5 million.

Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The Company may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 9.99% of the total number of shares of common stock outstanding immediately after giving effect to the exercise or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 9.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. The Company may not effect the exercise of any common warrant, and a holder will not be entitled to exercise any portion of any common warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99%, 9.99% or 19.99% (as applicable pursuant to the holder’s common warrant) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage, including 9.99%, 14.99% or 19.99%, and not in excess of 19.99%, upon at least 61 days’ notice to the Company. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders’ equity within additional paid-in capital.

As of September 30, 2022, no pre-funded or common warrants were exercised, and there were pre-funded and common warrants to purchase an aggregate of 33,123,714 shares of common stock outstanding. The 24,696,206 shares of common stock issuable upon the exercise of the pre-funded warrants and the 8,427,508 shares of common stock issuable upon the exercise of the common warrants are not included in the number of issued and outstanding shares of common stock as of September 30, 2022.

15


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

At-the-Market Offering

In August 2021, the Company entered into a sales agreement with Cowen and Company LLC, or Cowen, as sales agent, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering price of $100.0 million under an at-the-market offering program, or 2021 ATM program. The Company will pay Cowen up to 3% of gross proceeds for the common stock sold through the 2021 ATM program. As of September 30, 2022, no shares of common stock have been sold under the 2021 ATM program.

Common Stock

The Company has reserved the following shares of common stock for issuance as follows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Stock options issued and outstanding

 

 

8,178,136

 

 

 

5,662,824

 

Stock options reserved for 2020 Incentive Award Plan

 

 

334,001

 

 

 

2,039,951

 

Unvested restricted stock units outstanding

 

 

591,608

 

 

 

50,000

 

Common stock reserved for 2021 ATM program

 

 

5,265,929

 

 

 

5,265,929

 

Common stock reserved for Employee Stock Purchase
     Plan

 

 

1,075,042

 

 

 

729,775

 

Common stock reserved for Employment Inducement
    Award Plan

 

 

1,703,000

 

 

 

 

Common stock reserved for pre-funded warrants

 

 

24,696,206

 

 

 

 

Common stock reserved for common warrants

 

 

8,427,508

 

 

 

 

Total common stock reserved

 

 

50,271,430

 

 

 

13,748,479

 

 

7. Equity Incentive Plans

In July 2020, the Company’s board of directors and stockholders adopted and approved the 2020 Incentive Award Plan, or the 2020 Plan, and the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the Company’s initial public offering, or the IPO.

The Company may not grant any additional awards under the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder.

2020 Equity Incentive Plan

The number of shares of common stock reserved for issuance under the 2020 Plan automatically increases on the first day of January, in an amount equal to 4% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors.

Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than 100% of the estimated fair value on the date of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms. As of September 30, 2022, there were 334,001 shares available for issuance under the 2020 Plan.

2022 Employment Inducement Award Plan

In July 2022, the Company’s board of directors adopted the Annexon, Inc. 2022 Employment Inducement Award Plan, or the Inducement Plan, and together with the 2011 Plan and the 2020 Plan, the Plans. The Inducement Plan was adopted by the Company’s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4), or Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan may only be granted to newly hired employees as an inducement material to the employees entering into employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of 2,000,000 shares of common stock were reserved for issuance under the Inducement Plan. As of September 30, 2022, there were 1,703,000 shares available for issuance under the Inducement Plan.

16


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

Stock Options

The following table presents stock option activity under the Plans for the period:

 

 

 

Number of
Shares

 

 

Weighted-
Average
Exercise
Price Per
Share

 

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Balances as of December 31, 2021

 

 

5,662,824

 

 

$

16.98

 

 

 

8.26

 

 

$

10,186

 

Stock options granted

 

 

3,645,435

 

 

 

5.59

 

 

 

 

 

 

 

Stock options exercised

 

 

(11,474

)

 

 

5.65

 

 

 

 

 

 

 

Stock options forfeited

 

 

(1,118,649

)

 

 

16.24

 

 

 

 

 

 

 

Balances as of September 30, 2022

 

 

8,178,136

 

 

$

12.02

 

 

 

8.39

 

 

$

6,084

 

Exercisable as of September 30, 2022

 

 

2,968,956

 

 

$

12.75

 

 

 

7.17

 

 

$

2,494

 

 

The total intrinsic value of options exercised were $2,500 and $0.7 million during the three months ended September 30, 2022 and 2021, respectively, and $5,000 and $3.9 million for the nine months ended September 30, 2022 and 2021, respectively. The intrinsic value is the difference between the fair value of the Company’s common stock at the time of exercise and the exercise price of the stock option.

The weighted-average grant date fair value of options granted to employees during the nine months ended September 30, 2022 and 2021 was $3.93 and $19.41 per share, respectively.

As of September 30, 2022, the total unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $42.7 million, which the Company expects to recognize over an estimated weighted-average period of 2.6 years.

Restricted Stock Units

RSUs are equity awards that entitle the holder to receive shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a three-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.

A summary of RSU activity under the 2020 Plan and related information is as follows:

 

 

Number of Shares

 

 

Weighted-Average Grant Date Fair Value Per Share

 

Unvested as of December 31, 2021

 

 

50,000

 

 

$

12.84

 

Granted

 

 

600,583

 

 

 

5.40

 

Cancelled

 

 

(58,975

)

 

 

8.04

 

Unvested as of September 30, 2022

 

 

591,608

 

 

$

5.76

 

As of September 30, 2022, unrecognized stock-based compensation expense related to outstanding unvested RSUs was $2.8 million, which is expected to be recognized over a weighted-average period of 2.5 years.

Employee Stock Purchase Plan

The ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least 1%, and up to 15% of an employee’s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP

17


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

increase automatically on the first day of each fiscal year, by a number equal to the least of 360,086 shares, 1% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or such number of shares determined by the Company’s board of directors. As of September 30, 2022, 1,075,042 shares were available for future purchase. The ESPP generally provides for six-month consecutive offering periods beginning on May 15th and November 15th of each year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense has been recorded for the three and nine months ended September 30, 2022.

The stock-based compensation expense related to the ESPP was $29,000 and $42,000 for the three months ended September 30, 2022 and 2021, respectively, and $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively.

Stock-Based Compensation Expense

The total stock-based compensation expense related to all equity-based awards recognized in the period was as follows (in thousands):

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

2,433

 

 

$

2,382

 

 

$

6,509

 

 

$

6,330

 

General and administrative

 

 

2,478

 

 

 

2,046

 

 

 

7,174

 

 

 

5,577

 

Total stock-based compensation expense

 

$

4,911

 

 

$

4,428

 

 

$

13,683

 

 

$

11,907

 

To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.

The fair value of each award issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2022

 

2021

 

2022

 

2021

Expected term (in years)

 

5.77 - 6.08

 

4.33 - 6.08

 

5.50 - 6.08

 

4.33 - 6.08

Expected volatility

 

81.70% - 82.70%

 

88.3% - 89%

 

78.80% - 82.80%

 

88.3% - 90.7%

Risk-free interest rate

 

2.92% - 3.61%

 

0.70% - 1.10%

 

1.49% - 3.61%

 

0.35% - 1.10%

Dividend yield

 

 

 

 

 

8. Income Taxes

For the three and nine months ended September 30, 2022 and 2021, the Company incurred insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company’s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.

9. Net Loss Per Share Attributable to Common Stockholders

The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding, excluding restricted common stock. The weighted-average number of shares of common stock used in the basic and diluted net loss per share calculation include the pre-funded warrants issued in connection with the Private Placement as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2022, no pre-funded warrants have been exercised and there were pre-funded warrants to purchase an aggregate of 24,696,206 shares of common stock outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.

18


ANNEXON, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

 

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

Stock options to purchase common stock

 

 

8,178,136

 

 

 

5,918,981

 

Shares subject to Employee Stock Purchase Plan

 

 

110,897

 

 

 

9,538

 

Unvested restricted stock units

 

 

591,608

 

 

 

 

Common warrants to purchase common stock

 

 

8,427,508

 

 

 

 

Total

 

 

17,308,149

 

 

 

5,928,519

 

 

19


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our consolidated financial statements and related notes thereto for the year ended December 31, 2021, included in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission, or the SEC, on March 1, 2022.

In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled “Risk Factors” under Part II, Item 1A below. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “should,” “will” or the negative of these terms or other similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ from those anticipated. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

Overview

We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. The classical complement pathway is a core component to the body’s immune system that activates a powerful inflammatory cascade. We believe that by stopping the classical complement pathway at its start, our approach may have the potential to provide more complete protection against complement-mediated disorders of the body, brain and eye.

Our proprietary platform targets C1q, the initiating molecule of the classical complement pathway. Our product candidates are designed to block the early classical cascade and all downstream pathway components and their tissue-damaging functions. Our goal is to suppress excessive or aberrant classical complement activity that contributes to chronic inflammation and tissue damage to slow or even halt disease progression, while preserving the beneficial immune functions of the lectin and alternative complement pathways involved in the clearance of pathogens and damaged cells.

Using our proprietary platform, we are identifying and characterizing the role of the classical complement pathway in three therapeutic areas–autoimmune, neurodegeneration and ophthalmology. Our precision medicine approach is aimed at identifying the patient populations we believe will be most likely to benefit from our therapeutic candidates and guides the design of well-tailored patient studies to increase the overall likelihood of clinical success.

We are advancing a broad pipeline of five complement-targeted product candidates, each with distinct routes of administration and dosing schedules, designed to selectively inhibit the classical complement pathway in specific compartments of the body, brain or eye:

ANX005. Our lead candidate, ANX005, an investigational, full-length monoclonal antibody formulated for intravenous administration, is designed to fully inhibit C1q and the classical complement pathway in the body and across the blood brain barrier for autoimmune and neurodegenerative diseases. ANX005 is currently being evaluated in a Phase 2/3 clinical trial for the potential treatment of patients with Guillain-Barré Syndrome (GBS) and a Phase 2 trial in patients with warm autoimmune hemolytic anemia (wAIHA).
During the second quarter, we reported final data from an open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease (HD). The data showed that ANX005 demonstrated full C1q target inhibition and was generally well-tolerated. Additionally, disease progression was stabilized in the overall patient population through the nine-month study and the rapid improvement in clinical outcome measures was maintained in patients with high baseline complement activity through the entire nine-month study. Based on these data, we plan to engage with regulatory authorities to assess the opportunity for a well-controlled trial in HD leveraging a precision medicine approach. ANX005 is also being evaluated in a Phase 2a trial in amyotrophic lateral sclerosis (ALS).

20


 

ANX007. ANX007 is an investigational antibody Fab formulated for intravitreal administration that is designed to inhibit C1q locally in the eye for patients with complement-mediated neurodegenerative diseases of the eye. ANX007 is being evaluated in a global Phase 2 trial in patients with geographic atrophy (GA).
ANX009. ANX009 is an investigational subcutaneous formulation of an antigen-binding fragment, or Fab, that is designed to selectively inhibit C1q in the vascular space. ANX009 is currently being evaluated in a Phase 1b trial in patients with lupus nephritis (LN).
ANX105 and ANX1502. Our next generation product candidates include ANX105, an investigational monoclonal antibody targeting neurodegenerative and autoimmune indications, and ANX1502, an investigational oral small molecule in development for the treatment of certain autoimmune indications. Both programs are currently being evaluated in Phase 1 first-in-human trials in healthy volunteers.

With compelling clinical and biomarker data from our lead candidate, ANX005, in both GBS and HD, we are advancing late-stage trials for each indication. We are on track to evaluate data in December 2022 from multiple signal-finding studies in our autoimmune franchise, as well as safety and target engagement data with our oral, small molecule, ANX1502. Additionally, we anticipate reviewing data from our Phase 2 program of ANX007 in GA in the first half of 2023. We plan to provide a portfolio update and anticipated milestones across our autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January 2023.

We hold worldwide development and commercialization rights, including through exclusive licenses, to all of our product candidates, which allows us to strategically maximize value from our product portfolio over time. Our patent portfolio includes patent protection for our upstream complement platform and each of our product candidates.

We were incorporated in March 2011 and commenced operations later that year. To date, we have focused primarily on performing research and development activities, hiring personnel and raising capital to support and expand these activities. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have incurred net losses each year since our inception. Our net losses were $35.1 million and $35.6 million for the three months ended September 30, 2022 and 2021, respectively, and $107.6 million and $93.0 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $403.9 million and cash and cash equivalents and short-term investments of $269.5 million.

Impact of COVID-19 Pandemic

The COVID-19 pandemic has had an adverse effect on the global economy, and its ongoing impact is uncertain and subject to change. For instance, we have experienced interruption in clinical trial activities, shortages in clinical site staff, longer timelines for clinical site initiation and temporary shortages in lab kits and supplies. We will continue to monitor the COVID-19 situation closely. The extent of the ongoing impact of the COVID-19 pandemic on our clinical trials, business, financial condition, results of operations and clinical development timelines and plans remains uncertain, and will depend on, among other factors, the duration and severity of the pandemic, the emergence of variants, rates of infection in the locations in which we do business, restrictions that may be requested or mandated by governmental authorities, and the impact of the pandemic on our clinical trial enrollment, trial sites, contract research organizations, or CROs, third-party manufacturers, regulatory authorities and other third parties with whom we do business.

Components of Operating Results

Revenue

Our product candidates are not approved for commercial sale. We have not generated any revenue from sales of our product candidates and do not expect to do so in the foreseeable future and until we complete clinical development, submit regulatory filings and receive approvals from applicable regulatory bodies for such product candidates, if ever.

Operating Expenses

Research and Development

Research and development expenses account for a significant portion of our operating expenses. Research and development expenses consist primarily of direct and indirect costs incurred for the development of our product candidates.

Direct expenses include:

preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of our product candidates;

21


 

professional services agreements with third party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on our behalf;
contract manufacturing costs to produce clinical trial materials; and
laboratory supplies and materials.

Indirect expenses include:

compensation and personnel-related expenses (including stock-based compensation);
allocated expenses for facilities and depreciation; and
other indirect costs.

We record research and development expenses as incurred. Payments made to other entities are under agreements that are generally cancelable by us. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred as prepaid expenses. The prepaid amounts are then expensed as the related services are performed. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates.

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, particularly as they advance into later stages of development and as we conduct larger clinical trials, engage in other research and development activities and seek regulatory approvals for any product candidates that successfully complete clinical trials and as we incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain.

General and Administrative

General and administrative expenses consist primarily of compensation and personnel-related expenses (including stock-based compensation) for our personnel in executive, finance and other administrative functions. General and administrative expenses also include professional fees paid for accounting, legal and tax services, allocated expenses for facilities and depreciation and other general and administrative costs.

We expect our general and administrative expenses to increase substantially for the foreseeable future as we continue to support our research and development activities, grow our business and, if any of our product candidates receive marketing approval, commercialization activities. We also incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, Sarbanes-Oxley Act and the Nasdaq Stock Market, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to increase the size of our administrative function to support the growth of our business.

Interest and Other Income, Net

Interest and other income, net, primarily consists of interest income earned on our cash equivalents and short-term investments.

Results of Operations

Comparison of the Three Months Ended September 30, 2022 and 2021

The following tables summarize our results of operations for the periods presented:

 

22


 

 

 

Three Months Ended
September 30,

 

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Dollar
Change

 

 

%
Change

 

 

(in thousands)

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

27,862

 

 

$

27,581

 

 

$

281

 

 

1%

General and administrative

 

 

8,207

 

 

 

8,099

 

 

 

108

 

 

1%

Total operating expenses

 

 

36,069

 

 

 

35,680

 

 

 

389

 

 

1%

Loss from operations

 

 

(36,069

)

 

 

(35,680

)

 

 

(389

)

 

1%

Interest and other income, net

 

 

1,015

 

 

 

82

 

 

 

933

 

 

*

Net loss

 

$

(35,054

)

 

$

(35,598

)

 

$

544

 

 

(2%)

* Not meaningful

Research and Development Expenses

 

 

Three Months Ended
September 30,

 

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Dollar
Change

 

 

%
Change

 

 

(in thousands)

 

 

 

 

 

 

Direct costs:

 

 

 

 

 

 

 

 

 

 

 

Clinical and nonclinical outside services

 

$

12,925

 

 

$

12,591

 

 

$

334

 

 

3%

Consulting and professional services

 

 

1,478

 

 

 

1,763

 

 

 

(285

)

 

(16%)

Contract manufacturing

 

 

3,720

 

 

 

4,759

 

 

 

(1,039

)

 

(22%)

Laboratory supplies and materials

 

 

282

 

 

 

270

 

 

 

12

 

 

4%

Indirect costs:

 

 

 

 

 

 

 

 

 

 

 

Compensation and personnel-related
(including stock-based compensation)

 

 

8,218

 

 

 

6,720

 

 

 

1,498

 

 

22%

Facilities and depreciation

 

 

1,228

 

 

 

1,441

 

 

 

(213

)

 

(15%)

Other

 

 

11

 

 

 

37

 

 

 

(26

)

 

(70%)

Total research and development expenses

 

$

27,862

 

 

$

27,581

 

 

$

281

 

 

1%

Research and development expenses increased by $0.3 million, or 1%, for the three months ended September 30, 2022 compared to the same period in 2021. The increase was primarily due to an increase of $1.5 million in compensation and personnel-related expenses, related to an increase in headcount. Direct clinical outside services costs increased by $0.3 million due to our multiple active clinical trials in GBS, warm autoimmune hemolytic anemia, amyotrophic lateral sclerosis, geographic atrophy, and first in human trials of ANX105 and ANX1502. Contract manufacturing expense decreased by $1.0 million due to completion of ANX005 production runs in the prior year period. Direct consulting and professional services costs decreased by $0.3 million due to timing of costs related to the support of multiple functions including clinical development, translational, regulatory and project management. Facilities and depreciation costs decreased by $0.2 million due to sublease income offsetting rent expense associated with our lease for office space in Brisbane, California, which commenced in November 2021.

General and Administrative Expenses

 

 

Three Months Ended
September 30,

 

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Dollar
Change

 

 

%
Change

 

 

(in thousands)

 

 

 

 

 

 

Compensation and personnel-related
(including stock-based compensation)

 

$

4,426

 

 

$

3,503

 

 

$

923

 

 

26%

Consulting and professional services

 

 

2,907

 

 

 

3,792

 

 

 

(885

)

 

(23%)

Facilities and depreciation

 

 

622

 

 

 

669

 

 

 

(47

)

 

(7%)

Other

 

 

252

 

 

 

135

 

 

 

117

 

 

87%

Total general and administrative expenses

 

$

8,207

 

 

$

8,099

 

 

$

108

 

 

1%

General and administrative expenses increased by $0.1 million, or 1%, for the three months ended September 30, 2022 compared to the same period in 2021. The increase was primarily due to an increase of $0.9 million in compensation and personnel-related expenses, including an increase of $0.4 million in stock-based compensation, related to an increase in headcount. Consulting and professional services for accounting, legal and audit fees, and directors’ and officers’ insurance decreased by $0.9 million during the

23


 

three months ended September 30, 2022. Facilities and depreciation costs decreased by $0.1 million due to sublease income offsetting rent expense associated with our lease for office space in Brisbane, California, which commenced in November 2021.

Interest and other income, net

Interest and other income increased by $0.9 million for the three months ended September 30, 2022 compared to the same period in 2021. The increase was primarily due to the increase in cash and cash equivalents and short-term investments balances, which was a result of the private placement completed in July 2022.

Comparison of the Nine Months Ended September 30, 2022 and 2021

The following tables summarize our results of operations for the periods presented:

 

 

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Dollar
Change

 

 

%
Change

 

 

(in thousands)

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

83,966

 

 

$

72,849

 

 

$

11,117

 

 

15%

General and administrative

 

 

24,938

 

 

 

20,406

 

 

 

4,532

 

 

22%

Total operating expenses

 

 

108,904

 

 

 

93,255

 

 

 

15,649

 

 

17%

Loss from operations

 

 

(108,904

)

 

 

(93,255

)

 

 

(15,649

)

 

17%

Interest and other income, net

 

 

1,340

 

 

 

303

 

 

 

1,037

 

 

*

Net loss

 

$

(107,564

)

 

$

(92,952

)

 

$

(14,612

)

 

16%

* Not meaningful

 

Research and Development Expenses

 

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Dollar
Change

 

 

%
Change

 

 

(in thousands)

 

 

 

 

 

 

Direct costs:

 

 

 

 

 

 

 

 

 

 

 

Clinical and nonclinical outside services

 

$

39,640

 

 

$

30,608

 

 

$

9,032

 

 

30%

Consulting and professional services

 

 

5,386

 

 

 

5,606

 

 

 

(220

)

 

(4%)

Contract manufacturing

 

 

12,553

 

 

 

14,464

 

 

 

(1,911

)

 

(13%)

Laboratory supplies and materials

 

 

829

 

 

 

871

 

 

 

(42

)

 

(5%)

Indirect costs:

 

 

 

 

 

 

 

 

 

 

 

Compensation and personnel-related
(including stock-based compensation)

 

 

21,740

 

 

 

18,031

 

 

 

3,709

 

 

21%

Facilities and depreciation

 

 

3,752

 

 

 

3,127

 

 

 

625

 

 

20%

Other

 

 

66

 

 

 

142

 

 

 

(76

)

 

(54%)

Total research and development expenses

 

$

83,966

 

 

$

72,849

 

 

$

11,117

 

 

15%

Research and development expenses increased by $11.1 million, or 15%, for the nine months ended September 30, 2022 compared to the same period in 2021. The increase was primarily due to an increase of $9.0 million in direct clinical outside services related to our multiple clinical trials in GBS, warm autoimmune hemolytic anemia, Huntington’s Disease, amyotrophic lateral sclerosis, geographic atrophy, and first in human trials of ANX105 and ANX1502. Contract manufacturing expense decreased by $1.9 million due to completion of ANX005 production runs in the prior year period. Compensation and personnel-related expenses increased by $3.7 million, including an increase of $0.2 million in stock-based compensation, due to an increase in headcount. Facilities and depreciation costs increased by $0.6 million due to the commencement of our office lease in November 2021 in Brisbane, California.

24


 

General and Administrative Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

 

2022

 

 

2021

 

 

Dollar
Change

 

 

%
Change

 

 

(in thousands)

 

 

 

 

 

 

Compensation and personnel-related
(including stock-based compensation)

 

$

12,579

 

 

$

9,622

 

 

$

2,957

 

 

31%

Consulting and professional services

 

 

9,653

 

 

 

8,673

 

 

 

980

 

 

11%

Facilities and depreciation

 

 

1,921

 

 

 

1,578

 

 

 

343

 

 

22%

Other

 

 

785

 

 

 

533

 

 

 

252

 

 

47%

Total general and administrative expenses

 

$

24,938

 

 

$

20,406

 

 

$

4,532

 

 

22%

General and administrative expenses increased by $4.5 million, or 22%, for the nine months ended September 30, 2022 compared to the same period in 2021. The increase was primarily due to an increase of $3.0 million in compensation and personnel-related expenses, including an increase of $1.6 million in stock-based compensation, related to an increase in headcount. Consulting and professional services for accounting, legal and audit fees, and directors’ and officers’ insurance increased by $1.0 million during the nine months ended September 30, 2022. Facilities and depreciation costs increased by $0.3 million due to the commencement of our office lease in November 2021 in Brisbane, California.

Interest and other income, net

Interest and other income increased by $1.0 million for the nine months ended September 30, 2022 compared to the same period in 2021. The increase was primarily due to the increase in cash and cash equivalents and short-term investments balances, which was the result of the private placement completed in July 2022.

Liquidity and Capital Resources

Sources of Liquidity

Due to our significant research and development expenditures, we have generated operating losses since our inception.

We have funded our operations primarily through the sale of equity securities. From our inception through September 30, 2022, we have raised net cash proceeds of $356.5 million from private placements of our redeemable convertible preferred stock, common stock, pre-funded warrants and common warrants, and $262.4 million from the initial public offering of our common stock, or our IPO. As of September 30, 2022, we had available cash and cash equivalents and short-term investments of $269.5 million and an accumulated deficit of $403.9 million.

Historical Cash Flows

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

 

(in thousands)

 

Net cash used in operating activities

 

$

(89,170

)

 

$

(77,789

)

Net cash provided by (used in) investing activities

 

 

102,058

 

 

 

(121,933

)

Net cash provided by financing activities

 

 

122,800

 

 

 

847

 

Increase (decrease) in cash, cash equivalents and restricted cash

 

$

135,688

 

 

$

(198,875

)

Cash Flows from Operating Activities

Cash used in operating activities for the nine months ended September 30, 2022 was $89.2 million, which consisted of a net loss of $107.6 million, partially offset by $16.5 million in non-cash charges and a net change of $1.9 million in our operating assets and liabilities. The non-cash charges consisted of stock-based compensation of $13.7 million, depreciation and amortization of $1.6 million, accretion of discount on available-for-sale securities of $0.5 million, and reduction in the carrying amount of right-of-use assets of $0.7 million.

Cash used in operating activities for the nine months ended September 30, 2021 was $77.8 million, which consisted of a net loss of $93.0 million, partially offset by $15.4 million in non-cash charges and a net change of $0.2 million in our operating assets and liabilities. The non-cash charges consisted of stock-based compensation of $11.9 million, depreciation and amortization of $1.6 million,

25


 

accretion of discount on available-for-sale securities of $0.9 million, and reduction in the carrying amount of right-of-use assets of $0.9 million.

Cash Flows from Investing Activities

Cash provided by investing activities for the nine months ended September 30, 2022 was $102.1 million, which consisted of $154.7 million of proceeds from maturities of available-for-sale securities, partially offset by $46.4 million of purchases of available-for-sale securities and $6.2 million of tenant improvement costs associated with our new lease in Brisbane, California.

Cash used in investing activities for the nine months ended September 30, 2021 was $121.9 million, which consisted of $191.1 million of purchases of available-for-sale securities and $0.8 million of purchase of property and equipment, partially offset by $62.0 million of proceeds from maturities of available-for-sale securities and $8.0 million of proceeds from sale of available-for-sale securities.

Cash Flows from Financing Activities

Cash provided by financing activities for the nine months ended September 30, 2022 was $122.8 million, which consisted of $130.5 million of proceeds from issuance of common stock and pre-funded warrants, and $0.2 million of proceeds from the exercise of common stock options and employee stock purchase plan purchases, partially offset by $7.9 million of issuance costs payment.

Cash provided by financing activities for the nine months ended September 30, 2021 was $0.8 million, million, related to $1.2 million of proceeds from the exercise of common stock options and employee stock purchase plan purchases, partially offset by $0.4 million of deferred offering costs related to the 2021 ATM program.

Funding Requirements

We use our cash to fund operations, primarily to fund our clinical trials, research and development expenditures and related personnel costs. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to our product candidates, particularly as they advance into later stages of development and as we conduct larger clinical trials, engage in other research and development activities, seek regulatory approvals for any product candidates that successfully complete clinical trials and as we incur expenses associated with hiring additional personnel to support our research and development efforts. In addition, we expect our general and administrative expenses to increase substantially for the foreseeable future as we continue to support our research and development activities and to grow our business and as we expect to engage in commercialization activities, if any of our product candidates receive marketing approval. We also incur additional expenses as a result of operating as a public company and also expect to increase the size of our administrative function to support the growth of our business. The timing and amount of our operating expenditures will depend on many factors, including:

the scope, progress, results and costs of researching and developing our current product candidates or any other future product candidates we choose to pursue, and conducting preclinical studies and clinical trials;
the timing of, and the costs involved in, obtaining regulatory approvals for our lead product candidates or any future product candidates;
the number and characteristics of any additional product candidates we develop or acquire;
the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to our current or any future license or collaboration agreements;
the cost of manufacturing our lead product candidates or any future product candidates and any products we successfully commercialize;
the cost of building a sales force in anticipation of product commercialization;
the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs;
our ability to establish strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;
any product liability or other lawsuits related to our products;
the expenses needed to attract, hire and retain skilled personnel;

26


 

the costs associated with operating as a public company;
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; and
the timing, receipt and amount of sales of any future approved products.

Based upon our current operating plan, we believe that our existing cash and cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We expect to continue to expend significant resources for the foreseeable future. Until such time, if ever, as we can generate substantial product revenue, we will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, we could be forced to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.

At-the-Market Offering

In August 2021, we entered into a sales agreement with Cowen and Company LLC, or Cowen, as sales agent, pursuant to which we may issue and sell shares of our common stock for an aggregate maximum offering price of $100.0 million under an at-the-market offering program, or the 2021 ATM program. We will pay Cowen up to 3% of gross proceeds for the common stock sold through the 2021 ATM program. As of September 30, 2022, no shares of common stock have been sold under the 2021 ATM program.

Private Placement

On July 11, 2022, we sold in a private placement an aggregate of 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of our common stock and accompanying common warrants to purchase up to 8,427,508 shares of our common stock. The offering price per share and accompanying common warrant was $3.87125 per share and the offering price per pre-funded warrant and accompanying common warrant was $3.87025 per share, which equals the per share offering price for the shares of common stock less the $0.001 exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $5.806875 per share and expire on June 30, 2025. The private placement resulted in net proceeds of approximately $122.6 million, after deducting placement agent fees and other expenses.

Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders’ equity within additional paid-in capital.

As of September 30, 2022, no pre-funded or common warrants were exercised, and there were pre-funded and common warrants to purchase an aggregate of 33,123,714 shares of common stock outstanding. The 24,696,206 shares of common stock issuable upon the exercise of the pre-funded warrants and the 8,427,508 shares of common stock issuable upon the exercise of the common warrants are not included in the number of issued and outstanding shares of common stock as of September 30, 2022.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent

27


 

from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

During the quarter ended September 30, 2022, there were no material changes to our critical accounting policies or in the methodology used for estimates from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Recent Accounting Pronouncements Not Yet Adopted

See Note 2—Basis of Presentation and Significant Accounting Policies to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Foreign Currency and Exchange Risk

Our expenses are generally denominated in the currencies of the jurisdictions in which we conduct our operations, which are primarily in the United States and Australia. Our results of current and future operations and cash flows are, therefore, subject to fluctuations due to changes in foreign currency exchange rates. A hypothetical 10% increase or decrease in the relative value of the U.S. dollar to other currencies would not have a material effect on our operating results. As the impact of foreign currency exchange rates has not been material to our historical operating results, we have not entered into derivative or hedging transactions, but we may do so in the future if our exposure to foreign currency becomes more significant.

Interest Rate Risk

We had cash and cash equivalents of $210.7 million and short-term investments of $58.9 million as of September 30, 2022. Cash and cash equivalents consist of bank deposits and money market funds. Our marketable securities generally consist of high-grade commercial paper, corporate and other debt securities, U.S. government agency securities, and treasury bills. The cash and cash equivalents and marketable securities are held for working capital purposes. Such interest-earning instruments carry a degree of interest rate risk. The primary objective of our investment activities is to preserve principal while maximizing income without significantly increasing risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. Due to the short-term nature of our investments, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. An immediate 10% increase or decrease in interest rates would not have a material effect on the fair value of our portfolio. We therefore do not expect our operating results or cash flows to be materially affected by a sudden change in market interest rates.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

28


 

Inherent Limitations on Effectiveness of Disclosure Controls and Procedures

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

29


 

PART II – OTHER INFORMATION

We are not party to any material legal proceedings at this time. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business.

Item 1A. Risk Factors.

RISK FACTORS

Our business involves significant risks, some of which are described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, operating results and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Quarterly Report on Form 10-Q also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Quarterly Report.

Risk Factor Summary

The following summarizes the most material risks that make an investment in our securities risky or speculative. If any of the following risks occur or persist, our business, financial condition and results of operations could be materially harmed and the price of our common stock could significantly decline.

We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.
We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.
Our business is heavily dependent on the successful development, regulatory approval and commercialization of our product candidates, which are in early stages of clinical development.
Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.
Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.
Adverse events or undesirable side effects caused by, or other unexpected properties of, any of our products could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.
Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.
Our current and any future product candidates or products could be alleged to infringe patent rights and other proprietary rights of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to commercialize our products.

30


 

Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements

We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred significant losses since our inception, and we anticipate that we will continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability.

We are a clinical-stage biopharmaceutical company, and we have only a limited operating history upon which you can evaluate our business and prospects. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We have no products approved for commercial sale and have not generated any revenue from sales of our product candidates and have incurred losses in each year since our inception in March 2011. We have only a limited operating history upon which you can evaluate our business and prospects. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical, biopharmaceutical and biotechnology industry.

We have had significant operating losses since our inception. Our net loss for the years ended December 31, 2021 and 2020 was approximately $130.3 million and $63.4 million, respectively, and our net loss for the three and nine months ended September 30, 2022 was approximately $35.1 million and $107.6 million, respectively. As of September 30, 2022, we had an accumulated deficit of $403.9 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase as we continue to develop our product candidates, conduct clinical trials and pursue research and development activities. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders’ equity and working capital.

We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations.

Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities. Our product candidates will require additional clinical development, and we intend to conduct additional research and development activities to discover and develop new product candidates, including conducting preclinical studies and clinical trials, all of which will require substantial additional funds. We will continue to expend significant resources for the foreseeable future in connection with these activities. These expenditures will include costs associated with conducting preclinical studies and clinical trials, obtaining regulatory approvals and manufacturing and supply, as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or any future product candidates.

As of September 30, 2022, we had capital resources consisting of cash and cash equivalents and short-term investments of approximately $269.5 million. We expect our existing capital resources to fund our planned operating expenses into the second half of 2025. However, our operating plans may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned through public or private equity offerings or debt financings or other sources, such as strategic collaborations. Such financing may result in dilution to our stockholders, imposition of burdensome debt covenants and repayment obligations, or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our future capital requirements depend on many factors, including:

the scope, progress, results and costs of researching and developing our current product candidates or any other future product candidates we choose to pursue, conducting preclinical studies and clinical trials, and delays related to the COVID-19 pandemic;
the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates or any future product candidates;
the number and characteristics of any additional product candidates we develop or acquire;
the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to our current or any future license or collaboration agreements;
the cost of manufacturing our product candidates or any future product candidates and any products we successfully commercialize;

31


 

the cost of building a sales force in anticipation of product commercialization;
the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs;
our ability to establish strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;
any product liability or other lawsuits related to our products;
the expenses needed to attract, hire and retain skilled personnel;
the costs associated with being a public company;
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio;
the timing, receipt and amount of sales of any future approved products; and
the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.

Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If adequate funds are not available to us on a timely basis, we may be required to:

delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any future product candidate;
delay, limit, reduce or terminate our research and development activities; or
delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates or any future product candidate or reduce our flexibility in developing or maintaining our sales and marketing strategy.

We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until our product candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations through the sale of equity securities. We will be required to seek additional funding in the future and currently intend to do so through public or private equity offerings or debt financings, credit or loan facilities, collaborations or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.

Due to the significant resources required for the development of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

We are currently focused on developing product candidates to address classical complement-mediated autoimmune and neurodegenerative diseases. We seek to maintain a process of prioritization and resource allocation among our programs to maintain a balance between aggressively advancing our product candidates in identified indications and exploring additional indications or mechanisms as well as developing future product candidates. However, due to the significant resources required for the development of our product candidates, we must focus on specific diseases and disease pathways and decide which product candidates to pursue and the amount of resources to allocate to each such product candidate.

Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert

32


 

resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the autoimmune or neurodegenerative or pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.

Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:

the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our product candidates, which may change from time to time;
the timing and status of enrollment for our clinical trials;
the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;
expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;
timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;
future accounting pronouncements or changes in our accounting policies;
the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;
the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally;
coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and
the level of demand for our product candidates, if approved, which may vary significantly over time.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.

Risks Related to Our Business

Our business is heavily dependent on the successful development, regulatory approval and commercialization of our product candidates, which are in early stages of clinical development.

We have no products approved for sale, and our product candidates are in early stages of clinical development. The success of our business, including our ability to finance our company and generate revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our product candidates and, in particular, the advancement of our current clinical-stage product candidates. However, given the stage of development of our product candidates, it may be many years, if we succeed at all, before we have demonstrated the safety, purity, potency and/or efficacy of a product candidate sufficient to warrant

33


 

approval for commercialization. We cannot be certain that our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval.

While inhibition of the complement pathway has been validated as a therapeutic approach, C1q inhibition is a novel therapeutic approach, which exposes us to certain risks. For example, we may discover that our product candidates do not possess certain properties required for therapeutic effectiveness, or even if found to be effective in one type of disease, they are not effective in other types of disease. In addition, given the novel nature of this therapeutic approach, designing preclinical studies and clinical trials to demonstrate the effect of the product candidates is complex and exposes us to risks, including that our biomarker-driven approach may not translate into therapeutic effectiveness.

In the future, we may also become dependent on other product candidates that we may develop or acquire. The clinical and commercial success of our product candidates and future product candidates will depend on a number of factors, including the following:

the COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment, patients discontinuing their treatment or follow up visits or changes to trial protocols;
our ability to raise any additional required capital on acceptable terms, or at all;
our ability to complete an investigational new drug application, or IND, enable studies and successfully submit INDs or comparable applications;
timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;
whether we are required by the U.S. Food and Drug Administration, or the FDA, or similar foreign regulatory agencies to conduct additional clinical trials or other studies beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;
acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;
our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of our product candidates or any future product candidates;
the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates or future approved products, if any;
the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;
achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;
the ability of third parties with whom we contract to manufacture adequate clinical trial and commercial supplies of our product candidates or any future product candidates remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMPs;
our ability to successfully develop a commercial strategy and thereafter commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others;
our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;
the convenience of our treatment or dosing regimen;
acceptance by physicians, payors and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;
the willingness of physicians, operators of clinics and patients to utilize or adopt any of our product candidates or any future product candidates, if approved;
the willingness of patients to enroll or continue to participate in a clinical trial during the COVID-19 pandemic;

34


 

patient demand for our product candidates, if approved, including the willingness of patients to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;
our ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates; and
our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims.

These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business or achieve profitability.

Public health crises such as pandemics or similar outbreaks have, and could in the future, materially and adversely affect our preclinical and clinical trials, business, financial condition and results of operations.

In March 2020, the World Health Organization declared COVID-19 a global pandemic and the United States declared a national emergency with respect to the COVID-19 pandemic. In response to the COVID-19 pandemic and in connection with the spread of the Omicron variants, “shelter in place” orders and other public health guidance measures were implemented across much of the United States and Europe, including in the locations of our offices, clinical trial sites, key vendors and partners. We expect that our clinical development program timelines will continue to be negatively affected by the COVID-19 pandemic, which could materially and adversely affect our business, financial condition and results of operations. For instance, we experienced interruption in clinical trial activities in Bangladesh due to quarantines, shortages in clinical site staff, longer timelines for clinical site initiation and temporary shortages in lab kits and supplies. Additionally, the COVID-19 pandemic has adversely impacted hospitals and medical facilities where we are currently conducting our clinical trials and has resulted in increased competition for more limited hospital resources among companies conducting clinical trials. Further, due to public health guidance measures, we maintain a work-from-home policy for all staff members excluding those necessary to maintain minimum basic operations. Our increased reliance on personnel working from home has, and may continue to, negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories have been delayed.

As a result of the COVID-19 pandemic, or similar pandemics, and related “shelter in place” orders and other public health guidance measures, we have experienced, and may in the future experience, disruptions that could materially and adversely impact our clinical trials, business, financial condition and results of operations. These disruptions include but are not limited to:

delays or difficulties in enrolling patients in our clinical trials;
delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff;
increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;
interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;
diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;
delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations, or CROs, and vendors;
interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;
interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;
delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;

35


 

limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials and pre-clinical work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home, school closures or mass transit disruptions;
changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether;
delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and
refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.

These and other factors arising from the COVID-19 pandemic could worsen or could return in countries where the COVID-19 pandemic has been partially contained, each of which could further adversely impact our ability to conduct clinical trials and our business generally, and could materially and adversely affect our business, financial condition and results of operations.

The COVID-19 pandemic continues to evolve. The extent to which the outbreak may continue to affect our clinical trials, business, financial condition, results of operations, and clinical development timelines and plans will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the duration of the outbreak, the emergence of new variants, rates of infection in the locations in which we and our CROs, third-party manufacturers, regulatory authorities and other third parties with whom we do business operate, travel restrictions and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials, business, financial condition and results of operations.

Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.

We are at an early stage of clinical development of our product candidates. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for and successfully commercialize our product candidates, and we may fail to do so for many reasons, including the following:

our product candidates may not successfully complete preclinical studies or clinical trials;
a product candidate may be shown to have harmful side effects or other characteristics that indicate it does not meet applicable regulatory criteria;
our competitors may develop therapeutics that render our product candidates obsolete or less attractive;
the market for a product candidate may change so that the continued development of that product candidate is no longer reasonable or commercially attractive;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;
if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing capabilities, or successfully market such approved product candidate; and
a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.

If any of these events occur, we may be forced to abandon our development efforts for a product candidate or candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations. Failure of a product candidate may occur at any stage of preclinical or clinical development, and we may never succeed in developing marketable products or generating product revenue.

We may not be successful in our efforts to further develop our current and future product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. Each of our product candidates will require significant additional clinical development, management of preclinical, clinical and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization and significant marketing efforts before we generate any revenue from product sales, if at all. Any clinical studies that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. If the results of our ongoing or future clinical studies are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical significance or if there are safety

36


 

concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates.

The FDA or other regulatory agencies may not agree with our clinical development plan and require that we conduct additional clinical trials to support our regulatory submissions, including the FDA may require that we conduct more than one pivotal trial in order to gain approval.

If any of our product candidates successfully completes clinical trials, we plan to seek regulatory approval to market our product candidates in the United States, the European Union, or the EU, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry, manufacturing and controls, clinical trials, commercial sales, pricing and distribution of our product candidates. We may also rely on collaborators or partners to conduct the required activities to support an application for regulatory approval and to seek approval for one or more of our product candidates. We cannot be sure that any such collaborators or partners will conduct these activities successfully or do so within the timeframe we desire. Even if we or any future collaborators or partners are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our revenue and results of operations could be negatively affected.

Even if we receive regulatory approval to market any of our product candidates, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. Any approval we may obtain could be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a Risk Evaluation and Mitigation Strategy, or REMS. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.

We may encounter substantial delays in our clinical trials or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an IND or a clinical trial application, or CTA, will result in the FDA or other regulatory authority, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical trials can occur at any stage of testing, and our future clinical trials may not be successful. Clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:

the COVID-19 pandemic, which may result in clinical site closures, delays to patient enrollment, patients discontinuing their treatment or follow up visits or changes to trial protocols;
generating sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation or continuation of clinical trials;
the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;
delays in obtaining regulatory authorization to commence a trial;
reaching agreements on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
identifying, recruiting and training suitable clinical investigators;
obtaining institutional review board, or IRB, approval at each trial site;
imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND or amendment, or equivalent foreign application or amendment;
new safety findings that present unreasonable risk to clinical trial participants;
a negative finding from an inspection of our clinical trial operations or study sites;

37


 

recruiting an adequate number of suitable patients to participate in a trial;
having subjects complete a trial or return for post-treatment follow-up;
clinical trial sites deviating from trial protocol or dropping out of a trial;
addressing subject safety concerns that arise during the course of a trial;
adding a sufficient number of clinical trial sites; or
obtaining sufficient product supply of product candidates for use in preclinical studies or clinical trials from third-party suppliers.

We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical trials which could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:

we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials or require that we submit additional data or information before allowing a clinical trial to be initiated;
clinical studies of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;
our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls or be unable to provide us with sufficient product supply to conduct and complete preclinical studies or clinical trials of our product candidates in a timely manner, or at all;
we or our investigators might have to suspend or terminate clinical trials of our product candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or a finding that the participants are being exposed to unacceptable health risks;
the cost of clinical trials of our product candidates may be greater than we anticipate;
the quality of our product candidates or other materials necessary to conduct preclinical studies or clinical trials of our product candidates may be insufficient or inadequate;
regulators may revise the requirements for approving our product candidates or such requirements may not be as we anticipate; and
any future collaborators may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us.

If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only moderately positive or if there are safety concerns, we may:

incur unplanned costs;
be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all;
obtain marketing approval in some countries and not in others;
obtain marketing approval for indications or patient populations that are not as broad as intended or desired;
obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;
be subject to additional post-marketing testing requirements; or
have the product removed from the market after obtaining marketing approval.

In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. For instance, we have experienced interruption in clinical trial activities in Bangladesh due to quarantines, shortages in clinical site staff, longer timelines for clinical site

38


 

initiation and temporary shortages in lab kits and supplies. We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Further, conducting clinical trials in foreign countries, as we plan to do for certain of our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs and managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks.

Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.

If we experience delays in the completion, or termination, of any preclinical study or clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed or not realized at all. In addition, any delays in completing our clinical trials may increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. If one or more of our product candidates proves to be ineffective, unsafe or commercially unviable, our business, financial condition, results of operations and prospects may be materially and adversely affected.

If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

We may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:

the severity and difficulty of diagnosing the disease under investigation;
the patient eligibility and exclusion criteria defined in the protocol;
the size of the patient population required for analysis of the trial’s primary endpoints;
the proximity of patients to trial sites;
the design of the trial;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
the existing body of safety and efficacy data with respect to the study drug and safety concerns;
patient referral practices of physicians;
risk that enrolled subjects will drop out before completion of the trial, including as a result of contracting COVID-19 or other health conditions or being forced to quarantine;
ability to monitor patients adequately during and after treatment;
availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or condition under investigation;

39


 

clinicians’ and patients’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; and
our ability to obtain and maintain patient consents.

In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.

Adverse events or undesirable side effects caused by, or other unexpected properties of, any of our product candidates could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

Adverse events or other undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. We have experienced adverse events during clinical trials, and may in the future experience, adverse or unforeseen events during, or as a result of, clinical trials. If unacceptable side effects arise in the development of our product candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.

In addition, early clinical trials may only include a limited number of subjects and limited duration of exposure to our product candidates. In particular, we are pursuing a novel approach to inhibiting upstream molecules of the classical complement pathway, primarily C1q, and as a result, our product candidates may cause unforeseen safety events when evaluated in larger patient populations. Further, clinical trials may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.

If any of our product candidates receives marketing approval, and we or others later identify undesirable and unforeseen side effects caused by such product, a number of potentially significant negative consequences could result, including but not limited to:

regulatory authorities may suspend, limit or withdraw approvals of such product, or seek an injunction against its manufacture or distribution;
we may be required to conduct additional clinical trials or post-approval studies;
we may be required to recall a product or change the way such product is administered to patients;
additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;
regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;
we may be required to implement a REMS or create a Medication Guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use;
we could be sued and held liable for harm caused to patients;
we may be subject to fines, injunctions or the imposition of criminal penalties;
the product may become less competitive; and
our reputation may suffer.

40


 

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our product candidates prove to be unsafe, our business, financial condition, results of operations and prospects may be materially and adversely affected.

Interim, “top-line” and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we publicly disclose interim, “top-line” or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the “top-line” results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. “Top-line” or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, “top-line” and preliminary data should be viewed with caution until the final data are available. From time to time, we also disclose interim, “top-line” or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim, “top-line” or preliminary data and final data could significantly harm our business prospects.

Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the “top-line,” preliminary or interim data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.

Even if our current or future product candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.

Even if one or more of our product candidates receive FDA or other regulatory approvals, the commercial success of any of our current or future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. Our product candidates may not be commercially successful. For a variety of reasons, including, among other things, competitive factors, pricing or physician preference, reimbursement by insurers, the degree and rate of physician and patient adoption of our current or future product candidates, if approved, will depend on a number of factors, including:

the clinical indications for which the product is approved and patient demand for approved products that treat those indications;
the safety and efficacy of our product as compared to other available therapies;
the availability of coverage and adequate reimbursement from managed care plans, insurers and other healthcare payors for any of our product candidates that may be approved;
acceptance by physicians, operators of clinics and patients of the product as a safe and effective treatment;
physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;
overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;
proper training and administration of our product candidates by physicians and medical staff;
public misperception regarding the use of our therapies, if approved for commercial sale;
patient satisfaction with the results and administration of our product candidates and overall treatment experience, including, for example, the convenience of any dosing regimen;

41


 

the cost of treatment with our product candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay for the product, if approved, on the part of insurance companies and other third-party payors, physicians and patients;
the revenue and profitability that our products may offer a physician as compared to alternative therapies;
the prevalence and severity of side effects;
limitations or warnings contained in the FDA-approved labeling for our products;
the willingness of physicians, operators of clinics and patients to utilize or adopt our products as a solution;
any FDA requirement to undertake a REMS;
the effectiveness of our sales, marketing and distribution efforts;
adverse publicity about our products or favorable publicity about competitive products; and
potential product liability claims.

We cannot assure you that our current or future product candidates, if approved, will achieve broad market acceptance among physicians and patients. Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our results of operations.

We have received Orphan Drug designation for ANX005 for the treatment of GBS and HD, and we may seek Orphan Drug designation for certain future product candidates. We may be unable to obtain such designations or to maintain the benefits associated with Orphan Drug designation, including market exclusivity, which may cause any revenue from product sales to be reduced.

We have received Orphan Drug designation in the United States for ANX005 for the treatment of GBS and HD. Although we may seek Orphan product designation for some or all of our other product candidates, we may never receive such designations. Under the Orphan Drug Act, the FDA may designate a drug or biologic product as an Orphan Drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. Orphan Drug designation must be requested before submitting a biologics license application, or BLA, or new drug application, or NDA. In the EU, the EMA’s Committee for Orphan Medicinal Products, or COMP, grants Orphan Drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.

In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants Orphan Drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.

In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same disease or condition for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with Orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. In the EU, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the Orphan Drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable to not justify maintenance of market exclusivity.

Even if we obtain Orphan Drug designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain Orphan Drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an Orphan Drug is approved, the FDA can subsequently approve the same drug for

42


 

the same condition if the FDA concludes that the later drug is clinically superior in that it is safer, more effective or makes a major contribution to patient care. Orphan Drug designation neither shortens the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review or approval process.

A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

We may seek a Breakthrough Therapy designation for our product candidates if the clinical data support such a designation for one or more product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs and biologics designated as breakthrough therapies by the FDA may also be eligible for priority review and rolling review of BLA or NDA submissions.

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

A Fast Track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval.

The FDA has granted Fast Track designation for ANX005 in GBS and for ANX007 in GA, and, in the future, we may seek Fast Track designation for other of our product candidates. If a drug or biologic is intended for the treatment of a serious or life-threatening condition and the drug or biologic demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for Fast Track designation. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once a BLA or NDA is submitted, the application may be eligible for priority review. A Fast Track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA or NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA or NDA, the FDA agrees to accept sections of the BLA or NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA or NDA. The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Fast Track designation may not result in a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Many drugs and biologics that have received Fast Track designation have failed to obtain approval.

Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.

If one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. We and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.

43


 

We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. We may not promote our products “off-label” for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety, purity, potency and/or efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

issue warning letters;
impose civil or criminal penalties;
suspend or withdraw regulatory approval;
suspend any of our clinical studies;
refuse to approve pending applications or supplements to approved applications submitted by us;
impose restrictions on our operations, including closing our contract manufacturers’ facilities; or
seize or detain products, or require a product recall.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.

Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.

The ability of the FDA to review and/or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.

Separately, in response to the COVID-19 pandemic, in March 2020, the FDA postponed most inspections of foreign and domestic manufacturing facilities. Subsequently, in July 2020, the FDA resumed certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA utilized this risk-based assessment system to assist in determining when and where it was safest to conduct prioritized domestic inspections. Additionally, on April 15, 2021, the FDA began conducting voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites, among other facilities, in circumstances where the FDA determines that such remote evaluation would be appropriate based on mission needs and travel limitations. In July 2021, the FDA resumed standard inspectional operations of domestic facilities. Since that time, the FDA has continued to monitor and implement changes to its inspectional activities to ensure the safety of its employees and those of the firms it regulates as it adapts to the evolving COVID-19 pandemic. Regulatory authorities outside the United States may adopt similar restrictions or other policy

44


 

measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

We conduct, and in the future plan to conduct, clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.

We conduct clinical trials of our product candidates outside the United States, and plan to continue to do so in the future for reasons including the relative impact of the COVID-19 pandemic on trial sites in the United States. For example, we conducted our Phase 1b clinical trial of ANX005 in Bangladesh. The acceptance of study data from clinical trials conducted outside the United States or the applicable jurisdiction by the FDA and comparable foreign regulatory authorities may be subject to certain conditions, or may not be accepted at all.

For example, where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the United States population and United States medical practice, the trials were performed by clinical investigators of recognized competence and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For trials that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with good clinical practice, or GCP, requirements, and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. In addition, foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction.

If the product candidates that we develop receive regulatory approval in the United States or another jurisdiction, they may never receive approval in other jurisdictions, which would limit market opportunities for our product candidates and adversely affect our business.

Approval of a product candidate in the United States by the FDA or by the requisite regulatory agencies in any other jurisdiction does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions. The approval process varies among countries and may limit our or any future collaborators’ ability to develop, manufacture, promote and sell product candidates internationally. Failure to obtain marketing approval in international jurisdictions would prevent the product candidates from being marketed outside of the jurisdictions in which regulatory approvals have been received. In order to market and sell product candidates in the EU, and many other jurisdictions, we and any future collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may involve additional preclinical studies or clinical trials both before and after approval. In many countries, any product candidate for human use must be approved for reimbursement before it can be approved for sale in that country. In some cases, the intended price for such product is also subject to approval. Further, while regulatory approval of a product candidate in one country does not ensure approval in any other country, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. If we or any future collaborators fail to comply with the regulatory requirements in international markets or to obtain all required marketing approvals, the target market for a particular potential product will be reduced, which would limit our ability to realize the full market potential for the product and adversely affect our business.

Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.

The Patient Protection and Affordable Care Act, signed into law on March 23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.

45


 

There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

We rely on third-party suppliers to manufacture our product candidates, and we intend to rely on third parties to produce commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.

We do not have the ability, and we do not plan to build or acquire the infrastructure or capability internally, to manufacture supplies of our product candidates or the materials necessary to produce our product candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a preclinical, clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing processes of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for the manufacture of our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.

We currently intend to supply our product candidates in all territories for our clinical development programs, and rely on third parties at key stages in our supply chain. For instance, the supply chains for our product candidates involve several manufacturers that specialize in specific operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a result, the supply chain for the manufacturing of our product candidates is complicated, and we expect the logistical challenges associated with our supply chain to grow more complex as our product candidates are further developed.

We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. We generally do not begin preclinical or clinical trials unless we believe we have access to a sufficient supply of a product candidate to complete such study. In addition, any significant delay in, or quality control problems with respect to, the supply of a product candidate, or the raw material components thereof, for an ongoing study could considerably delay completion of our preclinical or clinical trials, product testing and potential regulatory approval of our product candidates.

We have not yet engaged any manufacturers for the commercial supply of our product candidates. Although we intend to enter into such agreements prior to commercial launch of any of our product candidates, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which could have a material adverse impact upon our business. Moreover, if there is a disruption to one or more of our third-party manufacturers’ or suppliers’ relevant operations, or if we are unable to enter into arrangements for the commercial supply of our product candidates, we will have no other means of producing our product candidates until they restore the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or destruction of our third-party manufacturers’ or suppliers’ facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.

In addition, to manufacture our product candidates in the quantities we believe would be required to meet anticipated market demand, our third-party manufacturers would likely need to increase manufacturing capacity and we may need to secure alternative sources of commercial supply, which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial-scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for the manufacture of our product candidates on acceptable terms, at sufficient quality levels or in adequate quantities, if at all, the commercial launch of our product candidates would

46


 

be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of such product candidates, if approved.

We rely on third parties in the conduct of all of our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates.

We currently do not have the ability to independently conduct preclinical studies or clinical trials that comply with the regulatory requirements known as good laboratory practice, or GLP, requirements or GCP requirements, respectively. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and GCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials play a significant role in the conduct of these studies and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.

Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLPs or GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our business, financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenues could be delayed.

If we are not successful in identifying, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.

Although a substantial amount of our effort will focus on the continued development and potential approval of our current product candidates, a key element of our strategy is to identify, develop and commercialize a portfolio of products that address classical complement-mediated autoimmune and neurodegenerative diseases. A component of our strategy is to evaluate our product candidates in multiple indications based, in part, on our evaluation of certain biomarkers in a disease area. For example, we intend to evaluate ANX005 in neurodegenerative diseases, including amyotrophic lateral sclerosis, or ALS, and Huntington’s disease, or HD; however, we are continuing to evaluate ANX005 in these patient populations, and even if we believe we have obtained positive clinical results in patients with one of these neurodegenerative diseases, such results may not be replicated in later studies evaluating ANX005 in patients with the same disease or across other neurodegenerative or autoimmune diseases. Even though we are currently developing a pipeline of product candidates, our development efforts may still fail to yield product candidates potentially suitable for commercialization for many reasons, including the following:

competitors may develop alternatives that render our product candidates obsolete;
product candidates we develop may be covered by third parties’ patents or other exclusive rights;
a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
a product candidate may not be accepted as safe and effective by physicians and patients.

We therefore cannot provide any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, commercialize additional

47


 

product candidates. If we are unable to successfully identify, acquire, develop and commercialize additional product candidates, our commercial opportunities may be limited.

We face significant competition in an environment of rapid technological and scientific change, and our product candidates, if approved, will face significant competition, which may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do, and we may not be able to successfully compete.

The pharmaceutical, biopharmaceutical and biotechnology industries in particular are characterized by rapidly advancing technologies, intense competition and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing and marketing of healthcare products competitive with those that we are developing. We face competition from a number of sources, such as pharmaceutical, biopharmaceutical and biotechnology companies, generic drug companies and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales forces, manufacturing capabilities, research and development capabilities, clinical trial expertise, intellectual property portfolios, experience in obtaining patents and regulatory approvals for product candidates and other resources than we do. Some of the companies also have a broad range of other product offerings, large direct sales forces and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. Mergers and acquisitions in the pharmaceutical, biopharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

Certain alternative treatments offered by competitors may be available at lower prices and may offer greater efficacy or better safety profiles. Furthermore, currently approved products could be discovered to have application for the intended indication of our product candidates, which could give such products significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, European Medicines Agency, or EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. For additional information regarding our competition, see the section of our Annual Report on Form 10-K for the year ended December 31, 2021 captioned “Business—Competition.”

The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.

The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Even if we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

Third-party payors increasingly are challenging prices charged for pharmaceutical, biopharmaceutical and biotechnology products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the cost of the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amounts we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not

48


 

be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our investment in the development of product candidates.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other foreign jurisdictions have and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amounts that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products, and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.

We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to market and sell our product candidates, if approved, effectively in the United States and foreign jurisdictions or generate product revenue.

We currently do not have a marketing or sales organization. In order to commercialize our product candidates in the United States and foreign jurisdictions, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If any of our product candidates receive regulatory approval, we expect to establish a sales organization with technical expertise and supporting distribution capabilities to commercialize each such product candidate, which will be expensive and time consuming. We have no prior experience in the marketing, sale and distribution of pharmaceutical, biopharmaceutical and biotechnology products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. If we are not successful in commercializing our product candidates or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

We will need to increase the size of our organization, and we may experience difficulties in managing growth.

As of September 30, 2022, we had 83 full-time employees. We will need to continue to expand our managerial, operational, finance and other resources in order to manage our operations and clinical trials, continue our development activities and commercialize

49


 

our product candidates or any future product candidates. Our management and personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:

manage our clinical trials effectively;
identify, recruit, retain, incentivize and integrate additional employees, including sales personnel;
manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties; and
continue to improve our operational, financial and management controls, reports systems and procedures.

If we fail to attract and retain senior management and key scientific personnel, our business may be materially and adversely affected.

Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and clinical and scientific personnel. We are highly dependent upon members of our senior management, as well as our senior scientists. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, initiation or completion of our planned clinical trials or the commercialization of our product candidates or any future product candidates.

For example, we are engaged in a search for a chief medical officer, and we may experience difficulties or delays in identifying a qualified replacement. We cannot guarantee that we will not face turnover in the future. Our ability to execute our business strategies may be adversely affected by the uncertainty associated with any transition and the time and management attention needed to fill any vacant role could disrupt our business.

Competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current or future product candidates.

We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:

decreased demand for our current or future product candidates;
injury to our reputation;
withdrawal of clinical trial participants;
costs to defend the related litigation;
diversion of management’s time and our resources;
substantial monetary awards to trial participants or patients;
regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;
loss of revenue; and
the inability to commercialize our current or any future product candidates.

If we are unable to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims, the commercialization of our current or any future product candidates we develop could be inhibited or prevented. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance,

50


 

any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our product candidates, we intend to expand our insurance coverage to include the sale of such product candidate; however, we may be unable to obtain this liability insurance on commercially reasonable terms or at all.

Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.

While we have not entered into any collaboration agreements to date, we may seek collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. For example, certain of the disease areas that we believe our product candidates address, including, among others, ophthalmic indications, require large, costly and later-stage clinical trials, which a collaboration partner may be better positioned to finance and/or conduct. In addition, a component of our strategy is to maximize the commercial value of our current and future product candidates, which may also strategically align with partnering commercial rights with partners that have larger and established sales organizations. To the extent that we decide to enter into collaboration agreements, we may face significant competition for appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain and challenging to manage. We may not be successful in our efforts to enter into collaboration agreements. The terms of collaborations or other arrangements that we may establish may not be favorable to us.

The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include risks that:

collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;
collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;
collaborators with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;
we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
disputes may arise between us and collaborators that cause the delay or termination of the research, development or commercialization of our current or future product candidates or that result in costly litigation or arbitration that diverts management attention and resources;
collaborations may be terminated, and, if terminated, this may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates;
collaborators may own or co-own intellectual property covering products that result from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;
disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations; and
collaborators’ sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

51


 

Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.

Our business is susceptible to general conditions in the global economy and in the global financial markets. A global financial crisis or a global or regional political disruption has caused, and could in the future cause, extreme volatility in the capital and credit markets. A severe or prolonged economic downturn, including a recession or depression, the current inflationary economic environment, rising interest rates, debt and equity market fluctuations, diminished liquidity and credit availability, increased unemployment rates, decreased investor and consumer confidence, supply chain challenges, natural catastrophes, the effects of climate change, regional and global conflicts and terrorist attacks or political disruption or turmoil could result in a variety of risks to our business, including weakened demand for our product candidates or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our potential products. Any of the foregoing could materially and adversely affect our business, financial condition, results of operations and prospects, and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.

We or the third parties upon whom we depend on may be adversely affected by earthquakes or other natural disasters, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which has experienced both severe earthquakes and the effects of wildfires. We do not carry earthquake insurance. Earthquakes, wildfires or other natural disasters could severely disrupt our operations, and could materially and adversely affect our business, financial condition, results of operations and prospects.

If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.

Our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on our results of operations.

We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, other sanctions, imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

52


 

Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.

Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of hazardous materials owned by us, including the components of our product candidates and other hazardous compounds. We and any third-party manufacturers and suppliers are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products.

We cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials comply with the standards prescribed by these laws and regulations, nor can we eliminate the risk of accidental contamination or injury from these materials. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.

Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from hazardous materials or wastes. Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, results of operations and financial condition.

Risks Related to Intellectual Property

Our current and any future product candidates or products could be alleged to infringe patent rights and other proprietary rights of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to commercialize our products.

Our commercial success depends on our ability to develop, manufacture and market our current and any future product candidates that may be approved for sale, and to use our proprietary technology without infringing the patents and other proprietary rights of third parties. Intellectual property disputes can be costly to defend and may cause our business, operating results and financial condition to suffer. We operate in an industry with extensive intellectual property litigation. As the pharmaceutical, biopharmaceutical and biotechnology industries expand and more patents are issued, the risk increases that there may be patents issued to third parties that relate to our products and technology of which we are not aware or that we may need to challenge to continue our operations as currently contemplated.

Whether merited or not, we may face allegations that we have infringed the trademarks, copyrights, patents and other intellectual property rights of third parties, including patents held by our competitors or by non-practicing entities. We may also face allegations that our employees have misappropriated the intellectual property rights of their former employers or other third parties. Litigation may make it necessary to defend ourselves by determining the scope, enforceability and validity of third-party proprietary rights, or to establish our proprietary rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, such litigation can be time consuming, divert management attention and financial resources and are costly to evaluate and defend. There can be no assurance with respect to the outcome of any current or future litigation brought by or against us, and the outcome of any such litigation could have a material adverse impact on our business, operating results and financial condition. Litigation is inherently unpredictable, and outcomes are uncertain. Further, as the costs and outcome of such litigation can vary significantly, it is difficult to estimate potential losses that may occur. As a result of such litigation, we may be required to stop treating certain conditions, obtain licenses or modify our products and features while we develop non-infringing substitutes, or may result in significant settlement costs or royalty obligations. For example, litigation can involve substantial damages for infringement, and if the court finds that the

53


 

infringement was willful, we could be ordered to pay treble damages and the patent owner’s attorneys’ fees. We may also be prohibited from selling or licensing our products unless the third-party licenses rights to us, which it is not required to do at a commercially reasonable price or at all. If a license is available from a third party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual property rights for our products. We may also have to redesign our products so they do not infringe third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time, during which our products may not be available for manufacture, use or sale. Accordingly, we are unable at this time to estimate the effects of these potential future lawsuits on our financial condition, operations or cash flows.

Additionally, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

Although we have reviewed certain third-party patents and patent filings that we believe may be relevant to our product candidates, we have not conducted a comprehensive freedom-to-operate search or analysis for any of our product candidates, and we may not be aware of patents or pending or future patent applications that, if issued, would block us from commercializing our product candidates. Additionally, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to commercialize our product candidates. Thus, we cannot guarantee that our activities related to their product candidates, or our commercialization, do not and will not infringe any third party’s intellectual property.

In addition, patent applications in the United States and many other jurisdictions are typically not published until 18 months after the filing of certain priority documents (or, in some cases, are not published until they issue as patents), and publications in the scientific literature often lag behind actual discoveries. Therefore, we cannot be certain that others have not filed patent applications or made public disclosures relating to our technology or our contemplated technology. A third party may have already filed, and may in the future file, patent applications covering our product candidates or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, depending on whether the timing of the filing date falls under certain patent laws, we may have to participate in a priority contest (such as an interference proceeding) declared by the United States Patent and Trademark Office, or the USPTO, to determine priority of invention in the United States. The costs of patent litigation and other proceedings related to the protection of our global patent position could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our patent position with respect to such invention.

If we are unable to obtain, maintain and enforce intellectual property protection directed to our current and any future technologies that we develop, others may be able to make, use or sell products substantially the same as ours, which could adversely affect our ability to compete in the market.

The market for pharmaceuticals and biopharmaceuticals is highly competitive and subject to rapid technological change. Our success depends, in part, upon our ability to maintain a competitive position in the development and protection of technologies and any future products for use in these fields and upon our ability to obtain, maintain and enforce our intellectual property rights. We seek to obtain and maintain patents and other intellectual property rights to restrict the ability of others to market products that misappropriate our technology and/or infringe our intellectual property to unfairly and illegally compete with any future products. If we are unable to protect our intellectual property and proprietary rights, including due to the impact of the COVID-19 pandemic on our business operations, our competitive position and our business could be harmed, as third parties may be able to make, use or sell products that are substantially the same as any future products we may sell without incurring the sizeable development and licensing costs that we have incurred, which would adversely affect our ability to compete in the market.

We use a combination of patents, trademarks, know-how, confidentiality procedures and contractual provisions to protect our proprietary technology. However, these protections may not be adequate and may not provide us with any competitive advantage. For example, patents may not issue from any of our currently pending or any future patent applications, and our issued patents and any future patents that may issue may not survive legal challenges to their scope, validity or enforceability, or provide significant protection for us.

We have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products. In addition, we cannot be sure that any of our pending patent applications or pending trademark applications will issue or that, if issued, they will issue in a form that will provide adequate protection for our

54


 

products. The USPTO, patent offices in other jurisdictions, or judicial or other bodies in any jurisdiction may deny or significantly narrow claims made under our patent applications, and claims in our issued patents may be invalidated, may be designed around or may otherwise be unable to provide us with protection for our products. Further, the USPTO, trademark offices in other jurisdictions, or judicial or other bodies in any jurisdiction may deny our trademark applications and, even if published or registered, these trademarks may not effectively protect our brand and goodwill. Like patents, trademarks also may be successfully opposed or challenged.

We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse engineering of our technology that is material to our business. Moreover, third parties may independently develop technologies that are competitive with ours and such competitive technologies may or may not infringe our intellectual property. The enforcement of our intellectual property rights also depends on the success of any legal actions we may take against these third parties in the respective country or forum, but these actions may not be successful. As with all granted intellectual property, such intellectual property may be challenged, invalidated or circumvented, may not provide protection and/or may not prove to be enforceable in actions against specific alleged infringers.

If we or any future collaborators we may have were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or future product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including obviousness or lack of novelty, enablement or written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before the USPTO even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution, or that a defendant would not prevail on an assertion of invalidity based on prior art that we were aware of during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business.

Even if claims in our patents survive assertions of invalidity and unenforceability, they may not be broad enough to prevent others from marketing products similar to ours or designing around our patents. For example, third parties may be able to make products that are similar to ours but that are not covered by the claims of our patents. The claims of our issued patents or patent applications when issued may not cover our product candidates or any future products that we develop.

Patent law can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the United States and in many other jurisdictions, policies regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme Court and the Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, courts in other jurisdictions have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international legislative bodies. Those changes may materially affect the patents and patent applications of our licensors, our existing or future patents and patent applications and our ability to obtain additional patents in the future.

Patent reform legislation in the United States could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a “first-to-invent” system to a “first-to-file” system. Under a “first-to-file” system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-to-file provisions, only became effective on March 16, 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, which could have a material adverse effect on our business and financial condition. Any future changes in the patent laws of the United States, or even the possibility of such changes, may further increase these uncertainties and costs.

The USPTO and various patent agencies in other jurisdictions require compliance with a number of procedural, documentary, fee, annuity payment and other provisions to maintain patent applications and issued patents. Although an inadvertent lapse, including due to the effect of the COVID-19 pandemic on us or our patent maintenance vendors, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

55


 

In addition, we have a number of patents and patent applications outside of the United States and expect to continue to pursue patent protection in many of the significant markets in which we intend to do business. The laws of some international jurisdictions do not protect intellectual property rights to the same extent as laws in the United States, and many companies have encountered significant difficulties in obtaining, protecting and defending such rights in certain jurisdictions outside of the United States. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights in international jurisdictions, our business, financial condition, results of operations and prospects could be materially and adversely affected. Earlier patent filings in certain international countries may also permit third parties to allege priority to certain technology in those countries.

Patent terms may be shortened or lengthened in certain jurisdictions by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates and patent term extensions. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may not significantly lengthen patent term. Non-payment or delay in payment of patent extension filing (including any patent term extension or adjustment filing) fees, whether intentional or unintentional, may also result in the loss of patent rights important to our business. Certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. In addition, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.

Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our competitors’ products, and may in the future seek to enforce our patents or other rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Our competitors may also independently develop similar technology. Any inability to meaningfully protect our intellectual property could result in competitors offering products competitive to our products. In addition, we may need to defend our patents from third-party challenges, such as interferences, derivation proceedings, re-examination proceedings, post-grant review, inter partes review, third-party submissions, oppositions, nullity actions or other patent proceedings. We may need to initiate infringement claims or litigation.

Adverse proceedings such as litigation can be expensive, time consuming and may divert the efforts of our technical and managerial personnel, which could in turn materially and adversely affect our business, financial condition, results of operations and prospects, whether or not we receive a determination favorable to us. In addition, in an infringement proceeding, a court or other judicial body may decide that the patent we seek to enforce is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that the patent in question does not cover the technology in question or that stopping the other party would harm the public interest. An adverse result in any litigation could put one or more of our patents at risk of being invalidated or interpreted narrowly. Some of our competitors may be able to devote significantly more resources to intellectual property litigation, and may have significantly broader patent portfolios to assert against us if we assert our rights against them. Further, because of the substantial discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be disclosed or otherwise compromised during litigation.

We may not be able to correctly estimate or control our future operating expenses in relation to obtaining intellectual property, enforcing intellectual property and/or defending intellectual property, which could affect operating expenses. Our operating expenses may fluctuate significantly in the future as a result of a variety of factors, including the costs of preparing, filing, prosecuting, defending and enforcing patent and trademark claims and other intellectual property-related costs, including adverse proceedings and litigation costs.

If we are unable to prevent disclosure of our trade secrets or other confidential information to third parties, our competitive position may be impaired.

In addition to the protection afforded by patents, we rely on confidentiality agreements to protect confidential information and proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. Furthermore, the laws of some other jurisdictions do not protect proprietary rights to

56


 

the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and in other jurisdictions. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. The failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

We license patent rights from third-party owners. Such licenses may be subject to early termination if we fail to comply with our obligations in our licenses with third parties, which could result in the loss of rights or technology that are material to our business.

We are or may become a party to licenses that give us rights to third-party intellectual property that are necessary or useful for our business, and we may enter into additional licenses in the future. Under these license agreements, we are or may become obligated to pay the licensor fees, which may include annual license fees, milestone payments, royalties, a percentage of revenues associated with the licensed technology and a percentage of sublicensing revenue. These fees may be significant, which could make it difficult for us to achieve or maintain profitability. In addition, under certain of such agreements, we are or may become required to diligently pursue the development of products using the licensed technology. If we fail to comply with these obligations including due to the impact of the COVID-19 pandemic on our business operations or our use of the intellectual property licensed to us in an unauthorized manner, and fail to cure our breach within a specified period of time, the licensor may have the right to terminate the applicable license, in which event we could lose valuable rights and technology that are material to our business, harming our ability to develop, manufacture and/or commercialize our platform or product candidates. If the licensor retains control of prosecution of the patents and patent applications licensed to us, we may have limited or no control over the manner in which the licensor chooses to prosecute or maintain its patents and patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor elects to abandon.

If the licensor retains control of prosecution of the patents and patent applications licensed to us, we may have limited or no control over the manner in which the licensor chooses to prosecute or maintain its patents and patent applications and have limited or no right to continue to prosecute any patents or patent applications that the licensor elects to abandon.

The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.

Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.

Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.

We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.

Our product candidates may also require specific components to work effectively and efficiently, and rights to those components may be held by others. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition and results of operations.

57


 

We jointly own certain patent rights with third parties. Our ability to out-license these patent rights, or to prevent the third party from out-licensing these patent rights, may be limited in certain countries.

We jointly own certain patents and patent applications with third parties, and may jointly own patents and patent applications with third parties in the future. Unless we enter into an agreement with the joint owner, we will be subject to certain default rules pertaining to joint ownership. Certain countries require the consent of all joint owners to license jointly owned patents, and if we are unable to obtain such consent from the joint owner, we may not be able to license our rights under these patents and patent applications. In certain other countries, including the United States, the joint owner could license its rights under these patents and patent applications to another party without our consent and without any duty of accounting to us.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may also be subject to claims that former employees, any future collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and could even face litigation for infringing patents that we had regarded as ours. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees.

We or our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as national governments, such that we or our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our patents, including in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, declared generic or conflict with third-party rights. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition with potential partners, physicians or patients in our markets of interest. During trademark registration proceedings, our trademark applications may be rejected. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties can oppose pending trademark applications and seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Furthermore, third parties may file first for our trademarks in certain countries. If they succeeded in registering such trademarks, and if we are not successful in challenging such third-party rights, we may not be able to use these trademarks to market our future products in those countries. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. In such cases, over the long term, if we are unable to establish and maintain name recognition based on our trademarks and trade names, then our commercial success abilities may be impacted.

Moreover, any name we propose to use with our product candidates in the United States or any other country must be approved by the FDA, EMA or any other relevant health authority regardless of whether we have registered it, or applied to register it, as a trademark. The FDA as well as EMA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA, EMA or any other relevant approval authority objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA, EMA or any other relevant approval authority.

We may not be able to protect our intellectual property rights throughout the world.

Filing and prosecuting patent applications, and defending patents, related to our product candidates in all countries throughout the world would be prohibitively expensive, and the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may export otherwise infringing products to territories where we have patent protection but

58


 

enforcement is not as strong as that in the United States. These products may compete with any future products we may sell, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals and biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Risks Related to Government Regulation

Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.

If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.

We will have to comply with requirements concerning advertising and promotion for any future products. Promotional communications with respect to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s approved label. We may not promote products for indications or uses for which they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety, purity, potency and/or efficacy of our products in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

issue warning letters;
impose civil or criminal penalties;
suspend or withdraw regulatory approval;
suspend any of our clinical trials;
refuse to approve pending applications or supplements to approved applications submitted by us;
impose restrictions on our operations, including closing our contract manufacturers’ facilities; or
seize or detain products, or require a product recall.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from any future products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.

59


 

Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.

Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set.

In the United States, the EU and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical, biopharmaceutical and biotechnology industries include the following:

an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents (other than those designated as Orphan Drugs), which is apportioned among these entities according to their market share in certain government healthcare programs;
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D;
new requirements to report certain financial arrangements with physicians and teaching hospitals, including reporting “transfers of value” made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members;
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;
extension of a manufacturer’s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate liability;
a licensure framework for follow on biologic products;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
establishment of a Center for Medicare and Medicaid Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.

Since its enactment, there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on the constitutionality of the ACA. Prior to the U.S. Supreme Court’s decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures will impact our business.

60


 

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, or AMP, beginning January 1, 2024. Most recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (HHS) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated.

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could materially and adversely affect our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.

In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.

We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or judicial action in the United States, the EU or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

If we develop a small molecule product candidate that obtains regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products.

Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may submit an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a NDA under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA’s prior findings of safety and effectiveness of the small molecule innovator product. For example, a 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” known as the Orange Book. If

61


 

there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in their applications what is known as a “Paragraph IV” certification, challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the patent owner and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 505(b)(2) NDA is stayed for up to 30 months.

Accordingly, if our small molecule program results in a product that is approved, competitors could submit ANDAs for generic versions of our small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.

We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially.

Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, without limitation:

the U.S. federal civil and criminal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
the U.S. federal false claims laws, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
the Health Insurance Portability and Accountability Act of 1996, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;
the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians, as defined by such law, certain non-physician providers such as physician assistants and nurse practitioners, and

62


 

teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members;
analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state and local laws that require the registration of pharmaceutical sales representatives; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and
the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof.

Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, such as the provision of stock options to physicians who may influence the ordering, prescribing or use of our product candidates, if approved, as compensation for consulting services, do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

Risks Related to Our Common Stock

Our stock price has been volatile, and in the future, may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.

The trading price of our common stock has been, and in the future, may be subject to substantial volatility and wide fluctuations in response to various factors, some of which are beyond our control. In particular, the trading prices for pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of extreme volatility and disruptions in the global economy, including rising inflation and interest rates, declines in economic growth, the conflict between Russia and Ukraine, the COVID-19 pandemic and uncertainty about economic stability. These factors include those discussed in this “Risk Factors” section and others such as:

results from, and delays in, our clinical trials for our product candidates or any other future clinical development programs, including delays related to the COVID-19 pandemic;
announcements of regulatory approval or disapproval of our current or any future product candidates;
failure or discontinuation of any of our research and development programs;
the termination of any of our existing license agreements;
announcements relating to any future licensing, collaboration or development agreements;
delays in the commercialization of our current or any future product candidates;
public misperception regarding the use of our product candidates;
acquisitions and sales of new products or product candidates, technologies or businesses;
manufacturing and supply issues related to our product candidates for clinical trials or future product candidates for commercialization;
quarterly variations in our results of operations or those of our competitors;

63


 

changes in earnings estimates or recommendations by securities analysts;
announcements by us or our competitors of new products or product candidates, significant contracts, commercial relationships, acquisitions or capital commitments;
developments with respect to intellectual property rights;
our commencement of, or involvement in, litigation;
changes in financial estimates or guidance;
any major changes in our board of directors or management;
new legislation or regulation in the United States relating to the sale or pricing of pharmaceuticals;
FDA or other U.S. or foreign regulatory actions affecting us or our industry;
product liability claims or other litigation or public concern about the safety of our product candidates;
market conditions in the pharmaceutical, biopharmaceutical and biotechnology sectors;
general economic conditions in the United States and abroad, including as a result of an economic recession or depression and market volatility related to the COVID-19 pandemic, the current inflationary economic environment, rising interest rates and global health concerns;
sales of our common stock, including sales by our officers, directors and specific existing stockholders; and
the issuance of shares of our common stock pursuant to the exercise of outstanding warrants.

In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock.

An active, liquid and orderly market for our common stock may not develop, and you may not be able to resell your common stock at or above the price you paid.

Prior to our IPO in July 2020, there was no public market for shares of our common stock, and an active public trading market for our shares may not develop or, if it is developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other product candidates, businesses or technologies using our shares as consideration.

We are a “smaller reporting company,” and as a result of the reduced disclosure and governance requirements applicable to smaller reporting companies, our common stock may be less attractive to investors.

As of June 30, 2022, we re-qualified as a smaller reporting company. We are therefore entitled to take advantage of many of the same exemptions from disclosure requirements as an emerging growth company, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. In addition, as a smaller reporting company with less than $100 million in annual revenue, we are exempt from the requirement to obtain an auditor attestation on the effectiveness of our internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects.

We incur significant costs as a result of operating as a public company, and our management needs to devote substantial time to compliance initiatives. We may fail to comply with the rules that apply to public companies, which could result in sanctions or other penalties that could materially and adversely affect our business, financial condition, results of operations and prospects.

We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Stock Market and the rules of the SEC require that we satisfy certain corporate governance requirements relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel needs to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, these reporting requirements, rules and regulations increase our legal and financial compliance costs

64


 

and make some activities more time-consuming and costly. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’ and officers’ insurance, on acceptable terms.

If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations which may adversely affect investor confidence in us and, as a result, the value of our common stock.

We are subject to Section 404 of the Sarbanes-Oxley Act, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Pursuant to Section 404(a), we are required to file with the SEC an annual management assessment of the effectiveness of our internal control over financial reporting. Because we re-qualified as a smaller reporting company and we have less than $100 million in annual revenue, at the end of this fiscal year, we will be a non-accelerated filer and will no longer be required to comply with the auditor attestation requirements regarding the effectiveness of our internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act until we become an accelerated filer or large accelerated filer.

Our management’s assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual and interim financial statements will not be detected or prevented on a timely basis. If we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:

faulty human judgment and simple errors, omissions or mistakes;
fraudulent action of an individual or collusion of two or more people;
inappropriate management override of procedures; and
the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.

While we believe our internal control over financial reporting is currently effective, the effectiveness of our internal controls in future periods is subject to the risk that our controls may become inadequate because of changes in conditions. Establishing, testing and maintaining an effective system of internal control over financial reporting requires significant resources and time commitments on the part of our management and our finance staff, may require additional staffing and infrastructure investments and would increase our costs of doing business. We can give no assurance that material weaknesses in our internal control over financial reporting will not be identified in the future. Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. Effective internal control over financial reporting is necessary for us to provide reliable and timely financial reports and, together with adequate disclosure controls and procedures, are designed to reasonably detect and prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Select Market or other adverse consequences that would materially and adversely affect our business, financial condition, results of operations and prospects.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of September 30, 2022, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned a majority of our outstanding voting stock. In addition, in our July 2022 private placement, certain of the holders of 5% or more of our capital stock acquired pre-funded warrants to purchase shares of our common stock (which are immediately exercisable and have an exercise price of $0.001 per share) and common warrants to purchase shares of our common stock (which are immediately exercisable and have an exercise price of $5.806875 per share). Until exercised, the shares issuable upon the exercise of the pre-funded warrants and the common warrants are not included in the number of our outstanding shares of common stock. If such holders exercise their warrants, then the shares of our capital stock beneficially owned by our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates would increase significantly. Therefore, these stockholders will have the

65


 

ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

Our current shares outstanding and resulting market valuation do not reflect shares of our common stock issuable upon the exercise of pre-funded warrants and common warrants that are exercisable at the discretion of the holders of such warrants. If we sell shares of our common stock in the future, stockholders may experience immediate dilution. Stockholders may be unable to compute the dilutive impact of future financings.

We may from time to time issue additional shares of common stock, and as a result, our stockholders would experience immediate dilution. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. For example, in August 2021, we entered into a sales agreement with Cowen, as sales agent, pursuant to which we may issue and sell shares of our common stock for an aggregate maximum offering price of $100.0 million under an at-the-market offering program. In addition, in July 2022, we closed a private placement which included the sale of pre-funded warrants and common warrants to purchase shares of our common stock. Until exercised, the shares issuable upon the exercise of the pre-funded warrants or the common warrants are not included in the number of our outstanding shares of common stock. If we issue common stock or securities convertible into common stock in the future, our stockholders would experience additional dilution and such dilutive impact may be difficult to compute.

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of September 30, 2022, the number of shares of our common stock outstanding was 47,626,503. This number does not include 24,696,206 shares of common stock issuable upon the exercise of pre-funded warrants or 8,427,508 shares of common stock issuable upon the exercise of common warrants. We agreed to file a resale registration statement with the SEC to register the shares of common stock and the shares of common stock issuable upon exercise of the pre-funded warrants and the common warrants sold in the July 2022 private placement. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, may reduce the trading price of our common stock.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our ability to utilize our pre-change NOLs or credits if we undergo a future ownership change. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which are outside our control). As a result, our ability to use our pre-change NOLs and tax credits to offset future taxable income or income tax liabilities, if any, could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.

Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.

Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:

a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;
no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
the exclusive right of our board of directors to elect a director to fill a vacancy, however occurring, including by an expansion of the board of directors, which prevents stockholders from being able to fill vacancies on our board of directors;

66


 

the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including voting or other rights or preferences, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;
the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;
the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;
a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and
advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.

We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction.

As a California-domiciled public company, we are required to have a certain number of women and directors from underrepresented communities on our board of directors on certain timeframes, depending on the size of our board at the time.

Our success depends in part on our continued ability to attract, retain and motivate highly qualified individuals to our board of directors. As a public company headquartered in California, we were required to have three women and at least one director from an underrepresented community on our board of directors by the end of 2021 and two or three directors from an underrepresented community on our board of directors by the end of 2022, depending on the size of our board of directors at the time. We had one woman on our board of directors at the end of 2021, and we may be fined for failure to meet the California requirements. While we currently have two women and four directors from underrepresented communities on the board of directors, recruiting and retaining board members carries uncertainty, and failure to comply with these California requirements will result in financial penalties.

Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.

In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:

we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;
we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;
we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;
we are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;

67


 

the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and
we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.

While we maintain a directors’ and officers’ insurance policy, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may adversely impact our cash position.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for certain disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America are the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.

This choice of forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.

We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.

General Risk Factors

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and

68


 

may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with any future products we may sell, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals and biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. Generally, future changes in applicable U.S. and non-U.S. tax laws and regulations, or their interpretation and application, could have an adverse effect on our business, financial conditions and results of operations. We are unable to predict whether such changes will occur and, if so, the ultimate impact on our business.

We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

Significant disruptions of information technology systems, breaches of data security and other incidents could materially adversely affect our business, results of operations and financial condition.

We collect and maintain information in digital and other forms that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the privacy, security, confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may have access to our confidential information. Our internal information technology systems and infrastructure, and those of any future collaborators and our contractors, consultants, vendors and other third parties on which we rely, are vulnerable to attack, damage and interruption from computer viruses, malware (e.g., ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks, denial or degradation of service attacks, hacking, sophisticated nation-state and nation-state supported actors, phishing and other social

69


 

engineering attacks, attachments to emails, fraud, employee theft or misuse, and unauthorized access or use by persons inside our organization or persons with access to systems inside our organization.

The risk of a security breach or disruption, particularly through cyber-attacks, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. The prevalent use of mobile devices that access confidential information also increases the risk of lost or stolen devices, security incidents and data security breaches, which could lead to the loss of confidential information or other intellectual property. Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. As a result of the COVID-19 pandemic, we may also face increased risks of a security breach or disruption due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cyber criminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.

We and certain of our service providers are from time to time, subject to cyber-attacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or our critical third parties’ operations, it could result in a material disruption of our product development programs, and ultimately, our financial results. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. The costs to us to investigate, mitigate and remediate security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, negative publicity and other harm to our business and our competitive position. Any security compromise affecting us, our partners or our industry, whether real or perceived, could harm our reputation, erode confidence in the effectiveness of our security measures and lead to regulatory scrutiny. Moreover, if a computer security breach affects our systems or results in the unauthorized access to or unauthorized use, disclosure, release or other processing of personal information or clinical trial data, it may be necessary to notify individuals, governmental authorities, supervisory bodies, the media and other parties pursuant to privacy and security laws, and our reputation could be materially damaged. We would also be exposed to a risk of loss, governmental investigations or enforcement, or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.

Actual or perceived failure to comply with applicable data protection laws, regulations, standards and other requirements could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.

We and our current and future collaborators are or may become subject to federal, state and foreign data protection laws and regulations governing data privacy and security. In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy laws and consumer protection laws, including Section 5 of the Federal Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information, may apply to our operations and the operations of current and future collaborators.

In the United States, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, or collectively, HIPAA, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. We do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. Depending on the facts and circumstances, however, we could be subject to significant administrative, civil and criminal penalties if we obtain, use or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.

Further, various states have implemented similar privacy laws and regulations. For example, the California Consumer Privacy Act of 2018, or the CCPA, went into effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. It also provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy

70


 

Rights Act, or the CPRA, recently passed in California. The CPRA significantly amends the CCPA and will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. Similar laws have passed in Virginia, Colorado, Connecticut, Utah, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.

Foreign data protection laws, including the European Union General Data Protection Regulation, or the GDPR, may also apply to health-related and other personal data of data subjects in the European Economic Area, or EEA. The GDPR went into effect on May 25, 2018, and companies that must comply with the GDPR face increased compliance obligations and risk, including robust regulatory enforcement of data protection requirements as well as potential fines for noncompliance of up to €20 million or 4% of annual global revenue of the noncompliance company, whichever is greater. The GDPR imposes numerous requirements for the collection, use, storage and disclosure of personal data of EEA data subjects, including requirements relating to providing notice to and obtaining consent from data subjects, personal data breach notification, cross-border transfers of personal data, and honoring and providing for the rights of EEA individuals in relation to their personal data, including the right to access, correct and delete their data. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework for data transferred from the EU to the United States, called the Privacy Shield, but the Court of Justice of the EU, or the CJEU, invalidated the Privacy Shield in July 2020 and imposed further restrictions on use of the standard contractual clauses, or SCCs. In March 2022, the EU and the United States announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-US Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for Untied States Signals Intelligence Activities. The restrictions on use of SCCs include a requirement for companies to carry out a transfer impact assessment which, among other things, assesses the laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. The European Commission issued revised SCCs on June 4, 2021 to account for the decision of the CJEU and recommendations made by the European Data Protection Board. The revised SCCs must be used for relevant new data transfers from September 27, 2021; existing standard contractual clauses arrangements must be migrated to the revised clauses by December 27, 2022. The new SCCs apply only to the transfer of personal data outside of the EEA and not the UK. The UK’s Information Commissioner’s Office has published new data transfer standard contracts for transfers from the UK under the UK GDPR. This new documentation will be mandatory for relevant data transfers from September 21, 2022; existing standard contractual clauses arrangements must be migrated to the new documentation by March 21, 2024. There is some uncertainty around whether the revised clauses can be used for all types of data transfers, particularly whether they can be relied on for data transfers to non-EEA entities subject to the GDPR. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.

Further, from January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in United Kingdom, or UK, national law. The UK GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of €20 million (£17.5 million) or 4% of global turnover. The relationship between the UK and the EU in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term. The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data transfers from EU member states to the United Kingdom without additional safeguards. However, the UK adequacy decision will automatically expire in June 2025 unless the European Commission re-assesses and renews or extends that decision. In September 2021, the UK government launched a consultation on its proposals for wide-ranging reform of UK data protection laws following Brexit and the response to this consultation was published in June 2022. There is a risk that any material changes which are made to the UK data protection regime could result in the European Commission reviewing the UK adequacy decision, and the UK losing its adequacy decision if the European Commission deems the UK to no longer provide adequate protection for personal data.

The EU has also proposed a Regulation on Privacy and Electronic Communications, or ePrivacy Regulation, which, if adopted, would impose new obligations on the use of personal data in the context of electronic communications, particularly with respect to online tracking technologies and direct marketing. Additionally, the EU adopted the EU Clinical Trials Regulation, which came into effect on January 31, 2022. This regulation imposes new obligations on the use of data generated from clinical trials and enables European patients to have the opportunity to access information about clinical trials. Failure or perceived failure to comply with the

71


 

GDPR, the UK GDPR, the ePrivacy Regulation, the EU Clinical Trials Regulations, and other countries’ privacy or data security-related laws, rules or regulations could result in significant regulatory penalties and fines, and affect our compliance with contracts entered into with our partners, collaborators and other third parties.

Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could materially and adversely affect our business, financial condition, results of operations and prospects.

Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Compliance with these data protection laws and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners’ or suppliers’ ability to operate in certain jurisdictions. Any actual or perceived failure to comply by us or our employees, representatives, contractors, consultants, collaborators, or other third parties could result in government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business.

If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

We may be subject to securities litigation, which is expensive and could divert our management’s attention.

In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management’s attention from other business concerns.

 

72


 

Item 2. Recent Sales of Unregistered Securities and Use of Proceeds.

(a) Sales of Unregistered Securities

As described above, on July 11, 2022, we sold in a private placement an aggregate of 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of our common stock and accompanying common warrants to purchase up to 8,427,508 shares of our common stock. Please see our Current Report on Form 8-K filed with the SEC on July 8, 2022 and Note 6—Stockholders’ Equity to our unaudited condensed consolidated financial statements for additional information regarding the pre-funded warrants and the common warrants.

(b) Use of Proceeds from Public Offering of Common Stock

On July 23, 2020, our registration statement on Form S-1, as amended (Registration No. 333-239647), was declared effective in connection with our IPO. There has been no material change in the planned use of proceeds from our IPO as described in the registration statement on Form S-1. We invested the funds received in cash equivalents and other marketable securities in accordance with our investment policy.

(c) Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

 

73


 

Item 6. Exhibits.

EXHIBIT INDEX

 

Exhibit No

 

Description of Exhibit

 

Incorporated by Reference

 

 

 

 

 

 

Form

 

File No.

 

Exhibit

 

Filing Date

 

Filed

Herewith

 

 

 

 

 

 

 

 

 

 

    3.1

 

Amended and Restated Certificate of Incorporation.

 

8-K

 

001-39402

 

3.1

 

07/28/20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    3.2

 

Amended and Restated Bylaws.

 

8-K

 

001-39402

 

3.2

 

07/28/20

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    4.1

 

Form of Pre-Funded Warrant.

 

8-K

 

001-39402

 

4.1

 

07/08/22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    4.2

 

Form of Common Warrant.

 

8-K

 

001-39402

 

4.2

 

07/08/22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  10.1

 

Securities Purchase Agreement, dated July 7, 2022, by and among the Registrant and the Purchasers named within.

 

8-K

 

001-39402

 

10.1

 

07/08/22

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  10.2(a)#

 

Annexon, Inc. 2022 Employment Inducement Award Plan.

 

10-Q

 

001-39402

 

10.2(a)#

 

08/08/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  10.2(b)#

 

Form of Stock Option Grant Notice and Stock Option Agreement under the 2022 Employment Inducement Award Plan.

 

10-Q

 

001-39402

 

10.2(b)#

 

08/08/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  10.2(c)#

 

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Employment Inducement Award Plan.

 

10-Q

 

001-39402

 

10.2(c)#

 

08/08/2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

  31.2

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

  32.1*

 

Certification Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

74


 

 

 

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

 

 

104

 

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 

 

 

 

X

 

# Indicates management contract or compensatory plan.

* The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, is not deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall Exhibit 32.1 be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

 

75


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

Annexon, Inc.

Date: November 3, 2022

By:

 

/s/ Douglas Love, Esq.

 

 

 

Douglas Love, Esq.

 

 

 

President and Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

Date: November 3, 2022

By:

 

/s/ Jennifer Lew

 

 

 

Jennifer Lew

 

 

 

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 

76


EX-31.1 2 annx-ex31_1.htm EX-31.1 EX-31.1

 

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS AMENDED

I, Douglas Love, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Annexon, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 3, 2022

 

By:

/s/ Douglas Love

 

 

 

Douglas Love, Esq.

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

 


EX-31.2 3 annx-ex31_2.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS AMENDED

I, Jennifer Lew, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Annexon, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 3, 2022

 

By:

/s/ Jennifer Lew

 

 

 

Jennifer Lew

 

 

 

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 


EX-32.1 4 annx-ex32_1.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002, AS AMENDED

In connection with the Quarterly Report on Form 10-Q of Annexon, Inc. (the “Company”) for the quarter ended September 30, 2022 (the “Report”) filed with the Securities and Exchange Commission on the date hereof, Douglas Love, President and Chief Executive Officer of the Company, and Jennifer Lew, Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended, that:

1.
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 3, 2022

 

 

/s/ Douglas Love

 

 

 

Douglas Love, Esq.

 

 

 

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

Date: November 3, 2022

 

 

/s/ Jennifer Lew

 

 

 

Jennifer Lew

 

 

 

Executive Vice President and Chief Financial Officer

(Principal Financial and Accounting Officer)

 


EX-101.CAL 5 annx-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 6 annx-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 annx-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Entity Address, City or Town Other current liabilities Increase (Decrease) in Other Current Liabilities Entity Ex Transition Period Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Fair Value Disclosures [Abstract] Accounting Standards Update and Change in Accounting Principle [Table] Earnings Per Share [Abstract] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Summary of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Computer Equipment and Software [Member] Computer Equipment And Software [Member] Computer equipment and software. Issuance of common stock, net of issuance costs of issuance costs Stock Issued During Period, Value, New Issues Sale of shares Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Operating lease, expiration month and year Lessee Operating Lease Expiration Month And Year Lessee, operating lease, expiration month and year. Amendment Flag Amendment Flag Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment included in accounts payable and accrued liabilities Unvested Restricted Stock Units Outstanding [Member] Unvested Restricted Stock Units Outstanding [Member] Unvested restricted stock units outstanding. Operating lease right-of-use asset Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Document Quarterly Report Document Quarterly Report Proceeds from Sale of Debt Securities, Available-for-Sale Proceeds from sale of available-for-sale securities Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net Loss Per Share Attributable to Common Stockholders Earnings Per Share, Policy [Policy Text Block] Statement [Table] Statement [Table] Operating lease liabilities, non-current Operating Lease, Liability, Noncurrent Percentage of gross proceeds of common stock to be paid Percentage Of Gross Proceeds Of Common Stock To Be Paid Percentage of gross proceeds of common stock to be paid. Change in accounting principle, ASU, Immaterial effect Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock per Employee Stock Purchase Plan, Shares Common stock for future issuance Common stock reserved Common Stock, Capital Shares Reserved for Future Issuance Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of September 30, 2022 Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2021 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Shares Subject to Employee Stock Purchase Plan [Member] Employee Stock [Member] Employees [Member] Combined voting power Combined Voting Power Percentage Combined voting power percentage. Stock Options Issued and Outstanding [Member] Stock Options to Purchase Common Stock [Member] Options Issued and Outstanding [Member] Deferred offering costs included in accrued liabilities. Deferred Offering Costs Included In Accrued Liabilities Deferred offering costs included in accrued liabilities Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Total liabilities and stockholders’ equity Liabilities and Equity Other Liabilities, Current, Total Other current liabilities Other Liabilities, Current Change in accounting principle, ASU adopted Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Statement [Abstract] Proceeds from Stock Plans Proceeds from employee stock plan purchases Sale of Stock Sale of Stock [Domain] Total current liabilities Liabilities, Current Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock per Employee Stock Purchase Plan 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Loss Contingency Nature Loss Contingency Nature [Axis] Long-term Purchase Commitment, Category of Item Purchased Long-Term Purchase Commitment, Category of Item Purchased [Domain] Share purchases funded through payroll deductions maximum percentage of employee's eligible compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Common Stocks, Including Additional Paid in Capital, Net of Discount [Abstract] Entity Small Business Entity Small Business Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total Beginning of period End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] ASU 2020-06 [Member] Accounting Standards Update 2020-06 [Member] Disclosure Of Balance Sheet Components [Abstract] Disclosure Of Balance Sheet Components [Abstract] Total current assets Assets, Current Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2022 (remaining six months) Warrants Warrants Disclosure [Text Block] Warrants Disclosure. Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average shares used in computing net loss per share attributable to common stockholders, basic Research and Development Arrangement [Member] Research and Development Arrangement [Member] City Area Code City Area Code Aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Organization Business Description and Basis of Presentation [Text Block] Number of shares, Stock options forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Payment Arrangement [Abstract] Total liabilities Liabilities Gain Contingencies [Line Items] Gain Contingencies [Line Items] Private Placement [Member] Private Placement Warrants [Member] Private Placement Document Period End Date Document Period End Date Deferred offering costs payment related to the 2021 ATM program Deferred offering costs payment Payments of Stock Issuance Costs New Accounting Pronouncements or Change in Accounting Principle [Line Items] Operating lease, renewal term Lessee, Operating Lease, Renewal Term Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Accrued compensation Accrued Compensation Current Accrued compensation, current Statistical Measurement Statistical Measurement [Axis] Aggregate sublease payment receivable Aggregate Sublease Payment Receivable Aggregate sublease payment receivable. Other current assets Other Assets, Current Total assets Assets Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net loss per share attributable to common stockholders, diluted Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Interest and other income, net Interest And Other Non Operating Income Expense Interest and other non operating income (expense). Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance Table Table [Text Block] Schedule of common stock reserved for future issuance table. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Fiscal Period Focus Document Fiscal Period Focus Restricted Cash, Total Restricted cash Restricted Cash Class of Warrant or Right [Table] Loss Contingency, Pending Claims, Number, Ending Balance Loss Contingency, Pending Claims, Number, Beginning Balance Loss contingency pending claims Loss Contingency, Pending Claims, Number APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Maximum number of shares to be issued in accordance with plan as a proportion of outstanding capital stock Maximum Number of Shares to be Issued in Accordance with Plan as a Proportion of Outstanding Capital Stock Maximum number of shares to be issued in accordance with plan as a proportion of outstanding capital stock. Counterparty Name Counterparty Name [Domain] Lease liability Operating Lease, Liability, Total Lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Statement of Financial Position [Abstract] Entity File Number Entity File Number Statement of Cash Flows [Abstract] Sublease income Sublease Income Warrants exercised Class of Warrant or Right, Number of Securities Called by Warrants or Rights Purchase of shares Class of Warrant or Right [Line Items] Geographical Geographical [Domain] Statistical Measurement Statistical Measurement [Domain] Statement of Stockholders' Equity [Abstract] Sale of Stock Sale of Stock [Axis] Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Prepaid research and development costs Prepaid Research And Development Costs Current prepaid research and development costs, current Class of Stock Class of Stock [Domain] Stock Options Reserved for 2020 Incentive Award Plan [Member] Stock Options Reserved for Two Thousand Twenty Incentive Award Plan [Member] Stock options reserved for two thousand twenty incentive award plan. Loss Contingency Accrual, Ending Balance Loss Contingency Accrual, Beginning Balance Loss contingency accrual Loss Contingency Accrual Stockholders' Equity Note [Abstract] Accrued research and development expenses Accrued Research And Development Expenses Current Accrued research and development expenses, current Subsequent Events [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Other comprehensive gain (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Weighted- average remaining contractual term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds from the exercise common stock options Proceeds from Stock Options Exercised Proceeds from issuance of common stock, net of issuance costs Proceeds from Issuance of Common Stock Summary of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Antidilutive Securities Antidilutive Securities [Axis] Loss Contingency, Nature Loss Contingency, Nature [Domain] Gross Unrealized Holding Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Cash, Cash Equivalents, and Short-term Investments, Total Cash and cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Subsequent Events [Text Block] Subsequent Events Weighted Average Number of Shares Outstanding, Diluted, Total Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted Corporate Debt [Member] Corporate Debt Securities [Member] General and Administrative [Member] General and Administrative Expense [Member] Unrecognized stock-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Commercial Paper [Member] Commercial Paper [Member] Short-Term Investments Short Term Investments Policy [Text Block] Short-term investments. Current Fiscal Year End Date Current Fiscal Year End Date Depreciation, Total Depreciation expense Depreciation Financial Instruments [Domain] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Beginning Balance Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Total other non-current assets Other non-current assets Other Assets, Noncurrent Maximum expected research funding Maximum Expected Research Funding Maximum Expected Research Funding Entity Address, Address Line One Entity Address, Address Line One Exchange value Common Shares Exchange Value Common shares exchange value. Additional common shares purchased Additional Stock Issued During Period Common Shares Purchased Additional stock issued during period common shares purchased. Accrued Liabilities, Current [Abstract] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Restricted cash Restricted Cash, Noncurrent Income Taxes Income Tax Disclosure [Text Block] Other accrued expenses Other Accrued Liabilities, Current Payments to Acquire Property, Plant, and Equipment, Total Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Income Tax Disclosure [Abstract] Sponsor research agreements, commitment amount Long-Term Purchase Commitment, Amount Change in accounting principle, ASU, adoption date Change in Accounting Principle, Accounting Standards Update, Adoption Date Sale of shares Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs of issuance costs, Shares Sale of shares Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Weighted average exercise price per share, Stock options forfeited Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Operating Income (Loss), Total Loss from operations Operating Income (Loss) 2021 ATM Program [Member] Two Zero Two One At The Market Program [Member] Two zero two one at the market program. Accrued professional services Accrued Professional Fees, Current Entity Filer Category Entity Filer Category Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party Proceeds from Related Parties For The Issuance of Common Stock Prefunded Warrants and Common warrants Proceeds from related parties for the issuance of common stock, Pre-funded warrants and common warrants. Total operating expenses Operating Expenses Entity Current Reporting Status Entity Current Reporting Status Asset Class Asset Class [Domain] Aggregate intrinsic value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Debt Securities, Available-for-sale, Current, Total Short-term investments Debt Securities, Available-for-Sale, Current Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Total stockholders’ equity Beginning Balance, Values Ending Balance, Values Stockholders' Equity Attributable to Parent Accumulated Other Comprehensive Loss [Member] AOCI Attributable to Parent [Member] Asset Class Asset Class [Axis] Entity Tax Identification Number Entity Tax Identification Number Income Statement Location Income Statement Location [Axis] Number of Shares, Cancelled Number of Shares, Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Total Common stock Common Stock, Value, Issued Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Total Accumulated deficit Retained Earnings (Accumulated Deficit) Equity Components Equity Components [Axis] Employment Inducement Award Plan [Member] Employment Inducement Award Plan Member Employment Inducement Award Plan Member Accounting Standards Update [Domain] Entity Emerging Growth Company Entity Emerging Growth Company Operating expenses: Operating Expenses [Abstract] Proceeds from maturities of available-for-sale securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs of issuance costs Adjustments to Additional Paid in Capital, Warrant Issued Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected volatility, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Document Transition Report Document Transition Report 2026 and thereafter Lessee Operating Lease Liability Payments Due Year Four And Thereafter Lessee operating lease liability payments due year four and thereafter. Common Warrants [Member] Common Warrants Member Common Warrants Member Weighted-Average Grant Date Fair Value Per Share, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Combined voting power maximum Combined Voting Power Maximum Percentage Combined voting power maximum percentage. Depreciation, Depletion and Amortization, Total Depreciation and amortization Depreciation, Depletion and Amortization Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block] Schedule of cash and cash equivalents and restricted cash. Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements Policy [Text Block] Recently Adopted Accounting Pronouncements Policy Text Block. Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Weighted- average exercise price per share, Stock options exercised Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income (loss) Net loss Net loss Net Income (Loss) Attributable to Parent Operating lease liabilities, current Operating Lease, Liability, Current Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Payment of issuance costs related to the issuance of common stock, pre-funded warrants and common warrants Payments of Common Stock and Warrants Issuance Costs Payments of common stock and warrants issuance costs. Summary of RSU Activity under 2020 Plan Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Document Information [Line Items] Entity Registrant Name Entity Registrant Name Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net Loss Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Class of Stock Class of Stock [Axis] Share-based Payment Arrangement, Noncash Expense, Total Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Statement of Comprehensive Income [Abstract] Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Total property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Award Type Award Type [Domain] Statement [Line Items] Statement [Line Items] Warrants Warrants Policy [Text Block] Warrants. Title of 12(b) Security Title of 12(b) Security Increase (Decrease) in Accounts Payable, Total Accounts payable Increase (Decrease) in Accounts Payable Common Stock [Member] Common Stock [Member] Option expiry period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Equity Component Equity Component [Domain] Purchases of available-for-sale securities Payments to Acquire Debt Securities, Available-for-Sale Entity Address, State or Province Entity Address, State or Province Geographical Geographical [Axis] Document Type Document Type Proceeds from funding Proceeds from Collaborators Exercise of common warrant, description Exercise of Warrant Description Exercise of warrant description. Entity Shell Company Entity Shell Company Warrants outstanding Class of Warrant or Right, Outstanding Total stock-based compensation expense Share-Based Payment Arrangement, Expense Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Corporate Bonds [Member] Corporate Bond Securities [Member] Security Exchange Name Security Exchange Name Class Of Stock [Line Items] Class of Stock [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Unrecognized stock-based compensation cost expected period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted- average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Commitments and Contingencies Disclosure [Abstract] Operating Lease, Cost Operating lease costs Unvested Restricted Stock Units [Member] Restricted Stock Units [Member] Restricted Stock Units (RSUs) [Member] Future Minimum Lease Payments and Related Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Common Warrants to Purchase Common Stock [Member] Warrant [Member] Warrants or Common Warrants [Member] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Accretion of discount on available-for-sale securities Accretion (Amortization) of Discounts and Premiums, Investments Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Debt Securities, Available-for-sale, Total Aggregate Fair Value Debt Securities, Available-for-Sale Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Brisbane, California [Member] Brisbane California [Member] Brisbane, California. Commitments and contingencies (Note 5) Commitments and Contingencies Minimum [Member] Minimum [Member] Government Bonds [Member] US Treasury Bond Securities [Member] Stock option grants description Share-Based Compensation Arrangement by Share-Based Payment Award, Description Risk-free interest rate, Maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Construction-in-progress obtained in exchange for tenant improvement allowance from lessors. Construction in Progress Obtained in Exchange for Tenant Improvement Allowance from Lessors Construction-in-progress obtained in exchange for tenant improvement allowance from lessors Weighted- average exercise price per share, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Accounting Standards Update [Axis] Total accrued liabilities Accrued liabilities Accrued Liabilities, Current Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Variable lease payments Variable Lease, Payment Counterparty Name Counterparty Name [Axis] Entity Address, Address Line Two Entity Address, Address Line Two Maximum threshold period allowed for filing market authorization Maximum Threshold Period Allowed For Filing Market Authorisation Maximum Threshold Period Allowed For Filing Market Authorisation Weighted-Average Grant Date Fair Value Per Share, Cancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Award Type Award Type [Axis] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Net proceeds from private placement Net proceeds from private placement Research and Development Expense, Total Research and development Research and Development Expense Total undiscounted lease payments Lessee, Operating Lease, Liability, to be Paid Operating lease, term of contract Lessee, Operating Lease, Term of Contract Entity Central Index Key Entity Central Index Key Warrant expiration date Warrants and Rights Outstanding, Maturity Date Accounting Policies [Abstract] Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs [Member] Incentive Stock Options And Nonstatutory Stock Options [Member] Incentive stock options and nonstatutory stock options. Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Common stock reserved Options available for future grant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Share-Based Payment Arrangement [Text Block] Equity Incentive Plans Prepaid insurance Prepaid Insurance General and Administrative Expense, Total General and administrative General and Administrative Expense Document Information [Table] Weighted- average exercise price per share, Beginning balance Weighted- average exercise price per share, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Research and Development [Member] Research and Development Expense [Member] Risk-free interest rate, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for lease liability Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accumulated Deficit [Member] Retained Earnings [Member] Notice period Warrant Notice Period Warrant notice period. Money Market Funds [Member] Money Market Funds [Member] Summary of Prepaid Expenses and Other Current Assets Summary Of Prepaid Expenses And Other Current Assets [Text Block] Summary of prepaid expenses and other current assets. Property, Plant and Equipment, Gross, Ending Balance Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Total Total property and equipment, gross Property, Plant and Equipment, Gross Additional Paid in Capital, Ending Balance Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Total Additional paid-in capital Additional Paid in Capital Entity Interactive Data Current Entity Interactive Data Current Balance Sheet Components Balance Sheet Components Disclosure [Text Block] Balance sheet components disclosure. Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions [Abstract] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Leasehold Improvements [Member] Leasehold Improvements [Member] Stock issuance cost for related party Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Weighted average incremental borrowing rate Operating Lease Weighted Average Incremental Borrowing Rate Percent Operating lease weighted average incremental borrowing rate percent. Proceeds from the issuance of common stock, pre-funded warrants and common warrants Proceeds from Issuance of Warrants Local Phone Number Local Phone Number Offering price per share Offering Price Per Share Offering price per share. Vesting Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Number of shares, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Warrants and Rights Note Disclosure [Abstract] Share purchases funded through payroll deductions minimum percentage of employee's eligible compensation Share Based Compensation Arrangement By Share Based Payment Award Minimum Employee Subscription Rate Share based compensation arrangement by share based payment award minimum employee subscription rate. Number of shares, Stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Category of Item Purchased Category of Item Purchased [Axis] Pre-funded Warrants [Member] Prefunded Warrant Member Prefunded Warrant [Member] Income Statement Location Income Statement Location [Domain] Laboratory Equipment [Member] Laboratory Equipment [Member] Laboratory equipment. Property, Plant and Equipment [Abstract] Number of Shares, Unvested as of September 30, 2022 Number of Shares, Unvested as of December 31, 2021 Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Beginning Balance, Shares Ending Balance, Shares Shares, Outstanding Increase (Decrease) in Prepaid Expense and Other Assets, Total Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Stanford Agreement [Member] Stanford Agreementmember [Member] Stanford Agreement [Member] Common stock reserved Number of shares, Beginning balance Number of shares, Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Document Fiscal Year Focus Document Fiscal Year Focus Prepaid Expense and Other Assets, Current [Abstract] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Earnings Per Share, Basic Net loss per share attributable to common stockholders, basic Net loss per share attributable to common stockholders, basic Other prepaid expenses Other Prepaid Expense, Current Indemnification Agreement [Member] Indemnification Agreement [Member] Assets Assets [Abstract] Increase (Decrease) in Accrued Liabilities, Total Accrued liabilities Increase (Decrease) in Accrued Liabilities Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Expected volatility, Minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Total prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Financial Instrument [Axis] Sponsored Research Agreement [Member] Sponsored Research Agreement [Member] Sponsored Research Agreement [Member] Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Pre-Funded Warrants [Member] pre-funded warrants Member pre-funded warrants Member. Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Current assets: Assets, Current [Abstract] Class of Warrant or Right, Exercise Price of Warrants or Rights Purchase price per share Accrued construction costs Accrued Construction Costs Current Accrued construction costs current. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Cover [Abstract] Total number of common shares outstanding Common Shares Outstanding Percentage Common shares outstanding percentage. Current liabilities: Liabilities, Current [Abstract] Entity Address, Address Line Three Entity Address, Address Line Three Maximum [Member] Maximum [Member] Unrealized loss on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized gain (loss) on available-for-sale securities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Furniture and Fixtures [Member] Furniture and Fixtures [Member] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Number of shares, Stock options exercised Stock option exercises, Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Summary of Stock-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash Equivalents, at Carrying Value, Total Cash equivalents Cash Equivalents, at Carrying Value Cash, Ending Balance Cash, Beginning Balance Cash Cash Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year Percentage Of Shares Of Common Stock Outstanding On Last Day Of Immediately Preceding Fiscal Year Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year. Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Percentage of number of shares of capital stock outstanding on last day of preceding year Percentage Of Number Of Shares Of Capital Stock Outstanding On Last Day Of Preceding Year Percentage of number of shares of capital stock outstanding on last day of preceding year. Trading Symbol Trading Symbol Reduction in the carrying amount of right-of-use assets Operating Lease, Right-of-Use Asset, Amortization Expense Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock Reserved for Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Employee stock purchase plan. Accounts Payable, Current, Total Accounts payable Accounts Payable, Current Gross Unrealized Holding Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Operating lease liabilities Increase Decrease In Operating Lease Liabilities Increase decrease in operating lease liabilities. Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Cash paid for amounts included in the measurement of lease liability Cash Paid For Amounts Included In The Measurement Of Lease Liability Cash paid for amounts included in the measurement of lease liability. Sales Agreement with Cowen and Company LLC [Member] Sales Agreement With Cowen And Company L L C [Member] Sales agreement with Cowen and Company LLC. Number of Shares, Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares granted Weighted- average exercise price per share, Stock options granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Two Thousand Twenty Two Employment Inducement Award Plan. Two Thousand Twenty Two Employment Inducement Award Plan [Member] 2022 Employment Inducement Award Plan [Member] Anti-dilutive securities excluded from the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Other non-current assets Increase (Decrease) in Other Noncurrent Assets Noncash Investing and Financing Items [Abstract] Non-cash investing and financing activities: EX-101.SCH 8 annx-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 100070 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 100080 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 100090 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 100100 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 100110 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 100120 - Disclosure - Stockholder's Equity link:presentationLink link:calculationLink link:definitionLink 100130 - Disclosure - Equity Incentive Plans link:presentationLink link:calculationLink link:definitionLink 100140 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 100150 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 100160 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 100170 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 100180 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 100200 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 100210 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 100220 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 100230 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 100240 - Disclosure - Stockholder's Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 100250 - Disclosure - Equity Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 100270 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100280 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) link:presentationLink link:calculationLink link:definitionLink 100290 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 100310 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 100320 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail) link:presentationLink link:calculationLink link:definitionLink 100330 - Disclosure - Balance Sheet Components - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100340 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 100350 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100360 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 100380 - Disclosure - Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail) link:presentationLink link:calculationLink link:definitionLink 100390 - Disclosure - Stockholder's Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100400 - Disclosure - Equity Incentive Plans - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100410 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 100420 - Disclosure - Equity Incentive Plans - Summary of RSU Activity under 2020 Plan (Detail) link:presentationLink link:calculationLink link:definitionLink 100430 - Disclosure - Equity Incentive Plans - Summary of Stock-Based Compensation Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 100440 - Disclosure - Equity Incentive Plans - Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail) link:presentationLink link:calculationLink link:definitionLink 100450 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 100460 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 9 annx-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
9 Months Ended
Sep. 30, 2022
Oct. 28, 2022
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Amendment Flag false  
Document Period End Date Sep. 30, 2022  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Trading Symbol ANNX  
Entity Registrant Name ANNEXON, INC.  
Entity Central Index Key 0001528115  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Security Exchange Name NASDAQ  
Entity File Number 001-39402  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 27-5414423  
Entity Address, Address Line One 1400 Sierra Point Parkway  
Entity Address, Address Line Two Bldg C  
Entity Address, Address Line Three Suite 200  
Entity Address, City or Town Brisbane  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94005  
City Area Code 650  
Local Phone Number 822-5500  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Common Stock [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   47,630,393
Prefunded Warrant [Member]    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   24,696,206
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 210,658 $ 74,843
Short-term investments 58,861 167,872
Prepaid expenses and other current assets 5,258 4,978
Total current assets 274,777 247,693
Restricted cash 1,032 1,166
Property and equipment, net 17,093 17,848
Operating lease right-of-use assets 19,616 20,333
Other non-current assets 204  
Total assets 312,722 287,040
Current liabilities:    
Accounts payable 6,921 11,153
Accrued liabilities 11,323 9,250
Operating lease liabilities, current 1,806 1,202
Other current liabilities 170 139
Total current liabilities 20,220 21,744
Operating lease liabilities, non-current 31,900 33,387
Total liabilities 52,120 55,131
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Common stock 48 39
Additional paid-in capital 664,839 528,365
Accumulated other comprehensive loss (406) (180)
Accumulated deficit (403,879) (296,315)
Total stockholders’ equity 260,602 231,909
Total liabilities and stockholders’ equity $ 312,722 $ 287,040
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 27,862 $ 27,581 $ 83,966 $ 72,849
General and administrative 8,207 8,099 24,938 20,406
Total operating expenses 36,069 35,680 108,904 93,255
Loss from operations (36,069) (35,680) (108,904) (93,255)
Interest and other income, net 1,015 82 1,340 303
Net loss (35,054) (35,598) (107,564) (92,952)
Net loss attributable to common stockholders $ (35,054) $ (35,598) $ (107,564) $ (92,952)
Net loss per share attributable to common stockholders, basic $ (0.51) $ (0.93) $ (2.21) $ (2.43)
Net loss per share attributable to common stockholders, diluted $ (0.51) $ (0.93) $ (2.21) $ (2.43)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic 68,652,859 38,341,110 48,710,433 38,261,359
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted 68,652,859 38,341,110 48,710,433 38,261,359
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net loss $ (35,054) $ (35,598) $ (107,564) $ (92,952)
Other comprehensive gain (loss):        
Foreign currency translation adjustment (4) (3) (7) (5)
Unrealized gain (loss) on available-for-sale securities 37 (7) (219) 7
Comprehensive loss $ (35,021) $ (35,608) $ (107,790) $ (92,950)
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Beginning Balance, Values at Dec. 31, 2020 $ 344,278 $ 38 $ 510,309 $ (77) $ (165,992)
Beginning Balance, Shares at Dec. 31, 2020   38,157,618      
Stock-based compensation 2,962   2,962    
Stock option exercises 268   268    
Stock option exercises, Shares   74,930      
Foreign currency translation adjustment (1)     (1)  
Unrealized gain (loss) on available-for-sale securities (25)     (25)  
Net loss (26,060)       (26,060)
Ending Balance, Values at Mar. 31, 2021 321,422 $ 38 513,539 (103) (192,052)
Ending Balance, Shares at Mar. 31, 2021   38,232,548      
Beginning Balance, Values at Dec. 31, 2020 344,278 $ 38 510,309 (77) (165,992)
Beginning Balance, Shares at Dec. 31, 2020   38,157,618      
Foreign currency translation adjustment (5)        
Unrealized gain (loss) on available-for-sale securities 7        
Net loss (92,952)        
Ending Balance, Values at Sep. 30, 2021 264,477 $ 38 523,458 (75) (258,944)
Ending Balance, Shares at Sep. 30, 2021   38,370,098      
Beginning Balance, Values at Mar. 31, 2021 321,422 $ 38 513,539 (103) (192,052)
Beginning Balance, Shares at Mar. 31, 2021   38,232,548      
Stock-based compensation 4,517   4,517    
Stock option exercises 534   534    
Stock option exercises, Shares   82,805      
Issuance of common stock per Employee Stock Purchase Plan 118   118    
Issuance of common stock per Employee Stock Purchase Plan, Shares   6,759      
Foreign currency translation adjustment (1)     (1)  
Unrealized gain (loss) on available-for-sale securities 39     39  
Net loss (31,294)       (31,294)
Ending Balance, Values at Jun. 30, 2021 295,335 $ 38 518,708 (65) (223,346)
Ending Balance, Shares at Jun. 30, 2021   38,322,112      
Stock-based compensation 4,428   4,428    
Stock option exercises 322   322    
Stock option exercises, Shares   47,986      
Foreign currency translation adjustment (3)     (3)  
Unrealized gain (loss) on available-for-sale securities (7)     (7)  
Net loss (35,598)       (35,598)
Ending Balance, Values at Sep. 30, 2021 264,477 $ 38 523,458 (75) (258,944)
Ending Balance, Shares at Sep. 30, 2021   38,370,098      
Beginning Balance, Values at Dec. 31, 2021 231,909 $ 39 528,365 (180) (296,315)
Beginning Balance, Shares at Dec. 31, 2021   38,560,854      
Stock-based compensation 4,252   4,252    
Stock option exercises 19   19    
Stock option exercises, Shares   2,711      
Foreign currency translation adjustment 3     3  
Unrealized gain (loss) on available-for-sale securities (196)     (196)  
Net loss (35,373)       (35,373)
Ending Balance, Values at Mar. 31, 2022 200,614 $ 39 532,636 (373) (331,688)
Ending Balance, Shares at Mar. 31, 2022   38,563,565      
Beginning Balance, Values at Dec. 31, 2021 $ 231,909 $ 39 528,365 (180) (296,315)
Beginning Balance, Shares at Dec. 31, 2021   38,560,854      
Stock option exercises, Shares 11,474        
Foreign currency translation adjustment $ (7)        
Unrealized gain (loss) on available-for-sale securities (219)        
Net loss (107,564)        
Ending Balance, Values at Sep. 30, 2022 260,602 $ 48 664,839 (406) (403,879)
Ending Balance, Shares at Sep. 30, 2022   47,626,503      
Beginning Balance, Values at Mar. 31, 2022 200,614 $ 39 532,636 (373) (331,688)
Beginning Balance, Shares at Mar. 31, 2022   38,563,565      
Stock-based compensation 4,520   4,520    
Issuance of common stock per Employee Stock Purchase Plan 113   113    
Issuance of common stock per Employee Stock Purchase Plan, Shares   40,341      
Foreign currency translation adjustment (6)     (6)  
Unrealized gain (loss) on available-for-sale securities (60)     (60)  
Net loss (37,137)       (37,137)
Ending Balance, Values at Jun. 30, 2022 168,044 $ 39 537,269 (439) (368,825)
Ending Balance, Shares at Jun. 30, 2022   38,603,906      
Stock-based compensation 4,911   4,911    
Stock option exercises 45   45    
Stock option exercises, Shares   8,763      
Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs of issuance costs, Shares   9,013,834      
Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs of issuance costs 122,623 $ 9 122,614    
Foreign currency translation adjustment (4)     (4)  
Unrealized gain (loss) on available-for-sale securities 37     37  
Net loss (35,054)       (35,054)
Ending Balance, Values at Sep. 30, 2022 $ 260,602 $ 48 $ 664,839 $ (406) $ (403,879)
Ending Balance, Shares at Sep. 30, 2022   47,626,503      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)
$ in Thousands
3 Months Ended
Sep. 30, 2022
USD ($)
Stock issuance cost for related party $ 9,500
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Operating activities:    
Net loss $ (107,564) $ (92,952)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 1,576 1,635
Accretion of discount on available-for-sale securities 490 934
Stock-based compensation 13,683 11,907
Reduction in the carrying amount of right-of-use assets 717 926
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (280) (1,765)
Other non-current assets (204)  
Accounts payable (777) 874
Accrued liabilities 4,041 181
Operating lease liabilities (883) 471
Other current liabilities 31  
Net cash used in operating activities (89,170) (77,789)
Investing activities:    
Purchases of property and equipment (6,244) (799)
Purchases of available-for-sale securities (46,364) (191,122)
Proceeds from sale of available-for-sale securities   7,988
Proceeds from maturities of available-for-sale securities 154,666 62,000
Net cash provided by (used in) investing activities 102,058 (121,933)
Financing activities:    
Proceeds from the exercise common stock options 64 1,124
Proceeds from employee stock plan purchases 113 118
Proceeds from the issuance of common stock, pre-funded warrants and common warrants 120,976  
Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party 9,500  
Payment of issuance costs related to the issuance of common stock, pre-funded warrants and common warrants (7,853)  
Deferred offering costs payment related to the 2021 ATM program   (395)
Net cash provided by financing activities 122,800 847
increase (decrease) in cash, cash equivalents and restricted cash 135,688 (198,875)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (7) (5)
Cash, cash equivalents and restricted cash    
Beginning of period 76,009 268,565
End of period 211,690 69,685
Supplemental disclosure of cash flow information:    
Cash paid for amounts included in the measurement of lease liability 3,028 996
Non-cash investing and financing activities:    
Purchases of property and equipment included in accounts payable and accrued liabilities $ 118 372
Deferred offering costs included in accrued liabilities   198
Right-of-use assets obtained in exchange for lease liability   21,084
Construction-in-progress obtained in exchange for tenant improvement allowance from lessors   $ 10,748
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Organization

1. Organization

Annexon, Inc., or the Company, is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. The Company is located in Brisbane, California and was incorporated in Delaware in March 2011.

The Company’s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, or the Subsidiary, is a proprietary limited company incorporated in 2016 and domiciled in Australia. The Subsidiary is also engaged in research and development activities in support of its parent company.

Liquidity

Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of September 30, 2022, had an accumulated deficit of $403.9 million and cash and cash equivalents and short-term investments of $269.5 million.

The Company has historically funded its operations through the issuance of shares of its redeemable convertible preferred stock and common stock. On July 11, 2022, the Company closed a private placement of shares of common stock, pre-funded warrants and common warrants, or Private Placement, which resulted in net proceeds of approximately $122.6 million, after deducting placement agent fees and other expenses. Based on projected activities, management projects that cash on hand is sufficient to support operations for at least the next 12 months following issuance of these condensed consolidated financial statements. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.

XML 18 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and applicable rules and regulations of the SEC regarding interim financial reporting.

The condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations, comprehensive loss, stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows for the interim period presented. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to fair value of investments, useful lives for property and equipment, incremental borrowing rate used in lease accounting, stock options, income taxes and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.

Principles of Consolidation

The condensed consolidated financial statements include the operations of Annexon, Inc. and its wholly-owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds, are stated at fair value.

Restricted cash as of September 30, 2022 relates to the letters of credit established for the Company’s office leases.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Cash

 

$

570

 

 

$

734

 

Cash equivalents

 

 

210,088

 

 

 

74,109

 

Cash and cash equivalents

 

 

210,658

 

 

 

74,843

 

Restricted cash

 

 

1,032

 

 

 

1,166

 

Cash, cash equivalents and restricted cash

 

$

211,690

 

 

$

76,009

 

Short-Term Investments

Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.

The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.

The cost of investments sold is based on the specific-identification method. Interest on available-for-sale debt securities is included in interest and other income (expense), net.

Warrants

Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company’s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.

Research and Development Expense

Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company’s product candidates.

Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company’s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company’s behalf; (iii) contract manufacturing costs to produce clinical trial materials; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation); (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.

Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.

The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company’s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees, non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employee directors on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.

The Company grants certain employees performance-based stock options. For awards that include performance conditions, no compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service inception date would be recognized.

Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes option pricing model and recognized as expense on a straight-line basis (for all but performance-based awards for which the accelerated method is used) over the requisite service period, which is the vesting period.

Determining the appropriate fair value model and related assumptions requires judgment, including estimating the fair value of the underlying common stock, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company’s cash and cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits. Management believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity's Own Equity (Subtopic 815-40)” (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU 2020-06 effective as of January 1, 2022. The adoption of ASU 2020-06 did not have an impact on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material impact on its financial position or results of operations.

XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements

3. Fair Value Measurements

The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.

On a recurring basis, the Company measures certain financial assets and liabilities at fair value. The following tables summarize the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

 

September 30, 2022

 

 

 

Valuation
Hierarchy

 

Amortized
Cost

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

210,088

 

 

$

 

 

$

 

 

$

210,088

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

Level 2

 

 

23,825

 

 

 

 

 

 

(100

)

 

 

23,725

 

Government bonds

 

Level 2

 

 

35,354

 

 

 

 

 

 

(218

)

 

 

35,136

 

Total assets

 

 

 

$

269,267

 

 

$

 

 

$

(318

)

 

$

268,949

 

 

 

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Cost

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

74,109

 

 

$

 

 

$

 

 

$

74,109

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

Level 2

 

 

85,352

 

 

 

 

 

 

(27

)

 

 

85,325

 

Corporate bonds

 

Level 2

 

 

48,814

 

 

 

 

 

 

(24

)

 

 

48,790

 

Government bonds

 

Level 2

 

 

33,809

 

 

 

 

 

 

(52

)

 

 

33,757

 

Total assets

 

 

 

$

242,084

 

 

$

 

 

$

(103

)

 

$

241,981

 

 

For the three and nine months ended September 30, 2022 and 2021, the Company recognized no material realized gains or losses on financial instruments.

XML 20 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Components
9 Months Ended
Sep. 30, 2022
Disclosure Of Balance Sheet Components [Abstract]  
Balance Sheet Components

4. Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Prepaid research and development costs

 

$

3,562

 

 

$

3,002

 

Prepaid insurance

 

 

1,243

 

 

 

1,282

 

Other prepaid expenses

 

 

396

 

 

 

231

 

Other current assets

 

 

57

 

 

 

463

 

Total prepaid expenses and other current assets

 

$

5,258

 

 

$

4,978

 

Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Leasehold improvements

 

$

17,179

 

 

$

16,594

 

Laboratory equipment

 

 

1,552

 

 

 

1,353

 

Furniture and fixtures

 

 

682

 

 

 

649

 

Computer equipment and software

 

 

33

 

 

 

41

 

Total property and equipment, gross

 

 

19,446

 

 

 

18,637

 

Less: accumulated depreciation

 

 

(2,353

)

 

 

(789

)

Total property and equipment, net

 

$

17,093

 

 

$

17,848

 

 

The Company recognized depreciation for property and equipment of $0.5 million and $0.6 million for the three months ended September 30, 2022 and 2021, respectively, and $1.6 million and $1.6 million for the nine months ended September 30, 2022 and 2021, respectively.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Accrued research and development expenses

 

$

7,054

 

 

$

2,404

 

Accrued compensation

 

 

3,792

 

 

 

3,573

 

Accrued professional services

 

 

313

 

 

 

1,274

 

Accrued construction costs

 

 

 

 

 

1,917

 

Other accrued expenses

 

 

164

 

 

 

82

 

Total accrued liabilities

 

$

11,323

 

 

$

9,250

 

XML 21 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

5. Commitments and Contingencies

Leases

The Company leases its offices and laboratory in Brisbane, California, or the Brisbane Lease, under a ten-year noncancelable lease agreement that ends in October 2031 with a ten-year renewable option. In November 2021, the Company subleased unoccupied space for two years starting from December 2021 for aggregate sublease payments of $3.4 million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company’s sublease income was $0.4 million and $1.2 million for the three and nine months ended September 30, 2022, respectively.

As of September 30, 2022, the operating lease right-of-use assets were $19.6 million and lease liabilities were $33.7 million on the condensed consolidated balance sheet. The weighted-average remaining lease term is 9.1 years.

The weighted-average incremental borrowing rate used to measure the operating lease liability is 8.4%.

Operating lease costs were $0.5 million and $1.1 million for the three months ended September 30, 2022 and 2021, respectively, and $1.5 million and $2.0 million for the nine months ended September 30, 2022 and 2021, respectively. Variable lease payments were $0.1 million and $36,000 for the three months ended September 30, 2022 and 2021, respectively, and $0.7 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively.

Future minimum lease payments and related lease liabilities as of September 30, 2022, were as follows:

 

 

 

(in thousands)

 

2022 (remaining three months)

 

$

1,175

 

2023

 

 

4,742

 

2024

 

 

4,907

 

2025

 

 

5,079

 

2026 and thereafter

 

 

32,833

 

Total undiscounted lease payments

 

 

48,736

 

Less: Imputed interest

 

 

(15,030

)

Total

 

$

33,706

 

License and Other Agreements

In November 2011, the Company entered into an exclusive licensing agreement, or the Stanford Agreement, with The Board of Trustees of the Leland Stanford Junior University, or Stanford, whereby the Company was granted an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights, or the Licensed Patents, to make, use, offer for sale, sell, import and otherwise commercialize products covered by the Licensed Patents for human or animal diseases, disorders or conditions. Under the Stanford Agreement, the Company made an upfront payment and is obligated to pay Stanford annual license maintenance fees, potential future milestone payments totaling up to $0.5 million, and royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed products. The Company did not achieve any milestones or make any milestone payments for the three and nine months ended September 30, 2022 and 2021.

In December 2016, the Company entered into a sponsored research agreement, with a not-for-profit entity to perform research on multiple sclerosis. The sponsored research agreement was amended in March 2019, or as amended, the Sponsored Research Agreement. Under the terms of the Sponsored Research Agreement, the Company may receive up to $0.7 million in funding. If within 15 years of the end of the Sponsored Research Agreement, the Company files a marketing authorization application for a product treating multiple sclerosis, the Company will be obligated to pay milestone payments up to four times the amounts received under the Sponsored Research Agreement. The Company has received $0.6 million in funding to date, which was recorded as other income. The Company recognized no income during the nine months ended September 30, 2022 and $0.1 million in income during the nine months ended September 30, 2021.

Guarantees and Indemnifications

In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2022, the Company did not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholder's Equity
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Stockholders' Equity

6. Stockholders’ Equity

Private Placement

On July 11, 2022, the Company sold in a private placement an aggregate of 9,013,834 shares of common stock, pre-funded warrants to purchase up to 24,696,206 shares of its common stock and accompanying common warrants to purchase up to 8,427,508 shares of its common stock. The offering price per share and accompanying common warrant was $3.87125 per share and the offering price per pre-funded warrant and accompanying common warrant was $3.87025 per share, which equals the per share offering price for the shares of common stock less the $0.001 exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $5.806875 per share and expire on June 30, 2025.

An entity related to one of the Company’s directors participated in the Private Placement and purchased 2,453,988 shares of common stock and accompanying common warrants to purchase up to an additional 613,497 shares of common stock for an aggregate price of approximately $9.5 million.

Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The Company may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 9.99% of the total number of shares of common stock outstanding immediately after giving effect to the exercise or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 9.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company. The Company may not effect the exercise of any common warrant, and a holder will not be entitled to exercise any portion of any common warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99%, 9.99% or 19.99% (as applicable pursuant to the holder’s common warrant) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage, including 9.99%, 14.99% or 19.99%, and not in excess of 19.99%, upon at least 61 days’ notice to the Company. The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders’ equity within additional paid-in capital.

As of September 30, 2022, no pre-funded or common warrants were exercised, and there were pre-funded and common warrants to purchase an aggregate of 33,123,714 shares of common stock outstanding. The 24,696,206 shares of common stock issuable upon the exercise of the pre-funded warrants and the 8,427,508 shares of common stock issuable upon the exercise of the common warrants are not included in the number of issued and outstanding shares of common stock as of September 30, 2022.

At-the-Market Offering

In August 2021, the Company entered into a sales agreement with Cowen and Company LLC, or Cowen, as sales agent, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering price of $100.0 million under an at-the-market offering program, or 2021 ATM program. The Company will pay Cowen up to 3% of gross proceeds for the common stock sold through the 2021 ATM program. As of September 30, 2022, no shares of common stock have been sold under the 2021 ATM program.

Common Stock

The Company has reserved the following shares of common stock for issuance as follows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Stock options issued and outstanding

 

 

8,178,136

 

 

 

5,662,824

 

Stock options reserved for 2020 Incentive Award Plan

 

 

334,001

 

 

 

2,039,951

 

Unvested restricted stock units outstanding

 

 

591,608

 

 

 

50,000

 

Common stock reserved for 2021 ATM program

 

 

5,265,929

 

 

 

5,265,929

 

Common stock reserved for Employee Stock Purchase
     Plan

 

 

1,075,042

 

 

 

729,775

 

Common stock reserved for Employment Inducement
    Award Plan

 

 

1,703,000

 

 

 

 

Common stock reserved for pre-funded warrants

 

 

24,696,206

 

 

 

 

Common stock reserved for common warrants

 

 

8,427,508

 

 

 

 

Total common stock reserved

 

 

50,271,430

 

 

 

13,748,479

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Equity Incentive Plans

7. Equity Incentive Plans

In July 2020, the Company’s board of directors and stockholders adopted and approved the 2020 Incentive Award Plan, or the 2020 Plan, and the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the Company’s initial public offering, or the IPO.

The Company may not grant any additional awards under the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder.

2020 Equity Incentive Plan

The number of shares of common stock reserved for issuance under the 2020 Plan automatically increases on the first day of January, in an amount equal to 4% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors.

Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than 100% of the estimated fair value on the date of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms. As of September 30, 2022, there were 334,001 shares available for issuance under the 2020 Plan.

2022 Employment Inducement Award Plan

In July 2022, the Company’s board of directors adopted the Annexon, Inc. 2022 Employment Inducement Award Plan, or the Inducement Plan, and together with the 2011 Plan and the 2020 Plan, the Plans. The Inducement Plan was adopted by the Company’s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4), or Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan may only be granted to newly hired employees as an inducement material to the employees entering into employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of 2,000,000 shares of common stock were reserved for issuance under the Inducement Plan. As of September 30, 2022, there were 1,703,000 shares available for issuance under the Inducement Plan.

Stock Options

The following table presents stock option activity under the Plans for the period:

 

 

 

Number of
Shares

 

 

Weighted-
Average
Exercise
Price Per
Share

 

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Balances as of December 31, 2021

 

 

5,662,824

 

 

$

16.98

 

 

 

8.26

 

 

$

10,186

 

Stock options granted

 

 

3,645,435

 

 

 

5.59

 

 

 

 

 

 

 

Stock options exercised

 

 

(11,474

)

 

 

5.65

 

 

 

 

 

 

 

Stock options forfeited

 

 

(1,118,649

)

 

 

16.24

 

 

 

 

 

 

 

Balances as of September 30, 2022

 

 

8,178,136

 

 

$

12.02

 

 

 

8.39

 

 

$

6,084

 

Exercisable as of September 30, 2022

 

 

2,968,956

 

 

$

12.75

 

 

 

7.17

 

 

$

2,494

 

 

The total intrinsic value of options exercised were $2,500 and $0.7 million during the three months ended September 30, 2022 and 2021, respectively, and $5,000 and $3.9 million for the nine months ended September 30, 2022 and 2021, respectively. The intrinsic value is the difference between the fair value of the Company’s common stock at the time of exercise and the exercise price of the stock option.

The weighted-average grant date fair value of options granted to employees during the nine months ended September 30, 2022 and 2021 was $3.93 and $19.41 per share, respectively.

As of September 30, 2022, the total unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $42.7 million, which the Company expects to recognize over an estimated weighted-average period of 2.6 years.

Restricted Stock Units

RSUs are equity awards that entitle the holder to receive shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a three-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.

A summary of RSU activity under the 2020 Plan and related information is as follows:

 

 

Number of Shares

 

 

Weighted-Average Grant Date Fair Value Per Share

 

Unvested as of December 31, 2021

 

 

50,000

 

 

$

12.84

 

Granted

 

 

600,583

 

 

 

5.40

 

Cancelled

 

 

(58,975

)

 

 

8.04

 

Unvested as of September 30, 2022

 

 

591,608

 

 

$

5.76

 

As of September 30, 2022, unrecognized stock-based compensation expense related to outstanding unvested RSUs was $2.8 million, which is expected to be recognized over a weighted-average period of 2.5 years.

Employee Stock Purchase Plan

The ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least 1%, and up to 15% of an employee’s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP

increase automatically on the first day of each fiscal year, by a number equal to the least of 360,086 shares, 1% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or such number of shares determined by the Company’s board of directors. As of September 30, 2022, 1,075,042 shares were available for future purchase. The ESPP generally provides for six-month consecutive offering periods beginning on May 15th and November 15th of each year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense has been recorded for the three and nine months ended September 30, 2022.

The stock-based compensation expense related to the ESPP was $29,000 and $42,000 for the three months ended September 30, 2022 and 2021, respectively, and $0.1 million and $0.1 million for the nine months ended September 30, 2022 and 2021, respectively.

Stock-Based Compensation Expense

The total stock-based compensation expense related to all equity-based awards recognized in the period was as follows (in thousands):

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

2,433

 

 

$

2,382

 

 

$

6,509

 

 

$

6,330

 

General and administrative

 

 

2,478

 

 

 

2,046

 

 

 

7,174

 

 

 

5,577

 

Total stock-based compensation expense

 

$

4,911

 

 

$

4,428

 

 

$

13,683

 

 

$

11,907

 

To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.

The fair value of each award issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2022

 

2021

 

2022

 

2021

Expected term (in years)

 

5.77 - 6.08

 

4.33 - 6.08

 

5.50 - 6.08

 

4.33 - 6.08

Expected volatility

 

81.70% - 82.70%

 

88.3% - 89%

 

78.80% - 82.80%

 

88.3% - 90.7%

Risk-free interest rate

 

2.92% - 3.61%

 

0.70% - 1.10%

 

1.49% - 3.61%

 

0.35% - 1.10%

Dividend yield

 

 

 

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

8. Income Taxes

For the three and nine months ended September 30, 2022 and 2021, the Company incurred insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company’s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share Attributable to Common Stockholders
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Stockholders

9. Net Loss Per Share Attributable to Common Stockholders

The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding, excluding restricted common stock. The weighted-average number of shares of common stock used in the basic and diluted net loss per share calculation include the pre-funded warrants issued in connection with the Private Placement as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2022, no pre-funded warrants have been exercised and there were pre-funded warrants to purchase an aggregate of 24,696,206 shares of common stock outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

 

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

Stock options to purchase common stock

 

 

8,178,136

 

 

 

5,918,981

 

Shares subject to Employee Stock Purchase Plan

 

 

110,897

 

 

 

9,538

 

Unvested restricted stock units

 

 

591,608

 

 

 

 

Common warrants to purchase common stock

 

 

8,427,508

 

 

 

 

Total

 

 

17,308,149

 

 

 

5,928,519

 

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and applicable rules and regulations of the SEC regarding interim financial reporting.

The condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations, comprehensive loss, stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows for the interim period presented. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to fair value of investments, useful lives for property and equipment, incremental borrowing rate used in lease accounting, stock options, income taxes and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
Principles of Consolidation

Principles of Consolidation

The condensed consolidated financial statements include the operations of Annexon, Inc. and its wholly-owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.

Cash, Cash Equivalents and Restricted Cash

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds, are stated at fair value.

Restricted cash as of September 30, 2022 relates to the letters of credit established for the Company’s office leases.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Cash

 

$

570

 

 

$

734

 

Cash equivalents

 

 

210,088

 

 

 

74,109

 

Cash and cash equivalents

 

 

210,658

 

 

 

74,843

 

Restricted cash

 

 

1,032

 

 

 

1,166

 

Cash, cash equivalents and restricted cash

 

$

211,690

 

 

$

76,009

 

Short-Term Investments

Short-Term Investments

Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.

The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.

The cost of investments sold is based on the specific-identification method. Interest on available-for-sale debt securities is included in interest and other income (expense), net.

Warrants

Warrants

Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company’s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.

Research and Development Expense

Research and Development Expense

Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company’s product candidates.

Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company’s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company’s behalf; (iii) contract manufacturing costs to produce clinical trial materials; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation); (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.

Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.

The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company’s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.
Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees, non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employee directors on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.

The Company grants certain employees performance-based stock options. For awards that include performance conditions, no compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service inception date would be recognized.

Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes option pricing model and recognized as expense on a straight-line basis (for all but performance-based awards for which the accelerated method is used) over the requisite service period, which is the vesting period.

Determining the appropriate fair value model and related assumptions requires judgment, including estimating the fair value of the underlying common stock, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.

Net Loss Per Share Attributable to Common Stockholders

Net Loss Per Share Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company’s cash and cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits. Management believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity's Own Equity (Subtopic 815-40)” (“ASU No. 2020-06”). ASU No. 2020-06 simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The Company adopted ASU 2020-06 effective as of January 1, 2022. The adoption of ASU 2020-06 did not have an impact on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material impact on its financial position or results of operations.

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2022
Accounting Policies [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Cash

 

$

570

 

 

$

734

 

Cash equivalents

 

 

210,088

 

 

 

74,109

 

Cash and cash equivalents

 

 

210,658

 

 

 

74,843

 

Restricted cash

 

 

1,032

 

 

 

1,166

 

Cash, cash equivalents and restricted cash

 

$

211,690

 

 

$

76,009

 

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2022
Fair Value Disclosures [Abstract]  
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The following tables summarize the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

 

 

 

 

 

September 30, 2022

 

 

 

Valuation
Hierarchy

 

Amortized
Cost

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

210,088

 

 

$

 

 

$

 

 

$

210,088

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

Level 2

 

 

23,825

 

 

 

 

 

 

(100

)

 

 

23,725

 

Government bonds

 

Level 2

 

 

35,354

 

 

 

 

 

 

(218

)

 

 

35,136

 

Total assets

 

 

 

$

269,267

 

 

$

 

 

$

(318

)

 

$

268,949

 

 

 

 

 

 

 

December 31, 2021

 

 

 

Valuation
Hierarchy

 

Amortized
Cost

 

 

Gross
Unrealized
Holding
Gains

 

 

Gross
Unrealized
Holding
Losses

 

 

Aggregate
Fair Value

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

Level 1

 

$

74,109

 

 

$

 

 

$

 

 

$

74,109

 

Short-term investments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Commercial paper

 

Level 2

 

 

85,352

 

 

 

 

 

 

(27

)

 

 

85,325

 

Corporate bonds

 

Level 2

 

 

48,814

 

 

 

 

 

 

(24

)

 

 

48,790

 

Government bonds

 

Level 2

 

 

33,809

 

 

 

 

 

 

(52

)

 

 

33,757

 

Total assets

 

 

 

$

242,084

 

 

$

 

 

$

(103

)

 

$

241,981

 

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Components (Tables)
9 Months Ended
Sep. 30, 2022
Disclosure Of Balance Sheet Components [Abstract]  
Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Prepaid research and development costs

 

$

3,562

 

 

$

3,002

 

Prepaid insurance

 

 

1,243

 

 

 

1,282

 

Other prepaid expenses

 

 

396

 

 

 

231

 

Other current assets

 

 

57

 

 

 

463

 

Total prepaid expenses and other current assets

 

$

5,258

 

 

$

4,978

 

Summary of Property and Equipment, Net

Property and equipment, net, consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Leasehold improvements

 

$

17,179

 

 

$

16,594

 

Laboratory equipment

 

 

1,552

 

 

 

1,353

 

Furniture and fixtures

 

 

682

 

 

 

649

 

Computer equipment and software

 

 

33

 

 

 

41

 

Total property and equipment, gross

 

 

19,446

 

 

 

18,637

 

Less: accumulated depreciation

 

 

(2,353

)

 

 

(789

)

Total property and equipment, net

 

$

17,093

 

 

$

17,848

 

Summary of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Accrued research and development expenses

 

$

7,054

 

 

$

2,404

 

Accrued compensation

 

 

3,792

 

 

 

3,573

 

Accrued professional services

 

 

313

 

 

 

1,274

 

Accrued construction costs

 

 

 

 

 

1,917

 

Other accrued expenses

 

 

164

 

 

 

82

 

Total accrued liabilities

 

$

11,323

 

 

$

9,250

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Future Minimum Lease Payments and Related Lease Liabilities

Future minimum lease payments and related lease liabilities as of September 30, 2022, were as follows:

 

 

 

(in thousands)

 

2022 (remaining three months)

 

$

1,175

 

2023

 

 

4,742

 

2024

 

 

4,907

 

2025

 

 

5,079

 

2026 and thereafter

 

 

32,833

 

Total undiscounted lease payments

 

 

48,736

 

Less: Imputed interest

 

 

(15,030

)

Total

 

$

33,706

 

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholder's Equity (Tables)
9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Schedule of Common Stock Reserved for Future Issuance

The Company has reserved the following shares of common stock for issuance as follows:

 

 

 

September 30,
2022

 

 

December 31,
2021

 

Stock options issued and outstanding

 

 

8,178,136

 

 

 

5,662,824

 

Stock options reserved for 2020 Incentive Award Plan

 

 

334,001

 

 

 

2,039,951

 

Unvested restricted stock units outstanding

 

 

591,608

 

 

 

50,000

 

Common stock reserved for 2021 ATM program

 

 

5,265,929

 

 

 

5,265,929

 

Common stock reserved for Employee Stock Purchase
     Plan

 

 

1,075,042

 

 

 

729,775

 

Common stock reserved for Employment Inducement
    Award Plan

 

 

1,703,000

 

 

 

 

Common stock reserved for pre-funded warrants

 

 

24,696,206

 

 

 

 

Common stock reserved for common warrants

 

 

8,427,508

 

 

 

 

Total common stock reserved

 

 

50,271,430

 

 

 

13,748,479

 

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Option Activity

The following table presents stock option activity under the Plans for the period:

 

 

 

Number of
Shares

 

 

Weighted-
Average
Exercise
Price Per
Share

 

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Balances as of December 31, 2021

 

 

5,662,824

 

 

$

16.98

 

 

 

8.26

 

 

$

10,186

 

Stock options granted

 

 

3,645,435

 

 

 

5.59

 

 

 

 

 

 

 

Stock options exercised

 

 

(11,474

)

 

 

5.65

 

 

 

 

 

 

 

Stock options forfeited

 

 

(1,118,649

)

 

 

16.24

 

 

 

 

 

 

 

Balances as of September 30, 2022

 

 

8,178,136

 

 

$

12.02

 

 

 

8.39

 

 

$

6,084

 

Exercisable as of September 30, 2022

 

 

2,968,956

 

 

$

12.75

 

 

 

7.17

 

 

$

2,494

 

Summary of RSU Activity under 2020 Plan

A summary of RSU activity under the 2020 Plan and related information is as follows:

 

 

Number of Shares

 

 

Weighted-Average Grant Date Fair Value Per Share

 

Unvested as of December 31, 2021

 

 

50,000

 

 

$

12.84

 

Granted

 

 

600,583

 

 

 

5.40

 

Cancelled

 

 

(58,975

)

 

 

8.04

 

Unvested as of September 30, 2022

 

 

591,608

 

 

$

5.76

 

Summary of Stock-Based Compensation Expense

The total stock-based compensation expense related to all equity-based awards recognized in the period was as follows (in thousands):

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Research and development

 

$

2,433

 

 

$

2,382

 

 

$

6,509

 

 

$

6,330

 

General and administrative

 

 

2,478

 

 

 

2,046

 

 

 

7,174

 

 

 

5,577

 

Total stock-based compensation expense

 

$

4,911

 

 

$

4,428

 

 

$

13,683

 

 

$

11,907

 

Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model

The fair value of each award issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

 

 

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

 

2022

 

2021

 

2022

 

2021

Expected term (in years)

 

5.77 - 6.08

 

4.33 - 6.08

 

5.50 - 6.08

 

4.33 - 6.08

Expected volatility

 

81.70% - 82.70%

 

88.3% - 89%

 

78.80% - 82.80%

 

88.3% - 90.7%

Risk-free interest rate

 

2.92% - 3.61%

 

0.70% - 1.10%

 

1.49% - 3.61%

 

0.35% - 1.10%

Dividend yield

 

 

 

 

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share Attributable to Common Stockholders (Tables)
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

 

 

 

Nine Months Ended
September 30,

 

 

 

2022

 

 

2021

 

Stock options to purchase common stock

 

 

8,178,136

 

 

 

5,918,981

 

Shares subject to Employee Stock Purchase Plan

 

 

110,897

 

 

 

9,538

 

Unvested restricted stock units

 

 

591,608

 

 

 

 

Common warrants to purchase common stock

 

 

8,427,508

 

 

 

 

Total

 

 

17,308,149

 

 

 

5,928,519

 

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization - Additional Information (Detail) - USD ($)
$ in Thousands
Jul. 11, 2022
Sep. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]      
Accumulated deficit   $ 403,879 $ 296,315
Cash and cash equivalents and short-term investments   $ 269,500  
Net proceeds from private placement $ 122,600    
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]    
Cash $ 570 $ 734
Cash equivalents 210,088 74,109
Cash and cash equivalents 210,658 74,843
Restricted cash 1,032 1,166
Cash, cash equivalents and restricted cash $ 211,690 $ 76,009
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - ASU 2020-06 [Member]
Sep. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Change in accounting principle, ASU adopted true
Change in accounting principle, ASU, adoption date Jan. 01, 2022
Change in accounting principle, ASU, Immaterial effect true
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost $ 269,267 $ 242,084
Gross Unrealized Holding Losses (318) (103)
Aggregate Fair Value 268,949 241,981
Level 1 [Member] | Money Market Funds [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 210,088 74,109
Aggregate Fair Value 210,088 74,109
Level 2 [Member] | Commercial Paper [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 23,825 85,352
Gross Unrealized Holding Losses (100) (27)
Aggregate Fair Value 23,725 85,325
Level 2 [Member] | Government Bonds [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost 35,354 33,809
Gross Unrealized Holding Losses (218) (52)
Aggregate Fair Value $ 35,136 33,757
Level 2 [Member] | Corporate Bonds [Member]    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]    
Amortized Cost   48,814
Gross Unrealized Holding Losses   (24)
Aggregate Fair Value   $ 48,790
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]    
Prepaid research and development costs $ 3,562 $ 3,002
Prepaid insurance 1,243 1,282
Other prepaid expenses 396 231
Other current assets 57 463
Total prepaid expenses and other current assets $ 5,258 $ 4,978
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Components - Summary of Property and Equipment, Net (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Property Plant And Equipment [Line Items]    
Total property and equipment, gross $ 19,446 $ 18,637
Less: accumulated depreciation (2,353) (789)
Total property and equipment, net 17,093 17,848
Leasehold Improvements [Member]    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 17,179 16,594
Laboratory Equipment [Member]    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 1,552 1,353
Furniture and Fixtures [Member]    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross 682 649
Computer Equipment and Software [Member]    
Property Plant And Equipment [Line Items]    
Total property and equipment, gross $ 33 $ 41
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Components - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]        
Depreciation expense $ 0.5 $ 0.6 $ 1.6 $ 1.6
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Balance Sheet Components - Summary of Accrued Liabilities (Detail) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Accrued Liabilities, Current [Abstract]    
Accrued research and development expenses $ 7,054 $ 2,404
Accrued compensation 3,792 3,573
Accrued professional services 313 1,274
Accrued construction costs   1,917
Other accrued expenses 164 82
Total accrued liabilities $ 11,323 $ 9,250
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 01, 2021
USD ($)
Mar. 31, 2019
USD ($)
Nov. 30, 2011
USD ($)
Sep. 30, 2022
USD ($)
Claim
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
Claim
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Gain Contingencies [Line Items]                        
Aggregate sublease payment receivable $ 3,400,000                      
Sublease income       $ 400,000           $ 1,200,000    
Operating lease right-of-use asset       19,616,000           19,616,000   $ 20,333,000
Lease liabilities       $ 33,706,000           $ 33,706,000    
Weighted average incremental borrowing rate       8.40%           8.40%    
Operating lease costs       $ 500,000     $ 1,100,000     $ 1,500,000 $ 2,000,000.0  
Variable lease payments       100,000     36,000     700,000 100,000  
Income (loss)       (35,054,000) $ (37,137,000) $ (35,373,000) $ (35,598,000) $ (31,294,000) $ (26,060,000) (107,564,000) (92,952,000)  
Loss contingency accrual       $ 0           $ 0    
Indemnification Agreement [Member]                        
Gain Contingencies [Line Items]                        
Loss contingency pending claims | Claim       0           0    
Stanford Agreement [Member] | Research and Development Arrangement [Member]                        
Gain Contingencies [Line Items]                        
Sponsor research agreements, commitment amount     $ 500,000                  
Proceeds from funding                   $ 600,000    
Sponsored Research Agreement [Member]                        
Gain Contingencies [Line Items]                        
Maximum threshold period allowed for filing market authorization   15 years                    
Income (loss)                   $ 0 $ 100,000  
Sponsored Research Agreement [Member] | Research and Development Arrangement [Member]                        
Gain Contingencies [Line Items]                        
Maximum expected research funding   $ 700,000                    
Brisbane, California [Member]                        
Gain Contingencies [Line Items]                        
Operating lease, term of contract       10 years           10 years    
Operating lease, expiration month and year                   2031-10    
Operating lease, renewal term       10 years           10 years    
Operating lease right-of-use asset       $ 19,600,000           $ 19,600,000    
Lease liabilities       $ 33,700,000           $ 33,700,000    
Weighted average remaining lease term       9 years 1 month 6 days           9 years 1 month 6 days    
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)
$ in Thousands
Sep. 30, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2022 (remaining six months) $ 1,175
2023 4,742
2024 4,907
2025 5,079
2026 and thereafter 32,833
Total undiscounted lease payments 48,736
Less: Imputed interest (15,030)
Lease liabilities $ 33,706
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail) - shares
Sep. 30, 2022
Dec. 31, 2021
Class Of Stock [Line Items]    
Common stock reserved 8,178,136 5,662,824
Common stock reserved 334,001  
Common stock reserved 50,271,430 13,748,479
Stock Options Issued and Outstanding [Member]    
Class Of Stock [Line Items]    
Common stock reserved 8,178,136 5,662,824
Stock Options Reserved for 2020 Incentive Award Plan [Member]    
Class Of Stock [Line Items]    
Common stock reserved 334,001 2,039,951
Unvested Restricted Stock Units Outstanding [Member]    
Class Of Stock [Line Items]    
Common stock reserved 591,608 50,000
Common Stock Reserved for Employee Stock Purchase Plan [Member]    
Class Of Stock [Line Items]    
Common stock reserved 1,075,042 729,775
Employment Inducement Award Plan [Member]    
Class Of Stock [Line Items]    
Common stock reserved 1,703,000  
Pre-Funded Warrants [Member]    
Class Of Stock [Line Items]    
Common stock reserved 24,696,206  
Common Warrants [Member]    
Class Of Stock [Line Items]    
Common stock reserved 8,427,508  
2021 ATM Program [Member]    
Class Of Stock [Line Items]    
Common stock reserved 5,265,929 5,265,929
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholder's Equity - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended
Jul. 11, 2022
Jul. 31, 2022
Aug. 31, 2021
Sep. 30, 2022
Dec. 31, 2021
Class Of Stock [Line Items]          
Common stock       $ 48 $ 39
Exercise of common warrant, description       The Company may not effect the exercise of any common warrant, and a holder will not be entitled to exercise any portion of any common warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99%, 9.99% or 19.99% (as applicable pursuant to the holder’s common warrant) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage, including 9.99%, 14.99% or 19.99%, and not in excess of 19.99%, upon at least 61 days’ notice to the Company.  
Pre-funded Warrants [Member]          
Class Of Stock [Line Items]          
Purchase of shares       0  
Offering price per share $ 3.87025        
Combined voting power maximum 19.99%        
Notice period 61 days        
Warrants outstanding       24,696,206  
Pre-funded Warrants [Member] | Maximum [Member]          
Class Of Stock [Line Items]          
Purchase of shares 24,696,206        
Purchase price per share $ 0.001        
Pre-funded Warrants [Member] | Minimum [Member]          
Class Of Stock [Line Items]          
Total number of common shares outstanding 9.99%        
Combined voting power 9.99%        
Warrants or Common Warrants [Member]          
Class Of Stock [Line Items]          
Purchase of shares       0  
Offering price per share $ 3.87125        
Purchase price per share $ 5.806875        
Warrant expiration date Jun. 30, 2025        
Combined voting power 9.99%        
Combined voting power maximum 19.99%        
Notice period 61 days        
Warrants outstanding       8,427,508  
Warrants or Common Warrants [Member] | Maximum [Member]          
Class Of Stock [Line Items]          
Purchase of shares 8,427,508        
Combined voting power 19.99%        
Warrants or Common Warrants [Member] | Minimum [Member]          
Class Of Stock [Line Items]          
Total number of common shares outstanding 4.99%        
Combined voting power 14.99%        
Private Placement [Member]          
Class Of Stock [Line Items]          
Sale of shares 9,013,834 2,453,988      
Warrants outstanding       33,123,714  
Additional common shares purchased   613,497      
Exchange value   $ 9,500      
Sales Agreement with Cowen and Company LLC [Member] | 2021 ATM Program [Member]          
Class Of Stock [Line Items]          
Common stock     $ 100,000    
Percentage of gross proceeds of common stock to be paid     3.00%    
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Jul. 31, 2022
Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Percentage of number of shares of capital stock outstanding on last day of preceding year     4.00%      
Stock option grants description     Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than 100% of the estimated fair value on the date of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms.      
Option expiry period     10 years      
Vesting Period     4 years      
Options available for future grant 334,001   334,001      
Intrinsic value of options exercised $ 2,500 $ 700,000 $ 5,000 $ 3,900,000    
Weighted- average exercise price per share, Stock options granted     $ 5.59      
Unrecognized stock-based compensation cost expected period for recognition     2 years 7 months 6 days      
Common stock for future issuance 50,271,430   50,271,430     13,748,479
Total stock-based compensation expense $ 4,911,000 4,428,000 $ 13,683,000 $ 11,907,000    
Employees [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Weighted- average exercise price per share, Stock options granted     $ 3.93 $ 19.41    
2022 Employment Inducement Award Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Options available for future grant 1,703,000   1,703,000   2,000,000  
Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs [Member] | Minimum [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares     100.00%      
Options Issued and Outstanding [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Unrecognized stock-based compensation cost $ 42,700,000   $ 42,700,000      
Restricted Stock Units [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Unrecognized stock-based compensation cost $ 2,800,000   $ 2,800,000      
Unrecognized stock-based compensation cost expected period for recognition     2 years 6 months      
Employee Stock Purchase Plan [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares     85.00%      
Share purchases funded through payroll deductions minimum percentage of employee's eligible compensation 1.00%   1.00%      
Share purchases funded through payroll deductions maximum percentage of employee's eligible compensation 15.00%   15.00%      
Common stock for future issuance 1,075,042   1,075,042     729,775
Maximum number of shares to be issued in accordance with plan as a proportion of outstanding capital stock 360,086   360,086      
Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year     1.00%      
Total stock-based compensation expense $ 29,000 $ 42,000 $ 100,000 $ 100,000    
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans - Summary of Stock Option Activity (Detail)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Share-Based Payment Arrangement [Abstract]    
Number of shares, Beginning balance | shares 5,662,824  
Number of shares, Stock options granted | shares 3,645,435  
Number of shares, Stock options exercised | shares (11,474)  
Number of shares, Stock options forfeited | shares (1,118,649)  
Number of shares, Ending balance | shares 8,178,136 5,662,824
Number of shares, Exercisable | shares 2,968,956  
Weighted- average exercise price per share, Beginning balance | $ / shares $ 16.98  
Weighted- average exercise price per share, Stock options granted | $ / shares 5.59  
Weighted- average exercise price per share, Stock options exercised | $ / shares 5.65  
Weighted average exercise price per share, Stock options forfeited | $ / shares 16.24  
Weighted- average exercise price per share, Ending balance | $ / shares 12.02 $ 16.98
Weighted- average exercise price per share, Exercisable | $ / shares $ 12.75  
Weighted- average remaining contractual term 8 years 4 months 20 days 8 years 3 months 3 days
Weighted- average remaining contractual term, Exercisable 7 years 2 months 1 day  
Aggregate intrinsic value | $ $ 6,084 $ 10,186
Aggregate intrinsic value, Exercisable | $ $ 2,494  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans - Summary of RSU Activity under 2020 Plan (Detail)
9 Months Ended
Sep. 30, 2022
$ / shares
shares
Share-Based Payment Arrangement [Abstract]  
Number of Shares, Unvested as of December 31, 2021 | shares 50,000
Number of Shares, Granted | shares 600,583
Number of Shares, Cancelled | shares (58,975)
Number of Shares, Unvested as of September 30, 2022 | shares 591,608
Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2021 | $ / shares $ 12.84
Weighted-Average Grant Date Fair Value Per Share, Granted | $ / shares 5.40
Weighted-Average Grant Date Fair Value Per Share, Cancelled | $ / shares 8.04
Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of September 30, 2022 | $ / shares $ 5.76
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans - Summary of Stock-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense $ 4,911 $ 4,428 $ 13,683 $ 11,907
Research and Development [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense 2,433 2,382 6,509 6,330
General and Administrative [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Total stock-based compensation expense $ 2,478 $ 2,046 $ 7,174 $ 5,577
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity Incentive Plans - Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected volatility, Minimum 81.70% 88.30% 78.80% 88.30%
Expected volatility, Maximum 82.70% 89.00% 82.80% 90.70%
Risk-free interest rate, Minimum 2.92% 0.70% 1.49% 0.35%
Risk-free interest rate, Maximum 3.61% 1.10% 3.61% 1.10%
Minimum [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected term (in years) 5 years 9 months 7 days 4 years 3 months 29 days 5 years 6 months 4 years 3 months 29 days
Maximum [Member]        
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]        
Expected term (in years) 6 years 29 days 6 years 29 days 6 years 29 days 6 years 29 days
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) - Pre-funded Warrants [Member]
Sep. 30, 2022
shares
Class of Warrant or Right [Line Items]  
Warrants exercised 0
Warrants outstanding 24,696,206
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail) - shares
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from the computation of diluted net loss per share 17,308,149 5,928,519
Shares Subject to Employee Stock Purchase Plan [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from the computation of diluted net loss per share 110,897 9,538
Stock Options to Purchase Common Stock [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from the computation of diluted net loss per share 8,178,136 5,918,981
Unvested Restricted Stock Units [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from the computation of diluted net loss per share 591,608  
Common Warrants to Purchase Common Stock [Member]    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Anti-dilutive securities excluded from the computation of diluted net loss per share 8,427,508  
XML 53 annx-20220930_htm.xml IDEA: XBRL DOCUMENT 0001528115 annx:SponsoredResearchAgreementMember 2021-01-01 2021-09-30 0001528115 us-gaap:IndemnificationGuaranteeMember 2022-09-30 0001528115 2022-07-01 2022-09-30 0001528115 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001528115 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001528115 annx:UnvestedRestrictedStockUnitsOutstandingMember 2022-09-30 0001528115 2022-01-01 2022-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001528115 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member 2022-09-30 0001528115 annx:LaboratoryEquipmentMember 2022-09-30 0001528115 us-gaap:EmployeeStockOptionMember 2022-09-30 0001528115 us-gaap:RetainedEarningsMember 2022-06-30 0001528115 2021-04-01 2021-06-30 0001528115 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001528115 srt:MinimumMember annx:PrefundedWarrantMember 2022-07-11 2022-07-11 0001528115 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001528115 2022-06-30 0001528115 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001528115 annx:TwoZeroTwoOneAtTheMarketProgramMember 2021-12-31 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001528115 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001528115 us-gaap:CommonStockMember 2021-06-30 0001528115 srt:MaximumMember 2022-01-01 2022-09-30 0001528115 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001528115 2022-03-31 0001528115 srt:MinimumMember annx:IncentiveStockOptionsAndNonstatutoryStockOptionsMember 2022-01-01 2022-09-30 0001528115 us-gaap:PrivatePlacementMember 2022-09-30 0001528115 srt:MaximumMember 2021-07-01 2021-09-30 0001528115 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2021-12-31 0001528115 2022-01-01 2022-03-31 0001528115 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001528115 us-gaap:ResearchAndDevelopmentArrangementMember annx:SponsoredResearchAgreementMember 2019-03-31 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001528115 srt:MinimumMember 2021-01-01 2021-09-30 0001528115 us-gaap:WarrantMember 2022-07-11 0001528115 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001528115 annx:EmployeeStockPurchasePlanMember 2021-07-01 2021-09-30 0001528115 annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember 2021-12-31 0001528115 annx:ComputerEquipmentAndSoftwareMember 2022-09-30 0001528115 srt:MinimumMember 2021-07-01 2021-09-30 0001528115 us-gaap:CommonStockMember 2021-03-31 0001528115 us-gaap:RetainedEarningsMember 2022-03-31 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001528115 annx:SponsoredResearchAgreementMember 2019-03-01 2019-03-31 0001528115 us-gaap:CommonStockMember 2021-09-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001528115 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001528115 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001528115 2021-06-30 0001528115 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001528115 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001528115 us-gaap:LeaseholdImprovementsMember 2022-09-30 0001528115 2020-12-31 0001528115 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001528115 us-gaap:PrivatePlacementMember 2022-07-01 2022-07-31 0001528115 srt:MaximumMember us-gaap:WarrantMember 2022-07-11 2022-07-11 0001528115 2021-01-01 2021-12-31 0001528115 srt:MinimumMember us-gaap:WarrantMember 2022-07-11 2022-07-11 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001528115 2022-09-30 0001528115 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001528115 2021-07-01 2021-09-30 0001528115 annx:EmployeeStockPurchasePlanMember 2022-01-01 2022-09-30 0001528115 annx:SalesAgreementWithCowenAndCompanyLLCMember annx:TwoZeroTwoOneAtTheMarketProgramMember 2021-08-01 2021-08-31 0001528115 us-gaap:EmployeeStockOptionMember 2021-12-31 0001528115 us-gaap:WarrantMember 2022-07-11 2022-07-11 0001528115 annx:PrefundedWarrantMember 2022-10-28 0001528115 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001528115 annx:TwoZeroTwoOneAtTheMarketProgramMember 2022-09-30 0001528115 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001528115 annx:ComputerEquipmentAndSoftwareMember 2021-12-31 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001528115 annx:PreFundedWarrantsMember 2022-09-30 0001528115 annx:PrefundedWarrantMember 2022-09-30 0001528115 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001528115 2021-11-01 2021-11-01 0001528115 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001528115 us-gaap:RetainedEarningsMember 2021-12-31 0001528115 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001528115 srt:MaximumMember 2021-01-01 2021-09-30 0001528115 annx:EmploymentInducementIncentivePlanMember 2022-07-31 0001528115 us-gaap:CommonStockMember 2022-10-28 0001528115 annx:EmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0001528115 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001528115 annx:PrefundedWarrantMember 2022-07-11 2022-07-11 0001528115 annx:SponsoredResearchAgreementMember 2022-01-01 2022-09-30 0001528115 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001528115 us-gaap:WarrantMember 2022-09-30 0001528115 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001528115 us-gaap:PrivatePlacementMember 2022-07-11 2022-07-11 0001528115 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001528115 annx:EmployeeStockPurchasePlanMember 2022-07-01 2022-09-30 0001528115 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001528115 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001528115 annx:BrisbaneCaliforniaMember 2022-01-01 2022-09-30 0001528115 us-gaap:EmployeeStockOptionMember 2022-09-30 0001528115 us-gaap:RetainedEarningsMember 2021-03-31 0001528115 us-gaap:ResearchAndDevelopmentArrangementMember annx:StanfordAgreementmemberMember 2011-11-01 2011-11-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001528115 2022-04-01 2022-06-30 0001528115 us-gaap:RetainedEarningsMember 2022-09-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001528115 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001528115 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001528115 annx:EmployeeStockPurchasePlanMember 2022-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001528115 annx:SalesAgreementWithCowenAndCompanyLLCMember annx:TwoZeroTwoOneAtTheMarketProgramMember 2021-08-31 0001528115 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001528115 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001528115 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001528115 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001528115 annx:EmploymentInducementAwardPlanMember 2022-09-30 0001528115 srt:MinimumMember 2022-01-01 2022-09-30 0001528115 us-gaap:CommonStockMember 2022-06-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001528115 us-gaap:RetainedEarningsMember 2021-09-30 0001528115 us-gaap:FurnitureAndFixturesMember 2022-09-30 0001528115 us-gaap:CommonStockMember 2021-12-31 0001528115 annx:BrisbaneCaliforniaMember 2022-09-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001528115 us-gaap:CommonStockMember 2020-12-31 0001528115 annx:CommonWarrantsMember 2022-09-30 0001528115 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryBondSecuritiesMember 2022-09-30 0001528115 annx:LaboratoryEquipmentMember 2021-12-31 0001528115 us-gaap:RetainedEarningsMember 2020-12-31 0001528115 srt:MaximumMember 2022-07-01 2022-09-30 0001528115 srt:MinimumMember 2022-07-01 2022-09-30 0001528115 2021-01-01 2021-09-30 0001528115 2021-01-01 2021-03-31 0001528115 annx:UnvestedRestrictedStockUnitsOutstandingMember 2021-12-31 0001528115 2022-07-11 2022-07-11 0001528115 us-gaap:ResearchAndDevelopmentArrangementMember annx:StanfordAgreementmemberMember 2022-01-01 2022-09-30 0001528115 2021-03-31 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001528115 us-gaap:RetainedEarningsMember 2021-06-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001528115 us-gaap:CommonStockMember 2022-03-31 0001528115 2021-12-31 0001528115 annx:EmploymentInducementIncentivePlanMember 2022-09-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001528115 annx:EmployeeStockPurchasePlanMember 2021-12-31 0001528115 us-gaap:EmployeeStockMember 2022-01-01 2022-09-30 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001528115 srt:MaximumMember annx:PrefundedWarrantMember 2022-07-11 0001528115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001528115 us-gaap:CommonStockMember 2022-09-30 0001528115 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001528115 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001528115 srt:MaximumMember us-gaap:WarrantMember 2022-07-11 0001528115 2021-09-30 0001528115 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001528115 annx:StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember 2022-09-30 0001528115 us-gaap:AccountingStandardsUpdate202006Member 2022-09-30 pure annx:Claim iso4217:USD shares shares iso4217:USD --12-31 0001528115 Q3 false 10-Q true 2022-09-30 2022 false 001-39402 ANNEXON, INC. DE 27-5414423 1400 Sierra Point Parkway Bldg C Suite 200 Brisbane CA 94005 650 822-5500 Common Stock, par value $0.001 per share ANNX NASDAQ Yes Yes Large Accelerated Filer true false false 47630393 24696206 210658000 74843000 58861000 167872000 5258000 4978000 274777000 247693000 1032000 1166000 17093000 17848000 19616000 20333000 204000 312722000 287040000 6921000 11153000 11323000 9250000 1806000 1202000 170000 139000 20220000 21744000 31900000 33387000 52120000 55131000 48000 39000 664839000 528365000 -406000 -180000 -403879000 -296315000 260602000 231909000 312722000 287040000 27862000 27581000 83966000 72849000 8207000 8099000 24938000 20406000 36069000 35680000 108904000 93255000 -36069000 -35680000 -108904000 -93255000 1015000 82000 1340000 303000 -35054000 -35598000 -107564000 -92952000 -35054000 -35598000 -107564000 -92952000 -0.51 -0.51 -0.93 -0.93 -2.21 -2.21 -2.43 -2.43 68652859 68652859 38341110 38341110 48710433 48710433 38261359 38261359 -35054000 -35598000 -107564000 -92952000 -4000 -3000 -7000 -5000 37000 -7000 -219000 7000 -35021000 -35608000 -107790000 -92950000 38560854 39000 528365000 -180000 -296315000 231909000 4252000 4252000 2711 19000 19000 3000 3000 -196000 -196000 -35373000 -35373000 38563565 39000 532636000 -373000 -331688000 200614000 4520000 4520000 40341 113000 113000 -6000 -6000 -60000 -60000 -37137000 -37137000 38603906 39000 537269000 -439000 -368825000 168044000 4911000 4911000 8763 45000 45000 9500000 9013834 9000 122614000 122623000 -4000 -4000 37000 37000 -35054000 -35054000 47626503 48000 664839000 -406000 -403879000 260602000 38157618 38000 510309000 -77000 -165992000 344278000 2962000 2962000 74930 268000 268000 -1000 -1000 -25000 -25000 -26060000 -26060000 38232548 38000 513539000 -103000 -192052000 321422000 4517000 4517000 82805 534000 534000 6759 118000 118000 -1000 -1000 39000 39000 -31294000 -31294000 38322112 38000 518708000 -65000 -223346000 295335000 4428000 4428000 47986 322000 322000 -3000 -3000 -7000 -7000 -35598000 -35598000 38370098 38000 523458000 -75000 -258944000 264477000 -107564000 -92952000 1576000 1635000 -490000 -934000 13683000 11907000 717000 926000 280000 1765000 204000 -777000 874000 4041000 181000 -883000 471000 31000 -89170000 -77789000 6244000 799000 46364000 191122000 7988000 154666000 62000000 102058000 -121933000 64000 1124000 113000 118000 120976000 9500000 7853000 395000 122800000 847000 135688000 -198875000 -7000 -5000 76009000 268565000 211690000 69685000 3028000 996000 118000 372000 198000 21084000 10748000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annexon, Inc., or the Company, is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. The Company is located in Brisbane, California and was incorporated in Delaware in March 2011.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company’s wholly-owned subsidiary, Annexon Biosciences Australia Pty Ltd, or the Subsidiary, is a proprietary limited company incorporated in 2016 and domiciled in Australia. The Subsidiary is also engaged in research and development activities in support of its parent company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception, the Company has been involved primarily in performing research and development activities, conducting clinical trials, hiring personnel, and raising capital to support and expand these activities. The Company has experienced losses and negative cash flows from operations since its inception and, as of September 30, 2022, had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">403.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and cash and cash equivalents and short-term investments of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has historically funded its operations through the issuance of shares of its redeemable convertible preferred stock and common stock. On July 11, 2022, the Company closed a private placement of shares of common stock, pre-funded warrants and common warrants, or Private Placement, which resulted in net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, after deducting placement agent fees and other expenses. Based on projected activities, management projects that cash on hand is sufficient to support operations for at least the next 12 months following issuance of these condensed consolidated financial statements. Management expects to continue to incur losses and negative cash flows from operations for at least the next several years.</span></p> -403900000 269500000 122600000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. Basis of Presentation and Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and applicable rules and regulations of the SEC regarding interim financial reporting.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations, comprehensive loss, stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows for the interim period presented. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to fair value of investments, useful lives for property and equipment, incremental borrowing rate used in lease accounting, stock options,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">income taxes and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the operations of Annexon, Inc. and its wholly-owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds, are stated at fair value.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of September 30, 2022 relates to the letters of credit established for the Company’s office leases.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.704%;"/> <td style="width:2.356%;"/> <td style="width:1.0%;"/> <td style="width:19.415999999999997%;"/> <td style="width:1.0%;"/> <td style="width:1.994%;"/> <td style="width:1.0%;"/> <td style="width:19.528%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">570</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">734</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,658</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,843</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,032</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,166</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,690</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,009</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of investments sold is based on the specific-identification method. Interest on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">available-for-sale debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> securities is included in interest and other income (expense), net.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company’s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company’s product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company’s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company’s behalf; (iii) contract manufacturing costs to produce clinical trial materials; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation); (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company’s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees, non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employee directors on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants certain employees performance-based stock options. For awards that include performance conditions, no compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service inception date would be recognized.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes option pricing model and recognized as expense on a straight-line basis (for all but performance-based awards for which the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accelerated</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> method is used) over the requisite service period, which is the vesting period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Determining the appropriate fair value model and related assumptions requires judgment, including estimating the fair value of the underlying common stock, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company’s cash</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Management </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, “</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">” (“ASU No. 2020-06”</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). ASU No. 2020-06 simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ASU 2020-06 effective as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The adoption of ASU 2020-06 did not have an</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impac</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t on the Company’s condensed consolidated financial statements.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material impact on its financial position or results of operations.</span></p></div> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and applicable rules and regulations of the SEC regarding interim financial reporting.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations, comprehensive loss, stockholders’ equity for the three and nine months ended September 30, 2022 and 2021 and the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s consolidated financial position, results of operations and cash flows for the interim period presented. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and nine month periods are also unaudited. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021 included herein was derived from the audited financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 1, 2022.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including but not limited to fair value of investments, useful lives for property and equipment, incremental borrowing rate used in lease accounting, stock options,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">income taxes and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The condensed consolidated financial statements include the operations of Annexon, Inc. and its wholly-owned subsidiary and include the results of operations and cash flows of these entities. All intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid instruments with an original maturity of three months or less at time of purchase to be cash equivalents. Cash equivalents, which includes amounts invested in money market funds, are stated at fair value.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash as of September 30, 2022 relates to the letters of credit established for the Company’s office leases.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.704%;"/> <td style="width:2.356%;"/> <td style="width:1.0%;"/> <td style="width:19.415999999999997%;"/> <td style="width:1.0%;"/> <td style="width:1.994%;"/> <td style="width:1.0%;"/> <td style="width:19.528%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">570</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">734</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,658</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,843</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,032</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,166</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,690</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,009</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div> <p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:52.704%;"/> <td style="width:2.356%;"/> <td style="width:1.0%;"/> <td style="width:19.415999999999997%;"/> <td style="width:1.0%;"/> <td style="width:1.994%;"/> <td style="width:1.0%;"/> <td style="width:19.528%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">570</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">734</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,658</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,843</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,032</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,166</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">211,690</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,009</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 570000 734000 210088000 74109000 210658000 74843000 1032000 1166000 211690000 76009000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices or pricing models for similar securities. The Company determines the appropriate classification of its investments in debt securities at the time of purchase. Available-for-sale securities with original maturities beyond three months at the date of purchase are classified as current based on their availability for use in current operations.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates, on a quarterly basis, its available-for-sale debt securities for potential impairment. For available-for-sale debt securities in an unrealized loss position, the Company assesses whether such declines are due to credit loss based on factors such as changes to the rating of the security by a ratings agency, market conditions and supportable forecasts of economic and market conditions, among others. If credit loss exists, the Company assesses whether it has plans to sell the security or it is more likely than not it will be required to sell any available-for-sale debt security before recovery of its amortized cost basis. If either condition is met, the security’s amortized cost basis is written down to fair value and is recognized through interest and other income (expense), net. If neither condition is met, declines as a result of credit losses, if any, are recognized as an allowance for credit loss, limited to the amount of unrealized loss, through interest and other income (expense), net. Any portion of the unrealized loss that is not a result of a credit loss, is recognized in other comprehensive income (loss). Realized gains and losses, if any, on available-for-sale debt securities are included in interest and other income (expense), net.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cost of investments sold is based on the specific-identification method. Interest on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">available-for-sale debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> securities is included in interest and other income (expense), net.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Warrants</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants are accounted for as either derivative liabilities or as equity instruments depending on the specific terms of the agreement. The Company’s pre-funded and common warrants are equity-classified instruments that were recorded in additional paid-in capital at issuance and are not subject to remeasurement. The Company periodically evaluates changes in facts and circumstances that could impact the classification of warrants.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of direct and indirect costs incurred for the development of the Company’s product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct expenses include (i) preclinical and clinical outside service costs associated with discovery, preclinical and clinical testing of the Company’s product candidates; (ii) professional services agreements with third-party contract organizations, investigative clinical trial sites and consultants that conduct research and development activities on the Company’s behalf; (iii) contract manufacturing costs to produce clinical trial materials; and (iv) laboratory supplies and materials. Indirect expenses include (A) compensation and personnel-related expenses (including stock-based compensation); (B) allocated expenses for facilities and depreciation; and (C) other indirect costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Payments made to third parties are under agreements that are generally cancelable by the Company. Advance payments for research and development activities are deferred as prepaid expenses. The prepaid amounts are expensed as the related services are performed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company estimates preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on the Company’s behalf. In accruing service fees, the Company estimates the period over which services will be performed and the level of effort to be expended in each period. These estimates are based on the Company’s communications with the third-party service providers and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies significantly from the estimate, the Company will adjust the accrual accordingly to reflect the best information available at the time of the financial statement issuance. The Company has not experienced any material differences between accrued costs and actual costs incurred since its inception.</span> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for stock-based compensation arrangements with employees, non-employee directors and consultants using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units, or RSUs. The fair value method requires the Company to estimate the fair value of stock options to employees and non-employee directors on the date of grant using the Black-Scholes option pricing model. The fair value of RSU awards is based on the fair value of the underlying common stock as of the grant date.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company grants certain employees performance-based stock options. For awards that include performance conditions, no compensation cost is recognized until the performance goals are probable of being met, at which time the cumulative compensation expense from the service inception date would be recognized.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes option pricing model and recognized as expense on a straight-line basis (for all but performance-based awards for which the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accelerated</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> method is used) over the requisite service period, which is the vesting period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Determining the appropriate fair value model and related assumptions requires judgment, including estimating the fair value of the underlying common stock, expected term, expected stock price volatility, risk-free interest rate and dividend yield. The Company accounts for forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share Attributable to Common Stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders because the effects of potentially dilutive securities are antidilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company’s cash</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cash equivalents and short-term investments are held by high credit quality financial institutions in the United States. At times, such deposits may be in excess of the Federal Depository Insurance Corporation insured limits.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Management </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">believes that the financial institutions are financially sound, and accordingly, minimal credit risk exists with respect to the financial institutions.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, “</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity's Own Equity (Subtopic 815-40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">” (“ASU No. 2020-06”</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). ASU No. 2020-06 simplifies the accounting for convertible instruments. The guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments. The Company </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adopted</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ASU 2020-06 effective as of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The adoption of ASU 2020-06 did not have an</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impac</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t on the Company’s condensed consolidated financial statements.</span></p> true 2022-01-01 true <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company does not believe that any recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material impact on its financial position or results of operations.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1 Inputs:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2 Inputs:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.752626672113803%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 3 Inputs:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a recurring basis, the Company measures certain financial assets and liabilities at fair value. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.461%;"/> <td style="width:1.16%;"/> <td style="width:9.937%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:6.944%;"/> <td style="width:1.0%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:8.744%;"/> <td style="width:1.0%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:8.308%;"/> <td style="width:1.0%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:7.8069999999999995%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,825</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,725</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government bonds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,354</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">218</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,136</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,267</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">318</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,949</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.497%;"/> <td style="width:1.076%;"/> <td style="width:9.902%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:7.141%;"/> <td style="width:1.0%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:8.857000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:8.328%;"/> <td style="width:1.0%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:7.893%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,352</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,325</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,814</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,790</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government bonds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,809</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,084</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">241,981</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and 2021, the Company recognized no material realized gains or losses on financial instruments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.461%;"/> <td style="width:1.16%;"/> <td style="width:9.937%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:6.944%;"/> <td style="width:1.0%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:8.744%;"/> <td style="width:1.0%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:8.308%;"/> <td style="width:1.0%;"/> <td style="width:1.16%;"/> <td style="width:1.0%;"/> <td style="width:7.8069999999999995%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">210,088</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,825</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,725</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government bonds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,354</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">218</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,136</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">269,267</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">318</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">268,949</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:44.497%;"/> <td style="width:1.076%;"/> <td style="width:9.902%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:7.141%;"/> <td style="width:1.0%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:8.857000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:8.328%;"/> <td style="width:1.0%;"/> <td style="width:1.076%;"/> <td style="width:1.0%;"/> <td style="width:7.893%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash equivalents:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,109</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments:</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,352</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,325</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate bonds</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,814</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,790</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government bonds</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,809</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,757</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">242,084</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">241,981</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 210088000 210088000 23825000 100000 23725000 35354000 218000 35136000 269267000 318000 268949000 74109000 74109000 85352000 27000 85325000 48814000 24000 48790000 33809000 52000 33757000 242084000 103000 241981000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. Balance Sheet Components</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.031%;"/> <td style="width:1.697%;"/> <td style="width:1.0%;"/> <td style="width:13.860000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.697%;"/> <td style="width:1.0%;"/> <td style="width:13.713%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,562</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,002</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,243</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,282</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other prepaid expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">396</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">463</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,978</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.296%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.721%;"/> <td style="width:1.0%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.588%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,179</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,594</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,552</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,353</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">682</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">649</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, gross</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,446</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,637</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,353</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">789</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,848</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized depreciation for property and equipment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three months ended September 30, 2022 and 2021, respectively, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.279%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.583%;"/> <td style="width:1.0%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.742999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,054</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,404</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,792</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,274</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued construction costs</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,917</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,323</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,250</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div> <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.031%;"/> <td style="width:1.697%;"/> <td style="width:1.0%;"/> <td style="width:13.860000000000001%;"/> <td style="width:1.0%;"/> <td style="width:1.697%;"/> <td style="width:1.0%;"/> <td style="width:13.713%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid research and development costs</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,562</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,002</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid insurance</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,243</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,282</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other prepaid expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">396</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">231</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other current assets</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">463</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total prepaid expenses and other current assets</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,258</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,978</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 3562000 3002000 1243000 1282000 396000 231000 57000 463000 5258000 4978000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net, consisted of the following (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.296%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.721%;"/> <td style="width:1.0%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.588%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,179</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,594</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,552</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,353</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">682</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">649</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment and software</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, gross</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,446</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,637</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,353</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">789</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,093</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,848</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 17179000 16594000 1552000 1353000 682000 649000 33000 41000 19446000 18637000 2353000 789000 17093000 17848000 500000 600000 1600000 1600000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:65.279%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.583%;"/> <td style="width:1.0%;"/> <td style="width:1.698%;"/> <td style="width:1.0%;"/> <td style="width:13.742999999999999%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,054</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,404</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,792</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued professional services</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">313</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,274</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued construction costs</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,917</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued liabilities</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,323</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,250</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 7054000 2404000 3792000 3573000 313000 1274000 1917000 164000 82000 11323000 9250000 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company leases its offices and laboratory in Brisbane, California, or the Brisbane Lease, under a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> noncancelable lease agreement that ends in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 2031</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewable option. In November 2021, the Company subleased unoccupied space for two years starting from December 2021 for aggregate sublease payments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The sublease income, while it reduces the rent expense, is not considered in the value of the right-of-use assets or lease liabilities. The Company’s sublease income was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three and nine months ended September 30, 2022, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, the operating lease right-of-use assets were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and lease liabilities were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the condensed consolidated balance sheet. The weighted-average remaining lease term is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average incremental borrowing rate used to measure the operating lease liability is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease costs were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the three months ended September 30, 2022 and 2021, respectively, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022 and 2021, respectively. Variable lease payments were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the three months ended September 30, 2022 and 2021, respectively, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments and related lease liabilities as of September 30, 2022, were as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.75%;"/> <td style="width:5.155%;"/> <td style="width:1.0%;"/> <td style="width:16.095%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 (remaining three months)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,175</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,742</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,907</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,079</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026 and thereafter</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,833</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:25.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,736</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,030</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);text-indent:25.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,706</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License and Other Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2011, the Company entered into an exclusive licensing agreement, or the Stanford Agreement, with The Board of Trustees of the Leland Stanford Junior University, or Stanford, whereby the Company was granted an exclusive, worldwide, royalty-bearing, sublicensable license, under certain patent rights, or the Licensed Patents, to make, use, offer for sale, sell, import and otherwise commercialize products covered by the Licensed Patents for human or animal diseases, disorders or conditions. Under the Stanford Agreement, the Company made an upfront payment and is obligated to pay Stanford annual license maintenance fees, potential future milestone payments totaling up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and royalty payments at a rate equal to a low single-digit percentage of worldwide net sales of licensed products. The Company did not achieve any milestones or make any milestone payments for the three and nine months ended September 30, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2016, the Company entered into a sponsored research agreement, with a not-for-profit entity to perform research on multiple sclerosis. The sponsored research agreement was amended in March 2019, or as amended, the Sponsored Research Agreement. Under the terms of the Sponsored Research Agreement, the Company may receive up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in funding. If within </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years of the end of the Sponsored Research Agreement, the Company files a marketing authorization application for a product treating multiple sclerosis, the Company will be obligated to pay milestone payments up to four times the amounts received under the Sponsored Research Agreement. The Company has received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in funding to date, which was recorded as other income. The Company recognized </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> income during the nine months ended September 30, 2022 and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in income during the nine months ended September 30, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Guarantees and Indemnifications</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2022, the Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.</span></p> P10Y 2031-10 P10Y 3400000 400000 1200000 19600000 33700000 P9Y1M6D 0.084 500000 1100000 1500000 2000000.0 100000 36000 700000 100000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease payments and related lease liabilities as of September 30, 2022, were as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:76.75%;"/> <td style="width:5.155%;"/> <td style="width:1.0%;"/> <td style="width:16.095%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 (remaining three months)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,175</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,742</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,907</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,079</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026 and thereafter</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,833</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:25.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total undiscounted lease payments</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,736</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td> <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,030</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(255,255,255,1);text-indent:25.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:25.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,706</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 1175000 4742000 4907000 5079000 32833000 48736000 15030000 33706000 500000 700000 P15Y 600000 0 100000 0 0 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Stockholders’ Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Private Placement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 11, 2022, the Company sold in a private placement an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,013,834</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, pre-funded warrants to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,696,206</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock and accompanying common warrants to purchase up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,427,508</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock. The offering price per share and accompanying common warrant was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.87125</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and the offering price per pre-funded warrant and accompanying common warrant was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.87025</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, which equals the per share offering price for the shares of common stock less the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> exercise price for each such pre-funded warrant. The pre-funded warrants remain exercisable until exercised in full. The common warrants have an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.806875</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and expire on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An entity related to one of the Company’s directors participated in the Private Placement and purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,453,988</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock and accompanying common warrants to purchase up to an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">613,497</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock for an aggregate price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both the pre-funded and common warrants are immediately exercisable, subject to beneficial ownership limitations. The Company may not effect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of common stock outstanding immediately after giving effect to the exercise or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage not in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61 day</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s’ notice to the Company. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may not effect the exercise of any common warrant, and a holder will not be entitled to exercise any portion of any common warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or 19.99% (as applicable pursuant to the holder’s common warrant) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage, including 9.99%, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, and not in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, upon at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days’ notice to the Company.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The warrants meet the criteria for equity classification and were therefore recorded at fair value as of the grant date as a component of stockholders’ equity within additional paid-in capital.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded or common warrants were exercised, and there were pre-funded and common warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,123,714</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding. The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,696,206</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of the pre-funded warrants and the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,427,508</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issuable upon the exercise of the common warrants are not included in the number of issued and outstanding shares of common stock as of September 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">At-the-Market Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2021, the Company entered into a sales agreement with Cowen and Company LLC, or Cowen, as sales agent, pursuant to which the Company may issue and sell shares of its common stock for an aggregate maximum offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under an at-the-market offering program, or 2021 ATM program. The Company will pay Cowen up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of gross proceeds for the common stock sold through the 2021 ATM program. As of September 30, 2022, no shares of common stock have been sold under the 2021 ATM program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved the following shares of common stock for issuance as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.452%;"/> <td style="width:1.793%;"/> <td style="width:1.0%;"/> <td style="width:17.48%;"/> <td style="width:1.0%;"/> <td style="width:1.793%;"/> <td style="width:1.0%;"/> <td style="width:17.48%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options issued and outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,178,136</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,662,824</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options reserved for 2020 Incentive Award Plan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,001</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,039,951</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for 2021 ATM program</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,265,929</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,265,929</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for Employee Stock Purchase<br/>     Plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,075,042</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">729,775</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for Employment Inducement <br/>    Award Plan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,703,000</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for pre-funded warrants</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,696,206</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for common warrants</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,427,508</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total common stock reserved</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,271,430</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,748,479</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div> 9013834 24696206 8427508 3.87125 3.87025 0.001 5.806875 2025-06-30 2453988 613497 9500000 0.0999 0.0999 0.1999 P61D The Company may not effect the exercise of any common warrant, and a holder will not be entitled to exercise any portion of any common warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder, together with its affiliates, to exceed 4.99%, 9.99% or 19.99% (as applicable pursuant to the holder’s common warrant) of the total number of shares of common stock outstanding immediately after giving effect to the exercise, which such percentage may be changed at the holder’s election to a higher or lower percentage, including 9.99%, 14.99% or 19.99%, and not in excess of 19.99%, upon at least 61 days’ notice to the Company. 0.0499 0.0999 0.1499 0.1999 0.1999 P61D 0 0 33123714 24696206 8427508 100000000.0 0.03 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has reserved the following shares of common stock for issuance as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.452%;"/> <td style="width:1.793%;"/> <td style="width:1.0%;"/> <td style="width:17.48%;"/> <td style="width:1.0%;"/> <td style="width:1.793%;"/> <td style="width:1.0%;"/> <td style="width:17.48%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30,<br/>2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,<br/>2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options issued and outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,178,136</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,662,824</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options reserved for 2020 Incentive Award Plan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,001</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,039,951</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units outstanding</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for 2021 ATM program</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,265,929</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,265,929</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for Employee Stock Purchase<br/>     Plan</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,075,042</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">729,775</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for Employment Inducement <br/>    Award Plan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,703,000</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for pre-funded warrants</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,696,206</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for common warrants</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,427,508</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total common stock reserved</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,271,430</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,748,479</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 8178136 5662824 334001 2039951 591608 50000 5265929 5265929 1075042 729775 1703000 24696206 8427508 50271430 13748479 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2020, the Company’s board of directors and stockholders adopted and approved the 2020 Incentive Award Plan, or the 2020 Plan, and the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the Company’s initial public offering, or the IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may not grant any additional awards under the 2011 Equity Incentive Plan, or the 2011 Plan. The 2011 Plan will continue to govern outstanding equity awards granted thereunder.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance under the 2020 Plan automatically increases on the first day of January, in an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the total number of shares of the Company’s capital stock outstanding on the last day of the preceding year, or a lesser number of shares determined by the Company’s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Awards granted under the 2020 Plan expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. For Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period but may be granted with different vesting terms.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of September 30, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">334,001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2022 Employment Inducement Award Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, the Company’s board of directors adopted the Annexon, Inc. 2022 Employment Inducement Award Plan, or the Inducement Plan, and together with the 2011 Plan and the 2020 Plan, the Plans. The Inducement Plan was adopted by the Company’s board of directors without stockholder approval pursuant to Nasdaq Marketplace Rule 5635(c)(4), or Rule 5635(c)(4). In accordance with Rule 5635(c)(4), awards made under the Inducement Plan may only be granted to newly hired employees as an inducement material to the employees entering into employment with the Company. Awards granted under the Inducement Plan expire no later than ten years from the date of grant. An aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were reserved for issuance under the Inducement Plan. As of September 30, 2022, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,703,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for issuance under the Inducement Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents stock option activity under the Plans for the period:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.497%;"/> <td style="width:0.983%;"/> <td style="width:1.0%;"/> <td style="width:8.77%;"/> <td style="width:1.0%;"/> <td style="width:1.299%;"/> <td style="width:1.0%;"/> <td style="width:9.604999999999999%;"/> <td style="width:1.0%;"/> <td style="width:0.983%;"/> <td style="width:1.0%;"/> <td style="width:10.124%;"/> <td style="width:1.0%;"/> <td style="width:1.299%;"/> <td style="width:1.0%;"/> <td style="width:10.439%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,662,824</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.98</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.26</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,186</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,645,435</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.59</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,474</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options forfeited</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,118,649</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.24</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances as of September 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,178,136</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.02</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.39</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,084</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of September 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,968,956</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.75</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.17</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,494</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total intrinsic value of options exercised were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the three months ended September 30, 2022 and 2021, respectively, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022 and 2021, respectively. The intrinsic value is the difference between the fair value of the Company’s common stock at the time of exercise and the exercise price of the stock option.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair value of options granted to employees during the nine months ended September 30, 2022 and 2021 was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.93</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.41</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, the total unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which the Company expects to recognize over an estimated weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs are equity awards that entitle the holder to receive shares of the Company’s common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs generally vest over a three-year period in equal amounts on an annual basis, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of the Company’s common stock on the grant date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of RSU activity under the 2020 Plan and related information is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.687%;"/> <td style="width:1.278%;"/> <td style="width:1.0%;"/> <td style="width:12.918999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.742%;"/> <td style="width:1.0%;"/> <td style="width:13.373%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.84</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,583</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.40</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,975</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of September 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of September 30, 2022, unrecognized stock-based compensation expense related to outstanding unvested RSUs was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each offering period at a price equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, and up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of an employee’s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increase </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">automatically on the first day of each fiscal year, by a number equal to the least of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">360,086</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or such number of shares determined by the Company’s board of directors. As of September 30, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,075,042</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were available for future purchase. The ESPP generally provides for six-month consecutive offering periods beginning on May 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and November 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of each year. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense has been recorded for the three and nine months ended September 30, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The stock-based compensation expense related to the ESPP was </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the three months ended September 30, 2022 and 2021, respectively, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the nine months ended September 30, 2022 and 2021, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total stock-based compensation expense related to all equity-based awards recognized in the period was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.99%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:8.967%;"/> <td style="width:1.0%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:9.4%;"/> <td style="width:1.0%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:8.967%;"/> <td style="width:1.0%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:9.4%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,433</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,382</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,509</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,330</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,478</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,046</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,174</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,577</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,911</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,428</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,683</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,907</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To determine the value of stock option awards for stock-based compensation purposes, the Company uses the Black-Scholes option pricing model and the assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each award issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.588%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.77</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.33</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.33</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.92</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> </tr> </table></div> 0.04 Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs, the option price shall not be less than 100% of the estimated fair value on the date of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms. P10Y 1 P4Y 334001 2000000 1703000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents stock option activity under the Plans for the period:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:48.497%;"/> <td style="width:0.983%;"/> <td style="width:1.0%;"/> <td style="width:8.77%;"/> <td style="width:1.0%;"/> <td style="width:1.299%;"/> <td style="width:1.0%;"/> <td style="width:9.604999999999999%;"/> <td style="width:1.0%;"/> <td style="width:0.983%;"/> <td style="width:1.0%;"/> <td style="width:10.124%;"/> <td style="width:1.0%;"/> <td style="width:1.299%;"/> <td style="width:1.0%;"/> <td style="width:10.439%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Shares</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in years)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances as of December 31, 2021</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,662,824</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.98</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.26</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,186</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options granted</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,645,435</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.59</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options exercised</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,474</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options forfeited</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,118,649</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.24</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances as of September 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,178,136</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.02</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.39</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,084</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable as of September 30, 2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,968,956</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.75</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.17</span></span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,494</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 5662824 16.98 P8Y3M3D 10186000 3645435 5.59 11474 5.65 1118649 16.24 8178136 12.02 P8Y4M20D 6084000 2968956 12.75 P7Y2M1D 2494000 2500 700000 5000 3900000 3.93 19.41 42700000 P2Y7M6D <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of RSU activity under the 2020 Plan and related information is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.687%;"/> <td style="width:1.278%;"/> <td style="width:1.0%;"/> <td style="width:12.918999999999999%;"/> <td style="width:1.0%;"/> <td style="width:1.742%;"/> <td style="width:1.0%;"/> <td style="width:13.373%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Grant Date Fair Value Per Share</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50,000</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.84</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">600,583</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.40</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,975</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.04</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of September 30, 2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.76</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 50000 12.84 600583 5.40 58975 8.04 591608 5.76 2800000 P2Y6M 0.85 0.01 0.15 360086 0.01 1075042 29000 42000 100000 100000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The total stock-based compensation expense related to all equity-based awards recognized in the period was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.99%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:8.967%;"/> <td style="width:1.0%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:9.4%;"/> <td style="width:1.0%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:8.967%;"/> <td style="width:1.0%;"/> <td style="width:1.319%;"/> <td style="width:1.0%;"/> <td style="width:9.4%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,433</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,382</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,509</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,330</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,478</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,046</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,174</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,577</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,911</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,428</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,683</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,907</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 2433000 2382000 6509000 6330000 2478000 2046000 7174000 5577000 4911000 4428000 13683000 11907000 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of each award issued was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:23.588%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> <td style="width:2.0%;"/> <td style="width:17.103%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Three Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.77</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.33</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.33</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.08</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.92</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.61</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> </tr> </table> P5Y9M7D P6Y29D P4Y3M29D P6Y29D P5Y6M P6Y29D P4Y3M29D P6Y29D 0.8170 0.8270 0.883 0.89 0.7880 0.8280 0.883 0.907 0.0292 0.0361 0.0070 0.0110 0.0149 0.0361 0.0035 0.0110 <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. Income Taxes</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the three and nine months ended September 30, 2022 and 2021, the Company incurred insignificant amounts for an income tax provision. The U.S. federal and California deferred tax assets generated from the Company’s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.</span></p> <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. Net Loss Per Share Attributable to Common Stockholders</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding, excluding restricted common stock. The weighted-average number of shares of common stock used in the basic and diluted net loss per share calculation include the pre-funded warrants issued in connection with the Private Placement as the pre-funded warrants are exercisable at any time for nominal cash consideration. As of September 30, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> pre-funded warrants have been exercised and there were pre-funded warrants to purchase an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,696,206</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock outstanding. The Company has generated a net loss in all periods presented, so the basic and diluted net loss per share are the same, as the inclusion of the potentially dilutive securities would be anti-dilutive.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.368%;"/> <td style="width:1.289%;"/> <td style="width:1.0%;"/> <td style="width:12.857%;"/> <td style="width:1.0%;"/> <td style="width:1.289%;"/> <td style="width:1.0%;"/> <td style="width:13.197%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,178,136</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,918,981</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares subject to Employee Stock Purchase Plan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,897</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,538</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common warrants to purchase common stock</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,427,508</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,308,149</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,928,519</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table></div> 0 24696206 <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.368%;"/> <td style="width:1.289%;"/> <td style="width:1.0%;"/> <td style="width:12.857%;"/> <td style="width:1.0%;"/> <td style="width:1.289%;"/> <td style="width:1.0%;"/> <td style="width:13.197%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nine Months Ended<br/>September 30,</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options to purchase common stock</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,178,136</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,918,981</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares subject to Employee Stock Purchase Plan</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,897</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,538</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested restricted stock units</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">591,608</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common warrants to purchase common stock</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,427,508</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">—</span></p></td> <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,308,149</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,928,519</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"/> </p></td> </tr> </table> 8178136 5918981 110897 9538 591608 8427508 17308149 5928519 EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 162 241 1 false 46 0 false 5 false false R1.htm 100000 - Document - Cover Page Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage Cover Page Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Operations Sheet http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://annexonbio.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 100070 - Disclosure - Organization Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganization Organization Notes 8 false false R9.htm 100080 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Fair Value Measurements Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 100100 - Disclosure - Balance Sheet Components Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponents Balance Sheet Components Notes 11 false false R12.htm 100110 - Disclosure - Commitments and Contingencies Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 100120 - Disclosure - Stockholder's Equity Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquity Stockholder's Equity Notes 13 false false R14.htm 100130 - Disclosure - Equity Incentive Plans Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlans Equity Incentive Plans Notes 14 false false R15.htm 100160 - Disclosure - Income Taxes Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 100170 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 16 false false R17.htm 100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies 17 false false R18.htm 100200 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies 18 false false R19.htm 100210 - Disclosure - Fair Value Measurements (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurements 19 false false R20.htm 100220 - Disclosure - Balance Sheet Components (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponents 20 false false R21.htm 100230 - Disclosure - Commitments and Contingencies (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies 21 false false R22.htm 100240 - Disclosure - Stockholder's Equity (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityTables Stockholder's Equity (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquity 22 false false R23.htm 100250 - Disclosure - Equity Incentive Plans (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansTables Equity Incentive Plans (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlans 23 false false R24.htm 100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders 24 false false R25.htm 100270 - Disclosure - Organization - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 25 false false R26.htm 100280 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Details 26 false false R27.htm 100290 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) Details 27 false false R28.htm 100300 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) Details 28 false false R29.htm 100310 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail) Details 29 false false R30.htm 100320 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail Balance Sheet Components - Summary of Property and Equipment, Net (Detail) Details 30 false false R31.htm 100330 - Disclosure - Balance Sheet Components - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail Balance Sheet Components - Additional Information (Detail) Details 31 false false R32.htm 100340 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail Balance Sheet Components - Summary of Accrued Liabilities (Detail) Details 32 false false R33.htm 100350 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 33 false false R34.htm 100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail) Details 34 false false R35.htm 100380 - Disclosure - Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail) Details 35 false false R36.htm 100390 - Disclosure - Stockholder's Equity - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail Stockholder's Equity - Additional Information (Detail) Details 36 false false R37.htm 100400 - Disclosure - Equity Incentive Plans - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail Equity Incentive Plans - Additional Information (Detail) Details 37 false false R38.htm 100410 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail Equity Incentive Plans - Summary of Stock Option Activity (Detail) Details 38 false false R39.htm 100420 - Disclosure - Equity Incentive Plans - Summary of RSU Activity under 2020 Plan (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail Equity Incentive Plans - Summary of RSU Activity under 2020 Plan (Detail) Details 39 false false R40.htm 100430 - Disclosure - Equity Incentive Plans - Summary of Stock-Based Compensation Expense (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail Equity Incentive Plans - Summary of Stock-Based Compensation Expense (Detail) Details 40 false false R41.htm 100440 - Disclosure - Equity Incentive Plans - Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail Equity Incentive Plans - Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail) Details 41 false false R42.htm 100450 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail) Details 42 false false R43.htm 100460 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail) Sheet http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail) Details 43 false false All Reports Book All Reports annx-20220930.htm annx-20220930.xsd annx-20220930_cal.xml annx-20220930_def.xml annx-20220930_lab.xml annx-20220930_pre.xml annx-ex31_1.htm annx-ex31_2.htm annx-ex32_1.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "annx-20220930.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 162, "dts": { "calculationLink": { "local": [ "annx-20220930_cal.xml" ] }, "definitionLink": { "local": [ "annx-20220930_def.xml" ] }, "inline": { "local": [ "annx-20220930.htm" ] }, "labelLink": { "local": [ "annx-20220930_lab.xml" ] }, "presentationLink": { "local": [ "annx-20220930_pre.xml" ] }, "schema": { "local": [ "annx-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 380, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 2, "http://xbrl.sec.gov/dei/2022": 4, "total": 6 }, "keyCustom": 37, "keyStandard": 204, "memberCustom": 16, "memberStandard": 24, "nsprefix": "annx", "nsuri": "http://annexonbio.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Fair Value Measurements", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:BalanceSheetComponentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Balance Sheet Components", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:BalanceSheetComponentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Commitments and Contingencies", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Stockholder's Equity", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquity", "shortName": "Stockholder's Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Equity Incentive Plans", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlans", "shortName": "Equity Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Taxes", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Fair Value Measurements (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Balance Sheet Components (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Stockholder's Equity (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityTables", "shortName": "Stockholder's Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Equity Incentive Plans (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansTables", "shortName": "Equity Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Organization - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail", "shortName": "Organization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-5", "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "shortName": "Basis of Presentation and Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "annx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "annx:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_4af636cd-8179-466a-b590-caec7784c6ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "annx:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_4af636cd-8179-466a-b590-caec7784c6ea", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "annx:PrepaidResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail", "shortName": "Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "annx:SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "annx:PrepaidResearchAndDevelopmentCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Statements of Operations", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail", "shortName": "Balance Sheet Components - Summary of Property and Equipment, Net (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Balance Sheet Components - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail", "shortName": "Balance Sheet Components - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "annx:AccruedResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail", "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "annx:BalanceSheetComponentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "annx:AccruedResearchAndDevelopmentExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_9ff1b8bd-97be-4fa8-9111-7073d09bc9b7", "decimals": "-5", "first": true, "lang": null, "name": "annx:AggregateSubleasePaymentReceivable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_9ff1b8bd-97be-4fa8-9111-7073d09bc9b7", "decimals": "-5", "first": true, "lang": null, "name": "annx:AggregateSubleasePaymentReceivable", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail", "shortName": "Commitments and Contingencies - Future Minimum Lease Payments and Related Lease Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail", "shortName": "Stockholder's Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "annx:ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_4dbcb6a3-5211-4773-8067-43870ae43b4d", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_6a763431-34ce-47e1-9070-7616fb0bfde1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CommonStockValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Stockholder's Equity - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "shortName": "Stockholder's Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "lang": "en-US", "name": "annx:ExerciseOfWarrantDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "2", "first": true, "lang": null, "name": "annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Equity Incentive Plans - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "shortName": "Equity Incentive Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "2", "first": true, "lang": null, "name": "annx:PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_4f5452ad-1543-48e8-9cfa-9dd32f39199f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail", "shortName": "Equity Incentive Plans - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_4f5452ad-1543-48e8-9cfa-9dd32f39199f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Equity Incentive Plans - Summary of RSU Activity under 2020 Plan (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail", "shortName": "Equity Incentive Plans - Summary of RSU Activity under 2020 Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_4f5452ad-1543-48e8-9cfa-9dd32f39199f", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Equity Incentive Plans - Summary of Stock-Based Compensation Expense (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail", "shortName": "Equity Incentive Plans - Summary of Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_1b5298c0-5aea-4786-9746-f52289302559", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Equity Incentive Plans - Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "shortName": "Equity Incentive Plans - Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_74406171-43d8-4325-9cba-a40cfccd5789", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_ddb250d7-4c4e-4ab6-b122-744df46c6d3f", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_a4bd6199-a34a-45f3-9b8b-02e4fb50912c", "decimals": "-3", "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://annexonbio.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_cdba6883-bde2-4343-99d8-cf766db17088", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Organization", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Basis of Presentation and Significant Accounting Policies", "role": "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies", "shortName": "Basis of Presentation and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "annx-20220930.htm", "contextRef": "C_fae8c321-a147-4a9b-8665-985f106c01ed", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "annx_AccruedCompensationCurrent": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued compensation, current", "label": "Accrued Compensation Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedCompensationCurrent", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "annx_AccruedConstructionCostsCurrent": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued construction costs current.", "label": "Accrued Construction Costs Current", "terseLabel": "Accrued construction costs" } } }, "localname": "AccruedConstructionCostsCurrent", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "annx_AccruedResearchAndDevelopmentExpensesCurrent": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses, current", "label": "Accrued Research And Development Expenses Current", "terseLabel": "Accrued research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "annx_AdditionalStockIssuedDuringPeriodCommonSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional stock issued during period common shares purchased.", "label": "Additional Stock Issued During Period Common Shares Purchased", "terseLabel": "Additional common shares purchased" } } }, "localname": "AdditionalStockIssuedDuringPeriodCommonSharesPurchased", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "annx_AggregateSubleasePaymentReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate sublease payment receivable.", "label": "Aggregate Sublease Payment Receivable", "verboseLabel": "Aggregate sublease payment receivable" } } }, "localname": "AggregateSubleasePaymentReceivable", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "annx_BalanceSheetComponentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Balance sheet components disclosure.", "label": "Balance Sheet Components Disclosure [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "BalanceSheetComponentsDisclosureTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "annx_BrisbaneCaliforniaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brisbane, California.", "label": "Brisbane California [Member]", "terseLabel": "Brisbane, California [Member]" } } }, "localname": "BrisbaneCaliforniaMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "annx_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liability.", "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liability", "terseLabel": "Cash paid for amounts included in the measurement of lease liability" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiability", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "annx_CombinedVotingPowerMaximumPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Combined voting power maximum percentage.", "label": "Combined Voting Power Maximum Percentage", "terseLabel": "Combined voting power maximum" } } }, "localname": "CombinedVotingPowerMaximumPercentage", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_CombinedVotingPowerPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Combined voting power percentage.", "label": "Combined Voting Power Percentage", "terseLabel": "Combined voting power" } } }, "localname": "CombinedVotingPowerPercentage", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_CommonSharesExchangeValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Common shares exchange value.", "label": "Common Shares Exchange Value", "terseLabel": "Exchange value" } } }, "localname": "CommonSharesExchangeValue", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "annx_CommonSharesOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares outstanding percentage.", "label": "Common Shares Outstanding Percentage", "terseLabel": "Total number of common shares outstanding" } } }, "localname": "CommonSharesOutstandingPercentage", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Warrants Member", "label": "Common Warrants Member", "terseLabel": "Common Warrants [Member]" } } }, "localname": "CommonWarrantsMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Software [Member]" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "annx_ConstructionInProgressObtainedInExchangeForTenantImprovementAllowanceFromLessors": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Construction-in-progress obtained in exchange for tenant improvement allowance from lessors.", "label": "Construction in Progress Obtained in Exchange for Tenant Improvement Allowance from Lessors", "terseLabel": "Construction-in-progress obtained in exchange for tenant improvement allowance from lessors" } } }, "localname": "ConstructionInProgressObtainedInExchangeForTenantImprovementAllowanceFromLessors", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "annx_DeferredOfferingCostsIncludedInAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred offering costs included in accrued liabilities.", "label": "Deferred Offering Costs Included In Accrued Liabilities", "terseLabel": "Deferred offering costs included in accrued liabilities" } } }, "localname": "DeferredOfferingCostsIncludedInAccruedLiabilities", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "annx_DisclosureOfBalanceSheetComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Balance Sheet Components [Abstract]", "label": "Disclosure Of Balance Sheet Components [Abstract]" } } }, "localname": "DisclosureOfBalanceSheetComponentsAbstract", "nsuri": "http://annexonbio.com/20220930", "xbrltype": "stringItemType" }, "annx_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]", "verboseLabel": "Common Stock Reserved for Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_EmploymentInducementAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Inducement Award Plan Member", "label": "Employment Inducement Award Plan Member", "terseLabel": "Employment Inducement Award Plan [Member]" } } }, "localname": "EmploymentInducementAwardPlanMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_EmploymentInducementIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Twenty Two Employment Inducement Award Plan.", "label": "Two Thousand Twenty Two Employment Inducement Award Plan [Member]", "terseLabel": "2022 Employment Inducement Award Plan [Member]" } } }, "localname": "EmploymentInducementIncentivePlanMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "annx_ExerciseOfWarrantDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of warrant description.", "label": "Exercise of Warrant Description", "terseLabel": "Exercise of common warrant, description" } } }, "localname": "ExerciseOfWarrantDescription", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "annx_IncentiveStockOptionsAndNonstatutoryStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options and nonstatutory stock options.", "label": "Incentive Stock Options And Nonstatutory Stock Options [Member]", "terseLabel": "Incentive Stock Options, or ISOs, and Nonstatutory Stock Options, or NSOs [Member]" } } }, "localname": "IncentiveStockOptionsAndNonstatutoryStockOptionsMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "annx_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "annx_InterestAndOtherNonOperatingIncomeExpense": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest and other non operating income (expense).", "label": "Interest And Other Non Operating Income Expense", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherNonOperatingIncomeExpense", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "annx_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "annx_LesseeOperatingLeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, operating lease, expiration month and year.", "label": "Lessee Operating Lease Expiration Month And Year", "terseLabel": "Operating lease, expiration month and year" } } }, "localname": "LesseeOperatingLeaseExpirationMonthAndYear", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "gYearMonthItemType" }, "annx_LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due year four and thereafter.", "label": "Lessee Operating Lease Liability Payments Due Year Four And Thereafter", "terseLabel": "2026 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFourAndThereafter", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "annx_MaximumExpectedResearchFunding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum Expected Research Funding", "label": "Maximum Expected Research Funding", "terseLabel": "Maximum expected research funding" } } }, "localname": "MaximumExpectedResearchFunding", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "annx_MaximumNumberOfSharesToBeIssuedInAccordanceWithPlanAsAProportionOfOutstandingCapitalStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of shares to be issued in accordance with plan as a proportion of outstanding capital stock.", "label": "Maximum Number of Shares to be Issued in Accordance with Plan as a Proportion of Outstanding Capital Stock", "terseLabel": "Maximum number of shares to be issued in accordance with plan as a proportion of outstanding capital stock" } } }, "localname": "MaximumNumberOfSharesToBeIssuedInAccordanceWithPlanAsAProportionOfOutstandingCapitalStock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "annx_MaximumThresholdPeriodAllowedForFilingMarketAuthorisation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Threshold Period Allowed For Filing Market Authorisation", "label": "Maximum Threshold Period Allowed For Filing Market Authorisation", "terseLabel": "Maximum threshold period allowed for filing market authorization" } } }, "localname": "MaximumThresholdPeriodAllowedForFilingMarketAuthorisation", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "annx_OfferingPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offering price per share.", "label": "Offering Price Per Share", "terseLabel": "Offering price per share" } } }, "localname": "OfferingPricePerShare", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "annx_OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease weighted average incremental borrowing rate percent.", "label": "Operating Lease Weighted Average Incremental Borrowing Rate Percent", "terseLabel": "Weighted average incremental borrowing rate" } } }, "localname": "OperatingLeaseWeightedAverageIncrementalBorrowingRatePercent", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_PaymentsOfCommonStockAndWarrantsIssuanceCosts": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments of common stock and warrants issuance costs.", "label": "Payments of Common Stock and Warrants Issuance Costs", "negatedLabel": "Payment of issuance costs related to the issuance of common stock, pre-funded warrants and common warrants" } } }, "localname": "PaymentsOfCommonStockAndWarrantsIssuanceCosts", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "annx_PercentageOfGrossProceedsOfCommonStockToBePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of gross proceeds of common stock to be paid.", "label": "Percentage Of Gross Proceeds Of Common Stock To Be Paid", "terseLabel": "Percentage of gross proceeds of common stock to be paid" } } }, "localname": "PercentageOfGrossProceedsOfCommonStockToBePaid", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of number of shares of capital stock outstanding on last day of preceding year.", "label": "Percentage Of Number Of Shares Of Capital Stock Outstanding On Last Day Of Preceding Year", "terseLabel": "Percentage of number of shares of capital stock outstanding on last day of preceding year" } } }, "localname": "PercentageOfNumberOfSharesOfCapitalStockOutstandingOnLastDayOfPrecedingYear", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year.", "label": "Percentage Of Shares Of Common Stock Outstanding On Last Day Of Immediately Preceding Fiscal Year", "terseLabel": "Percentage of shares of common stock outstanding on last day of immediately preceding fiscal year" } } }, "localname": "PercentageOfSharesOfCommonStockOutstandingOnLastDayOfImmediatelyPrecedingFiscalYear", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "pre-funded warrants Member.", "label": "pre-funded warrants Member", "terseLabel": "Pre-Funded Warrants [Member]" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_PrefundedWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prefunded Warrant Member", "label": "Prefunded Warrant [Member]", "terseLabel": "Pre-funded Warrants [Member]" } } }, "localname": "PrefundedWarrantMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "domainItemType" }, "annx_PrepaidResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "prepaid research and development costs, current", "label": "Prepaid Research And Development Costs Current", "terseLabel": "Prepaid research and development costs" } } }, "localname": "PrepaidResearchAndDevelopmentCostsCurrent", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "annx_ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from related parties for the issuance of common stock, Pre-funded warrants and common warrants.", "label": "Proceeds from Related Parties For The Issuance of Common Stock Prefunded Warrants and Common warrants", "terseLabel": "Proceeds from the issuance of common stock, pre-funded warrants and common warrants - related party" } } }, "localname": "ProceedsFromRelatedPartiesForTheIssuanceOfCommonStockPrefundedWarrantsAndCommonWarrants", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "annx_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recently Adopted Accounting Pronouncements Policy Text Block.", "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "annx_SalesAgreementWithCowenAndCompanyLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales agreement with Cowen and Company LLC.", "label": "Sales Agreement With Cowen And Company L L C [Member]", "terseLabel": "Sales Agreement with Cowen and Company LLC [Member]" } } }, "localname": "SalesAgreementWithCowenAndCompanyLLCMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "annx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalents and restricted cash.", "label": "Schedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "annx_ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of common stock reserved for future issuance table.", "label": "Schedule Of Common Stock Reserved For Future Issuance Table Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTableTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityTables" ], "xbrltype": "textBlockItemType" }, "annx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award minimum employee subscription rate.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Employee Subscription Rate", "terseLabel": "Share purchases funded through payroll deductions minimum percentage of employee's eligible compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumEmployeeSubscriptionRate", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "annx_ShortTermInvestmentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term investments.", "label": "Short Term Investments Policy [Text Block]", "terseLabel": "Short-Term Investments" } } }, "localname": "ShortTermInvestmentsPolicyTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "annx_SponsoredResearchAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sponsored Research Agreement [Member]", "label": "Sponsored Research Agreement [Member]", "terseLabel": "Sponsored Research Agreement [Member]" } } }, "localname": "SponsoredResearchAgreementMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "annx_StanfordAgreementmemberMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stanford Agreement [Member]", "label": "Stanford Agreementmember [Member]", "terseLabel": "Stanford Agreement [Member]" } } }, "localname": "StanfordAgreementmemberMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "annx_StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options reserved for two thousand twenty incentive award plan.", "label": "Stock Options Reserved for Two Thousand Twenty Incentive Award Plan [Member]", "terseLabel": "Stock Options Reserved for 2020 Incentive Award Plan [Member]" } } }, "localname": "StockOptionsReservedForTwoThousandTwentyIncentiveAwardPlanMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of prepaid expenses and other current assets.", "label": "Summary Of Prepaid Expenses And Other Current Assets [Text Block]", "terseLabel": "Summary of Prepaid Expenses and Other Current Assets" } } }, "localname": "SummaryOfPrepaidExpensesAndOtherCurrentAssetsTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "annx_TwoZeroTwoOneAtTheMarketProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two zero two one at the market program.", "label": "Two Zero Two One At The Market Program [Member]", "terseLabel": "2021 ATM Program [Member]" } } }, "localname": "TwoZeroTwoOneAtTheMarketProgramMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_UnvestedRestrictedStockUnitsOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units outstanding.", "label": "Unvested Restricted Stock Units Outstanding [Member]", "terseLabel": "Unvested Restricted Stock Units Outstanding [Member]" } } }, "localname": "UnvestedRestrictedStockUnitsOutstandingMember", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "annx_WarrantNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant notice period.", "label": "Warrant Notice Period", "terseLabel": "Notice period" } } }, "localname": "WarrantNoticePeriod", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "annx_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants Disclosure.", "label": "Warrants Disclosure [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureWarrants1" ], "xbrltype": "textBlockItemType" }, "annx_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants.", "label": "Warrants Policy [Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://annexonbio.com/20220930", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r35", "r37", "r80", "r81", "r220", "r231" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r196", "r198", "r199", "r200", "r219", "r230", "r265", "r266", "r421", "r422", "r423", "r424", "r425", "r426", "r445", "r472", "r474", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r196", "r198", "r199", "r200", "r219", "r230", "r265", "r266", "r421", "r422", "r423", "r424", "r425", "r426", "r445", "r472", "r474", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r188", "r196", "r198", "r199", "r200", "r219", "r230", "r256", "r265", "r266", "r301", "r302", "r303", "r421", "r422", "r423", "r424", "r425", "r426", "r445", "r472", "r474", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r188", "r196", "r198", "r199", "r200", "r219", "r230", "r256", "r265", "r266", "r301", "r302", "r303", "r421", "r422", "r423", "r424", "r425", "r426", "r445", "r472", "r474", "r502", "r503" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r36", "r37", "r80", "r81", "r220", "r231" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r142", "r143", "r254", "r255", "r473", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r142", "r143", "r254", "r255", "r473", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate202006Member": { "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.", "label": "Accounting Standards Update 2020-06 [Member]", "terseLabel": "ASU 2020-06 [Member]" } } }, "localname": "AccountingStandardsUpdate202006Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r68" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discount on available-for-sale securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r13", "r185" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r41", "r42", "r43", "r464", "r482", "r486" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r40", "r43", "r49", "r50", "r51", "r83", "r84", "r85", "r341", "r404", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r83", "r84", "r85", "r313", "r314", "r315", "r355" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r88", "r89", "r90", "r91", "r102", "r145", "r146", "r164", "r165", "r166", "r167", "r169", "r170", "r313", "r314", "r315", "r324", "r325", "r326", "r327", "r334", "r335", "r336", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r382", "r383", "r385", "r386", "r387", "r388", "r399", "r400", "r401", "r402", "r403", "r404", "r448", "r449", "r450", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r268", "r317", "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r244", "r251" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "terseLabel": "Stock issuance cost for related party" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r218", "r244", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs of issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r306" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive securities excluded from the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r78", "r134", "r136", "r140", "r160", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r338", "r342", "r365", "r410", "r412", "r452", "r462" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r27", "r78", "r160", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r338", "r342", "r365", "r410", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r153" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": { "order": 0.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Holding Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r154" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Holding Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r151", "r176" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r148", "r152", "r176", "r454" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Aggregate Fair Value", "totalLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r150", "r176" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Short-term investments", "totalLabel": "Debt Securities, Available-for-sale, Current, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r272", "r273", "r274", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r6", "r82", "r132" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "Organization" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r71", "r72", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r11", "r412", "r488", "r489" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, Ending Balance", "periodStartLabel": "Cash, Beginning Balance", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r11", "r69" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 }, "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r70", "r451" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash and cash equivalents and short-term investments", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r63", "r69", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r63", "r69", "r74" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Beginning Balance", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r63", "r375" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r11" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents", "totalLabel": "Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r87", "r145", "r146", "r161", "r162", "r163", "r164", "r165", "r324", "r334", "r335", "r344", "r347", "r348", "r358", "r366", "r368", "r369", "r370", "r373", "r374", "r382", "r384", "r385", "r386", "r387", "r399", "r400", "r448", "r449", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Change in accounting principle, ASU adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r95", "r145", "r146", "r161", "r162", "r163", "r164", "r165", "r324", "r334", "r335", "r336", "r344", "r347", "r348", "r349", "r352", "r358", "r366", "r368", "r369", "r370", "r373", "r374", "r382", "r384", "r385", "r386", "r387", "r399", "r400", "r448", "r449", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Change in accounting principle, ASU, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r88", "r101", "r147", "r168", "r328" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]", "terseLabel": "Change in accounting principle, ASU, Immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r16", "r17", "r18", "r76", "r78", "r106", "r107", "r108", "r111", "r113", "r121", "r122", "r123", "r160", "r207", "r211", "r212", "r213", "r216", "r217", "r228", "r229", "r233", "r237", "r244", "r365", "r510" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Purchase price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Purchase of shares", "verboseLabel": "Warrants exercised" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r252", "r270" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r455", "r468" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r201", "r492" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved", "verboseLabel": "Common stock for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stocks, Including Additional Paid in Capital, Net of Discount [Abstract]" } } }, "localname": "CommonStockIncludingAdditionalPaidInCapitalNetOfDiscountAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r83", "r84", "r355" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r53", "r457", "r470" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r126", "r461" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r75", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate Bonds [Member]" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r257", "r264", "r487" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r67", "r183" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense", "totalLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r67", "r133" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r271", "r272", "r307", "r308", "r310", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Equity Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r54", "r93", "r94", "r95", "r96", "r97", "r103", "r106", "r111", "r112", "r113", "r117", "r118", "r356", "r357", "r458", "r471" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders, basic", "totalLabel": "Net loss per share attributable to common stockholders, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r54", "r93", "r94", "r95", "r96", "r97", "r106", "r111", "r112", "r113", "r117", "r118", "r356", "r357", "r458", "r471" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders, diluted", "totalLabel": "Earnings Per Share, Diluted, Total" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r114", "r115", "r116", "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation cost expected period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares Subject to Employee Stock Purchase Plan [Member]", "verboseLabel": "Employees [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options Issued and Outstanding [Member]", "terseLabel": "Options Issued and Outstanding [Member]", "verboseLabel": "Stock Options to Purchase Common Stock [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r49", "r50", "r51", "r83", "r84", "r85", "r89", "r98", "r100", "r120", "r167", "r244", "r251", "r313", "r314", "r315", "r326", "r327", "r355", "r376", "r377", "r378", "r379", "r380", "r381", "r404", "r477", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r359", "r360", "r364" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r359", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r221", "r223", "r224", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r360", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r221", "r257", "r258", "r263", "r264", "r360", "r418" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r221", "r223", "r224", "r257", "r258", "r263", "r264", "r360", "r419" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r221", "r223", "r224", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r418", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r155", "r156", "r157", "r158", "r159", "r171", "r172", "r173", "r174", "r175", "r177", "r178", "r179", "r180", "r222", "r242", "r345", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GainContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Gain Contingencies [Line Items]", "terseLabel": "Gain Contingencies [Line Items]" } } }, "localname": "GainContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and Administrative Expense, Total" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r79", "r321", "r322", "r323", "r329", "r330", "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r66" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r66" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r66" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r66" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndemnificationGuaranteeMember": { "auth_ref": [ "r202", "r205" ], "lang": { "en-us": { "role": { "documentation": "An agreement (contract) that contingently requires the guarantor to make payments to the guaranteed party in compensation for that party's or parties' loss or injury attributable to specified events or actions, such as a patent infringement action against an entity that relied on certain representations as to ownership rights made by a software vendor.", "label": "Indemnification Agreement [Member]", "terseLabel": "Indemnification Agreement [Member]" } } }, "localname": "IndemnificationGuaranteeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Future Minimum Lease Payments and Related Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r397" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r397" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r397" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r397" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r397" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (remaining six months)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r397" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r78", "r137", "r160", "r207", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r339", "r342", "r343", "r365", "r410", "r411" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r78", "r160", "r365", "r412", "r453", "r466" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r10", "r31", "r78", "r160", "r207", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r339", "r342", "r343", "r365", "r410", "r411", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Sponsor research agreements, commitment amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r193", "r195", "r196", "r197", "r198", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r193", "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "periodEndLabel": "Loss Contingency Accrual, Ending Balance", "periodStartLabel": "Loss Contingency Accrual, Beginning Balance", "terseLabel": "Loss contingency accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r193", "r195", "r196", "r197", "r198", "r203", "r204" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r195", "r197" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "periodEndLabel": "Loss Contingency, Pending Claims, Number, Ending Balance", "periodStartLabel": "Loss Contingency, Pending Claims, Number, Beginning Balance", "terseLabel": "Loss contingency pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r63" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r63", "r65", "r68" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r44", "r46", "r51", "r52", "r68", "r78", "r88", "r93", "r94", "r95", "r96", "r99", "r100", "r109", "r134", "r135", "r138", "r139", "r141", "r160", "r207", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r357", "r365", "r456", "r469" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r93", "r94", "r95", "r96", "r103", "r104", "r110", "r113", "r134", "r135", "r138", "r139", "r141" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r86", "r88", "r89", "r90", "r91", "r92", "r95", "r102", "r117", "r145", "r146", "r164", "r165", "r166", "r167", "r169", "r170", "r313", "r314", "r315", "r324", "r325", "r326", "r327", "r334", "r335", "r336", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r382", "r383", "r385", "r386", "r387", "r388", "r399", "r400", "r401", "r402", "r403", "r404", "r448", "r449", "r450", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r134", "r135", "r138", "r139", "r141" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Loss from operations", "totalLabel": "Operating Income (Loss), Total" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r393", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r390" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liabilities", "totalLabel": "Operating Lease, Liability, Total", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesFutureMinimumLeasePaymentsAndRelatedLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r390" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r390" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r389" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r67" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Reduction in the carrying amount of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r396", "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r26", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r14" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "totalLabel": "Total other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r38" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive gain (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r39", "r41" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized gain (loss) on available-for-sale securities", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r30", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "totalLabel": "Other Liabilities, Current, Total" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r25", "r182" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r62" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Deferred offering costs payment related to the 2021 ATM program", "terseLabel": "Deferred offering costs payment" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r57", "r59", "r149" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r8", "r181", "r182" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement", "terseLabel": "Private Placement Warrants [Member]", "verboseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Proceeds from Collaborators", "terseLabel": "Proceeds from funding" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Net proceeds from private placement", "terseLabel": "Net proceeds from private placement" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r61" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from the issuance of common stock, pre-funded warrants and common warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r57", "r58", "r149" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from maturities of available-for-sale securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r57", "r58", "r149" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sale of available-for-sale securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r61", "r312" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise common stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r61" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from employee stock plan purchases" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r12", "r184" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "terseLabel": "Total property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r186", "r412", "r460", "r467" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r405", "r406", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureRelatedPartyTransactions1" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Research and Development Arrangement [Member]", "terseLabel": "Research and Development Arrangement [Member]" } } }, "localname": "ResearchAndDevelopmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r320", "r446", "r504" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r11", "r74", "r451", "r463" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r14", "r74", "r491" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]", "verboseLabel": "Unvested Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r251", "r412", "r465", "r481", "r486" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r83", "r84", "r85", "r89", "r98", "r100", "r167", "r313", "r314", "r315", "r326", "r327", "r355", "r477", "r479" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r395", "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Outstanding Potentially Dilutive Shares Excluded From Calculation of Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of RSU Activity under 2020 Plan" } } }, "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentNetDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r267", "r269", "r272", "r273", "r274", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r276", "r292", "r295" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Fair Value of Each Award Issued Estimated on the Date of Grant Using the Black-Scholes Option Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r16", "r17", "r18", "r76", "r121", "r122", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r237", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r66" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "auth_ref": [ "r270", "r271" ], "lang": { "en-us": { "role": { "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Stock option grants description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Shares, Cancelled", "terseLabel": "Number of Shares, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Shares, Granted", "verboseLabel": "Number of shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, Unvested as of September 30, 2022", "periodStartLabel": "Number of Shares, Unvested as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of September 30, 2022", "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, Granted Unvested as of December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRsuActivityUnder2020PlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockbasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Share purchases funded through payroll deductions maximum percentage of employee's eligible compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Options available for future grant", "verboseLabel": "Common stock reserved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted- average exercise price per share, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r294" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of shares, Stock options forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of shares, Stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of shares, Ending balance", "periodStartLabel": "Number of shares, Beginning balance", "verboseLabel": "Common stock reserved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted- average exercise price per share, Ending balance", "periodStartLabel": "Weighted- average exercise price per share, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r272", "r273", "r274", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted- average exercise price per share, Stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price per share, Stock options forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted- average exercise price per share, Stock options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r275", "r298", "r299", "r300", "r301", "r304", "r316", "r319" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Option expiry period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfFairValueOfEachAwardIssuedEstimatedOnTheDateOfGrantUsingTheBlackscholesOptionPricingModelDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- average remaining contractual term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted- average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase of Common stock at end of each offering period at price equal to percentage of fair market value of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r76", "r78", "r106", "r107", "r108", "r111", "r113", "r121", "r122", "r123", "r160", "r207", "r211", "r212", "r213", "r216", "r217", "r228", "r229", "r233", "r237", "r244", "r365", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DocumentCoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r34", "r49", "r50", "r51", "r83", "r84", "r85", "r89", "r98", "r100", "r120", "r167", "r244", "r251", "r313", "r314", "r315", "r326", "r327", "r355", "r376", "r377", "r378", "r379", "r380", "r381", "r404", "r477", "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://annexonbio.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r83", "r84", "r85", "r120", "r447" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://annexonbio.com/20220930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r17", "r18", "r244", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock per Employee Stock Purchase Plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r244", "r251" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Sale of shares", "terseLabel": "Issuance of common stock, pre-funded warrants and common warrants, net of issuance costs of issuance costs, Shares", "verboseLabel": "Sale of shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r244", "r251", "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of shares, Stock options exercised", "terseLabel": "Stock option exercises, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfStockOptionActivityDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r17", "r18", "r244", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock per Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r244", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Sale of shares", "verboseLabel": "Issuance of common stock, net of issuance costs of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r34", "r244", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r22", "r23", "r78", "r144", "r160", "r365", "r412" ], "calculation": { "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance, Values", "periodStartLabel": "Beginning Balance, Values", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r229", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r243", "r251", "r253", "r346" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r394", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "Sublease Income", "terseLabel": "Sublease income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureSubsequentEvents1" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureEquityIncentivePlansAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r155", "r156", "r157", "r158", "r159", "r222", "r242", "r345", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r88", "r89", "r90", "r91", "r102", "r145", "r146", "r164", "r165", "r166", "r167", "r169", "r170", "r313", "r314", "r315", "r324", "r325", "r326", "r327", "r334", "r335", "r336", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r382", "r383", "r385", "r386", "r387", "r388", "r399", "r400", "r401", "r402", "r403", "r404", "r448", "r449", "r450", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityScheduleOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryBondSecuritiesMember": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government.", "label": "US Treasury Bond Securities [Member]", "terseLabel": "Government Bonds [Member]" } } }, "localname": "USTreasuryBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r124", "r125", "r127", "r128", "r129", "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeasePayment": { "auth_ref": [ "r391" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for variable lease payment excluded from lease liability.", "label": "Variable Lease, Payment", "terseLabel": "Variable lease payments" } } }, "localname": "VariableLeasePayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants or Common Warrants [Member]", "verboseLabel": "Common Warrants to Purchase Common Stock [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSharesExcludedFromCalculationOfDilutedNetLossPerShareDetail", "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants and Rights Note Disclosure [Abstract]" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.", "label": "Warrants and Rights Outstanding, Maturity Date", "terseLabel": "Warrant expiration date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_DisclosureStockholderSEquityAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r105", "r113" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r113" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://annexonbio.com/20220930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907419&loc=d3e10037-110241" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907907&loc=d3e13051-110250" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r506": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r507": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r508": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r509": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r510": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r511": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r512": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r513": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r514": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r515": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r516": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r517": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r518": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" } }, "version": "2.1" } ZIP 60 0000950170-22-021509-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-021509-xbrl.zip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

C*[F^@\-@AGVJ:3(W97(C9>+\X M7(SM/(9FFMO,@K8YA!LYB)-V]"$VXVE[TU)O=3VN4 I8P^)#0V#]*. 5>6C M4SU8J>Q5O="#])8K@JR,.0H5@)%:)I#4G ;*: BZEPX)YPQ6UQ9]][RY>C$! MZQ5_!YNU%^6\4JULUP7E*=)F] MGTJ:TVO"8FJ*5EGR<-^J[7RX+\0T\J.;]B&M"[R%DM]>%U!J"[&"D'JX+<0& MJ&DKF?X6F<:>$"5%EZE&$#?!(FNT1=@E3%QT4F'11[3P=9Q;$,[PS,XFH\G[ M]IS]^VUI_OH.$+)-KF#"*&7'K-W3:RHD9N,E)EE6(G5_1.K.\EKK/UJ M!Z,=E_UJVZ^7#ZYK_NO%SN^R@7AEYP7E!JPQ.Z^L]H354JE-D@S(J4D*<9ZK MC05I44A!A2B3P>Y2T9*;A O/EYM_UIF)7K;(4(DW):9%+KJO'7E]"#JO= PJ M;:BTX;Z1JK3AP=,&(R.C*D44;4[9 ^\/618]\ #+<(HTL,M[$FX2#%L5;6!D MT^ RJZ%5VE#25MROY^;5D-5@=-@R9#7^W.2[:Y+;?PBK+C 7RD57N"A!MVC6 MT&&Z<.,X,#9:]FK$OY4Q"Z\/=R6T0S &7UG=-392S3W"@F#$%E>"6F*E3.@:5BU0N4KE(Y2+K MP$5(CJ?98!%C4B*>E$#6>8)(X(Q%!V3D]M6VSE(J5Q MD=-@&_QK8>"ZEU\;HK_\\ B1.V<*=*7#=O/1H;V/SF?#,/#XWGZ,C?6YO)Z= M'(\F[YO)= YGF4]!@=E%&.4]N7 TC'.[?-7%T[NMNFDTL1,_ZC+:X(-#.&&[ M=54>=(G/W9Q3HC<7+%(EZZLCS+X8X8.S]80C^SXN30^R"1YVVXX_VN/VR4;S M>/ J<+66HZ31N3M!=<"L5C;&.WM[S_[Q;&WVY_V6NDM]Z.[5B<1'1<_ M,QKOSAN-=Y]-Q;OI49S9^=#E9_?,..Z>-X[[\ZMD:7!/=PI6,TW-RPXO<$#: M.DVJXGSZ:#1IY@?316LGH=ULXB*Q4CS> MGA+VG^K\7#_/MXL07)7O8A?SZ6DX)M\@.'';^$EW.!K;X^EB#J?_%,.3Y:4( M[H;TY <@%6-[U,;M-AY9T.[Q='"Z,./RW!M?Y@-]&+6C+OIUO'WZ^RNR@I:7 M$W U;/[2/=45H:J3>]IB1'WW&/R=(\P6EOK69^GK7JC!YMR?8NYK?<;H&ZEJ M^C:9:GT6!CW5)=<*?.K5QSVOMG7?T6YZL N /:W,W@$P-S Z=PD+@)"__V5# M;A1?YF(8<^X.^&6O O+F8!9C\P>\/VB;9S"8X6K=!NUU+S?>3] MWM%&X1\TT16D0@N85& J,!68JM8&!U(%I@)3@1F$6AM@^:J2<*M85:RJ\JO* MKTZHBE6I6-U)DP:Z/--JFC30<^-=F!X=8'CW=6RCG?F#KNY&B!_B>'J4R[:4 ML9Q3TJPNW7#V"\PW*WB6#DNM:KR>-O2VB Q0/U]=J]@KP31) 2D6+>+&4>1\ M%(@:9R,61@:FOJQ5[(.S4FN&7(@4<<89,B9HY).2,CBBL-9?UBH^M0X[D_#; M9]OP;+D0V$^A8K6I99D]$TJ:#F44':X$H!* 0YDL!WJ0+G4K M2C9JSRA!EG XTAH']$$*9+1(!$N/2;P' J#9II&R$H!* :)024 1<)2"4 E M &M- (B.%G.:$.9@PCF3#IE +!*:61*8BTRF+PD $9+ ?Q%I:C#BP1ODDM0H M6&:#YI)H(>^> "BZJ;FI!& 0!&!E&_]J_L@@\T?^%B=Q9L==^H@-<-2HG>?] M@A]BW26X7O3Q1X'Y@1ZP7]^Z7SI\:X%4_V46*ILL5F%?S2:UCSY0F1"3D@.; M5!8YGB-%B3KB(Q-.X3X22D[,!9#)G0O&HM> TB;,@+[HY%UJO2!1]U'4LR=4 B\R7%O>;&50I2E_^ZD#@M;91X-JWDT M/4K*F^GTU/K/2S(*0J_7SP]#,1G2*A"1&/&>+8 M<&28B2AYX3A3P41]B7[>)(OFK"?#"=]L>R&<3&YB668>=B6< ]1XI6-024,E M#?>-5"4-#YXT@/V-)F"/G*8!<NE M%LH)<[EL_$W28U;#&@S+PEY)PWIJO-I1_J&DNOP^;=LFS::'I^DNT\E-TUQJ MEG6A-++7=,/285D+!-:O5. 5>.C4SU8Z>L5]-5@Q32V'$6I).)6<&2HEHAZ MR@E/Q#K12Y&:,_KZ8N*GAS';J^L3V!;D$5[=8:;-@]*U9==U_:GRF,IC!@O+ M6B!0>4P!]KORF&_QF$@O$TX:JY9KQD_*^,QO2;_ M/"A=6WE,Y3$%6]%!SZVU0*#RF +L=^4QW^(QV'+)F!! 8:Q!W#*'C(570KC$ M!9')B]!K$M*J>$S/^4@/2ME6(E.)3,%F=-!S:RT0J$2F ->BTU[RH51&9?E.D'I2N'2"/65D-H9HR59C:>I$- M8VSG79NMZ?P@SII1IT(VFTF[$S"2^SM=B;3K[@GGU6JB2; MF-2\_*H%*Y$8.#"52 P%J4HD'CR1D,12CXU"7GJ#.'<,6:\(\E1Q(W%2VI+; M9!'= Y'0M+*(J@(KBQ@V,)5%# 6IRB(>/(M@S)(0G4&2BXBXL1991B6B0J9( M!8Z!Q-OD\-Q+.(+Q6I&P:L%*) 8.3"420T&J$HD'3R1$B(RYB!'\#:0@8HN, MD!IQE0RE25!L+R4#_T@.S3T0"899I1'KJ0-KM:&'DCJS%^?->-K6"D-K1B9K M'](2-YHQDUN2\^Q1T)$*Q11WMI+]29O4J=IA12*P/05LH:A*H>J'*IR MJ,JAAH%4Y5 #X@Z50WTSO2TFFX1/B),8;6C6,SGX+Z.CR;^C\/IF.8 MDC=-FZM[, HEVRM,1*9;-.OM,%UD<1H6W2Y;7_];&;/P^G!7QEX9^[TS=AD< M_?_9>]?FMHZC6_BOH'Q.3ME5:'GN%SM/JA393G0JC^BRY)SGFVNN(A(0H+$! MQ7I__3L;H"2*$"6*V@!F#]NIT#1QV^BUN]>:GNZ>1#DDSHIB#T:#T_S*S>8]G;Y8/MF2Z?-K7/I7U\U"S=5YQR4'5/5U)$91JZ%60ZV& M6@VU&FJU4YV(:)TC+G P05@0DB1P@@@(FF=A1,R>[0U%_>(BOQ-HM0'+ %&K MC9DE4*NA5D.M=FHO1*V&6@VUVF=J-:V#)#[KHM!TT5U<*3"B5V"!,2DB8R'O MS9W]XFK"8VNU@>L-4:R-F290K*%80[%V:B]$L89B#<7:YQX2H*T)1!2EY9WO MA1?M4VS]:+XDK+0I8TX[:_J*/BVM/$R%:3/ MW2K=I M=C^GU?.>?S^@]\NO*3Y?NW7JSO+CB_)E@OMA.9^[5;=]R=O5 +F^&F!W6PS< M,D4H)6J"]\"<[@D7UBNH5U2NJ5U2O)U*ON3_?E@@&D>:B7A558%51KX0(DRFG-%,W M1(%HG>I52YL8ZT_4T:0H4MGJM?(BVPED0+++OG6>QL""AIA]T>Z)"7!&60@V)9]5L%P=Y-L?7[V6.(2Y5^1-5*^H7E&]UNB% MJ%Y1O:)Z_=SF?"IB5L2!5-R!Z'?$C>JWTIE5C+$DO=C+/MZGAKA.]6J#LM91 MWROVW(\FB'T>50-Q6LL0-*5Q+_,\Q+<_A7H5F'M%WL2!L=4A?6I>^'_;3TDE M\A5[NY=I5UG=339=BI/9HB^IOMRL2_2:+/;JKV\MJKYS6?;DR^NOL1.STE44 M=F*.Y_0';*2\^R((%P]OSIY*A"K39VYSID4^1PW.6@.:^NRR]9+K00IOWU#4 MXQU#/=M<^+0ZRUM5W)UMUMVZL$AAJ/U%Q8[+KNME\6BWL?=TO^J;*3%71ZT;:@RT+L-D2B:!V#%!- MH9HZ/5:HIE!-_>9,(#)D#X;$/A5++%AJ/;@D&/>1:./VQCG@IE*B3N5D@5H90<@DP7FIP5/F RV_9CK()--3JRGO%=6L:,5L8[EF MSOK*4\X@"A4]2=FP* _X/0^BIH29:DJF@A]NRQK5%!)![1B@FD(U=7JL4$VA MFOJ-:1M<%A12M@*$81I,Y!Y$9I+3/C=E]G(V]RF4.[6:DE%&EGD$1PPO:LH7 M-65M^;*"*RVIX3ZE W[/0^6FF*)3CCM]#X@(WM3OE7_W15C;7V\ST9\^VT+T MZ%J''=1L][<.&]PZ[[AQY(6%SU.:N-"7#[K%ZVW]X')=WF6]+,',;6)?[=Q' MTF+G;O=;MYS/HNO_G&<+MP@S-R]?O_SAHKQA]^A#=?PU?N_)M2!Z_QN+XIUU MJX7%#0N?ORU1OBQDNJ,><+E\V>_<_#_N=??]5Y-O1Q\"#\L<-5GG>#>J7\[C MP6S\^-FS'__G[-ET\O39D^&BUT$O>9C8=;@[8BO3WY+&;]=)X[=W5/%;3SJK M-/;[Y\E;DV4N#_5?];P\;_8J3?H3&O!.P]CSEZ]GB\GZ?+GI MR@*R^P9M?5!;__I&SWZ#OO+WNX^B9&O5JQ>$OKGSLDO?=>G2K4I0 M?V.?;2YR]]Y?W6S">S7K9GXVGZU??_?F]1]HQ=M]G"R?1NR?MM_J \F?T\79:EH$^K"2?3.MJG/W'/ M[._=C.[FJ2@R8,"N$A8,V \]8#\K%L%X7<>]4T=@P 536W@B_]8+RUO^9(SQN!^>C_$8XS'&X]/#@O$8XS'J8XS'&(_K@ 7C M,<9CU,*+: 1[/T(M!3SVI'9:ZCS"I MY.BO$4ZX&&$\Q0.]/CI%UEF6:>"0*+$@N)'@HF1 LF!&&<\EWSN0]3ZSZ@NK M/5V$Y47J6\[>/\CJ^0]OCZKBU\=4 +_;656\2$LIJCRY% QB7P/"7@D4O# M-7=N_RRA^TR%/Z $HL4MI<(T4'MQ&C40:J#QPE*W;Z$&0@V$&FBK@51FB2HO M(!)1-)!*'IQ._297E%*E$+@:9&;] 36095,K&4J@YL+T!R70@"5A0Q4%8DG8 M0> _6Y^GU22\-[KUI9LM)E_WA6+??%='*6CMP-Z=ADL27S\@ MA5VS=V5Q=(1YXY^6J_(YBTG8K%9I$5Y/UBNWZ.9NN^OE8G]^3G\P6!U[P#4Y M>>T\BAMW)SPK&U> MYWNG5+ZKEKCBLR=7=/:B9[/=13Y>Q!?ON.WQ6VI[EM9G^87[8]@Z"ZPR?2 E M%JB"4 6- I8F$$ 55 '[HPKZZ+B4D(K@H1RB)T71*"O!)T? 2$:88DRPON#S MRWN%QZ"".*H@5$&H@E %50-+$PB@"JJ _5$%?4P%"9.YY%1"$LR!<)Z"MZK\ MIQ,V&&VSB&&(=N$QJ""-*@A5$*H@5$'5P-($ JB"*F!_5$$?W1%+BF:J A3) M4U00BQJ,Z]N M6199ZN)]T,T#(]!!4E400]#!1VLZ1A+S$9)$;\N"C+S\K[Q M>D?RI*\O>^5F<^?G"4K<@*[$EO)68;.:K6?IOH=;8.EVI0+[>0> Q@!!,@^>&@LPD^1"%=X8?LO3K'+Y6T9YO)IUY:$?RG\N7OYC;IBBCFHLMXA"#(48"K':D$(A-B(!@D+L8T+,J)B5 MV]T#+IB\:PYZ(M&3IH)>_[L94]8GUPC1"=&Z%X.5G =W=[A' MJ&5'&*TQK?@Q34X4]5YZ!4EE!R*'HLEI4B LXT'X:#5-0]3'?4".'VBR1U&H MC%;9TO')R# ^F5TW(V O+.HRU&6G]D+49:C+4)=]IB[+T@1*A0"9 BD:2V:P M7#$@QD;)9")!TR'J[HZIRQ0QJ,N0$5"7H2Y#779Z+T1=AKH,==EGZK)@,F=> M*["Q[R=UE('GHOQ01C"GDO=D3Y?=IPSO:+J,%G?6EJ P0TI 88;"#(79Z;T0 MA1D*,Q1FGUM<**PA*AG@R8DBLGB16RDF2$J9*(5/,@Y27'@T86;9U$K49<@( MGQIG5_[=CRK;_GJ;C?_TV2:F7V3B?F+C++_^7.'$#BJ<[F\@-KB!WO'DR%GI M>4H3%TH8+%_C]6SQ_\:B>&?=:F%YP\+G;\NJ+]W+M*,O<+E\ MV>_<_#_N=??]5Y-OJXJ"]UD[UAH"A[?.\6Y4OYS'@]VFCY\]^_%_SIY-)T^? M/7DT2% XG*FW6OEM-/[M>C3^[5T,+K\NP[_/QP[,D[>L\^0ZZSQ_^STGRUS^ MJ_^JY3+2JOL__^L/1JC]?O+C[YO9^G7E6(XN"A?9-U]@P@<%(%?WPBT;P8370>]X&$D5Q4T;Q\,RU=IG.V"^^ZN;+8*O9MW,S^:%;[Y[\_H/- KN/HZ31URS/VV_ MU0=2/U?7](@(_NGG?.(9^A$UW%[[YXO?D3Z2[ [7_HEGJ$?$FDJNQ3PBG%1H MH^+6G)L*+\P\HKJ22[$EK'WFFWRDP7<7L>YY>L20!PJ]B;9WRK7JPZ=:/RR5 M/A'_=37;IR>:$W,$8.Y!R\>$I8#0/_Y?7ZFOJI]#\ED^9T_E8SRN 1:,QP\^'KO+69]MPI",(1E#<@6P8$A^Z"'Y'_<_M@SC,<9CC,<8 MCRN!MHUX_$/*LS##K 6&Y"HW8!&H4P3IBUF,\X1!NI8@O3<8Z!2>?+>; F-T ML[4TGW.L]XFD]=@<^Z]N[A:AO,YMIX+]D$*Z\&DUX70Z8=OS1&N0996#7H>_ M'@"6CPY#KAR4%NQ_=TT[EO'S7XC*4::Y#GN_?'!H>S0I4I\86)K[ >P\@+&: M E,ALRRY<)[?'-KNM8PRAP21;D^?CKH_?9H"#39(ZQA7WMX[ZS/:GS[[Z>.'&9JI5&1JI!AJ/CN&I*9"4N4((%-7",K0 M1Q ,BN)]SZ1!JD>JWQV<%Q,56OGR =Z#$-:"%9Y#4I)+GPR71@U"]==ZF7;I MFKL?R_(QQK?(],CTXT, F;Y"4)#ID>G;97I#.;%!&>"*%M8.Q(#G3@#1EJA( M M-<[C&]$#QEQL HHT!(K\%16HA?&AU=L(DG<22FE\Q,N9)(]TCWXT, Z;Y" M4)#NFZ3[\?'U)TZ0?="J)9 '"$:!"\_/ L2N'6.&6.%4RUV.C:5FL#-C,497$J,_>/PK:A_4/O6# M4K5?H?9![8/:YZ??+:6 M6IN/M-7#.)U:@I4=8]CJ&:X-A^@I$Z3 Q-[VS%W9ENV^^G"=.=>/%F;7[%H7 MEN.+1MMX4().E_JNS(O+M.A<[[GW=-SW[PC4B97HQ,^%!>/I:>U_,)EW!$P: MR7+MIO>+^T[O1X]KRN,J1P")J$)06K _$A$2$7I<11Y7.0)(1!6"TH+],?'= M:.([9JLIEQ:L<@J$%1R\5P:249'()*0/^6;BFRF;;"8&0I:NO$8S\)(($%I[ MYY+1-,J;B>_'\5^;;GU1+J5[L7QW1'M_./O3Q=54[>UP@VTN[,FU5-@OZ??- MK"NF>YY6KV8A_5R^Y3+^DL+RY6+[+O]T\TT:)(TN>H<8*HF.(:ZI$%5Y''58X $E&%H+1@?\R% M-IH+S51IHFP"EX,$(0@'[Y@'W7<&!6DLWQ_BZK00V64"DA$+(@4#WN?R%C3K M&)*2EG',A6*(&T5!\?MUWUA0/$*)OBTHGBPOMV$M_9%68=:E2L['J]QQ1R,8 ML3UC7/9'P=BH8#116DHU@ZRB[3?"!5@2+)!DLDK!)&$9^:,':(6^Y;EY';OX-.KR?MN*% <3X(! M:X0(((]7"$H+]L<%Y4Z'&C00")J$)06K _$A$2$7I<11Y7.0)(1!6" MTH+],;/9:&8S1&IT- RX$AE$]!YLMAZ<3=2Q*/K#,8>HK,;,)@8L'+R,==*? MODU^6J[*QRPF8;-:I45X/5FOW**;;[LL)G_VJ\FW5[?0[J=[V[*!DYE;4HC8 MF#(N^V.JXN21$YO T>-&@P 2486@M&!_)"(D(O2XBCRN<@20B"H$I07[(Q$A M$:''5>1QE2. 1%0A*"W8'S=O&]V\U30;KQ4'S;0#D9,'ZY. [#DWP5KMQ=X1 M =EYQ;EWD#CC(!CQ8&)DP)*WG/.L578W-V_/UN=IU4^[6J7SM.AFK]+315A> MI'\LN^YJN^;)U6[-BWZS9G>1CQ?QQ;NMFW>CM9ZE]5E^X?X89(>7XR L#&KC M0P"YOD)06K _+CI/SM6XZ$2/&PT"2$05@M*"_7'1V>BB,RF37502 A<21+^4 M-#YE,"XZZZCGU.Z-UKM/Q3 N.C&H55)5C-.71R_*?UT47.;E;>-D7@+(I(0S M]\K-YL[/$Q17AZY$@0^4%W5SE"" 150A*"_9'(D(B0H^KR.,J1P")J$)06K!_ M>SN]XV.BK]]0$&Y8[X^XDMDD8S+0%#P(80-X*APDZPFW*47J]X;W#UDE_6[K MZ>_+>9PM7O[-S1;]+O;9XOG;W:7'JUE7'KH^&^OSMZR[7WSXQ$DOA3*RC M['@>[[[_!O-&@P 2486@M&!_7(F?GHEP)7[[ M2MQGIWR2&8AG924>H@#KO0(B-,W>NJ #/63I.*[$&PC4XUN)XWCKFFZ&$T?& M$DNV%>@XK;HEI3QH(X\OSTZK=X:2E^M)MYS/XN3].[ER\%K Z1/ND, 54 M?0KHF!Y\7:\5.-"5*W#ERA% )D0FK-E]D F1"9$)FW#ERA% )D0FK-E]D F1 M"9$)FW#ERA% )D0FK-E]D F1"9$)FW#ERA% )D0FK-E]#L^$6*&'%7H#5.@I MEXQ0G($5PH P5(-CV8'4DB@A?5!!WJS0XY;RX 6!I"0#(9,#Z[('RLI_&^FE M3/%FA=ZSM'XWS778LCHNIUS7.:&U->$SOE(\5$ZHG% YU803*J?Q: 943K66SWZ6U Y83*:=Q-#$-UM=WL6&@# MYD\&-[^ZR3)/_MNMPOF$T^F$$<9PR$1+>OHAM8RU8/_V M>GM1.&Z%8Z:)Q^@$*&-E$8XI@C61 "]_)XXZ88*Y*1Q3%('+4)2BLA2$HK:( MS> AFN0U5Y&*L)=R>W[N5JD[VZR[M5OTS:_OB<=N^^AUU?CTV4\?5XMF*A4O M_Y?8Q8HA:7P((%-7"$H+]D>F;I2IO29*6.* *MUOCGD%QF<#.0;ADG;:)3<( M4Z^7X=_G99F75MV/OV]FZ]?#G%IHD:@Q(HT/ 23J"D%IP?Y(U(T2M?9,2!TH M,,HM"!H#.!TU)$4=%T'&P.(>43/'#$L$J"2%J+UU8+@.H#4/,O,HF#L644O. MIHKC<"@,2R-$ -FZ0E!:L'][;#T^NL4"D-M%A[/>,^("6.<(B$P4F++X!^6= M4/UJ7^1P4W08PT122H.45(!P4H+CD@.7UC.:J7%]N>UPHN-.52##E8 \I! [ MOHH.E"XH7>H'I07[HW0Y/6FC=/F(=#'*QRPS1,%S+UT(&.<-V,RXU3$Z%_:D M"WXXV2(*0BX(,5((TBDC(3V7[7S\&E"Z=390S*%Y0O*%]0OM0 2@OV M;T^^(._O2@^MRI(Q#3RGPN$B!_"*.F Q964I9]3N\;[.D3*?&"BE*0CC*%BM M3*\:LHVZ4+#Q1]HG881,%15(]R,(2W@&1DW2[<31:!L/P+LNQ1)=+B[3HG.] MYV+'=DLR;] &P,I!:<'^>(SIR0-C35/:*D+W@7I\U"&BJ M@M("6,@6!&<"UT_9FXOMQ_->F6U^42^E>+!_'..NOP-!@$DH@I!:<'^ M2$1(1.AQ%7E3;Z]NH=W/'R\NY\O7*4VVAK M<%Z"SN3G>3'"_M,OKQ['+K26!"BV>XS+_BA &Q6@(8BD=(B022YBLN\I=XS) MHBT#S5:+:!/;&YPCN5/6)W"B_!#1\2) $P$5+&/,,1H\^6 76L\4*?ZP6MRPJMSL2MZXI!]FJH!3GM&+4&B$"2.85@M*"_7%5>7(RQE4E>MQH M$$ BJA"4%NR/1(1$A!Y7D<=5C@ 2486@M&!_3&\VFMXT5DK#308M- =A20;# MI 8:5'*)2,?T($7;F-[$J(6#G;$.^XZWR4_+5?F8Q21L5JNT"*\GZY5;=/-M M%\<'"JO=VY80G/S/G-ADCAXW&@20B"H$I07[(Q$A$:'' M5>1QE2. 1%0A*"W8'XD(B0@]KB*/JQP!)*(*06G!_NWMX(Z/B;Y^0T&X$;VW M$9V,B$YE#Y;I"$(G!S8P II0'9+*F>6]C6@C6;8Q."#1>1#!=ZJY\0/GMHUO6"@>''663\WCW_#>X+XGB9YR@ MM&!_7(6?G/5Q%8X>-QH$D(@J!*4%^^,J_/1,A*OPVU?A*CLEB?0@B7 @1 C@ M>W"L?YWS7=#">.BK\N"B[S\K9Q,B^A:%(" MHWOE9G/GYPE*K("NQ),/%*!W*6Q6L_4L=3C;NR5]C1T_X[(_)GI.'D*Q81X] M;C0((!%5"$H+]DEQ%'E2@<^!@)"\W,_&6= Y94E<\)RF0Q:@O]MZ^OMR M'F>+EW]SLT6_'WZV>/YV=^GQ:M:5AZZ/4#O0YO=@AU<_I#@]OMUOU#^H?^H' MI07[XT+\Y,2/"W'TN-$@@$14(2@MV!\7XJ=G(ER(W[X09\HPXP0'&8T&$5-9 M5'-*P(K$>8XJLJP.68.."_'QQ^GQ+<1Q_'E--\.) V,))=OZ#T"?>Y*U*8 :H^ W1,#[ZNUPH=\WUM'D3G'(AL.5B? M.:3@LY4Y,L+V3F\))A#95^K1Z"4(X@B4-TF@G,DN."59]C=K]IZE];M!L<,6 MVG$]I5Q7.?.U->$SONH\5$ZHG% YU803*J?Q: 943KV R@F5T[C[&H;J<[O9Q- &S)\,;GXYCX="_J]N[A:A MO,YUDV6>_-_-(DTXF4[*LH_AU(F6Y/1#:B)KP?[M-?NB;MQEW*S-LNA#D,DJ M$"$$L($X\%I:8VD1@7I/-RJ>I8^NW#(Z\O(:$\&RY"$Q;2+W+OLH;NK&Y^=N ME;JSS;I;NT7?#?N>=NRVCUX7C4^?_?1QL6BFBO"I)8,=KX0A"4,25I:BIZ"G M('F/A+Q%XLH[1<%%%T X:L K2L 31;QEEBK+!R'O]3+\^[PL_-*J^_'WS6S] M^NZ9GX]QN$7NQHB$W%TS4N@IC7H*"S38G>FSIPI69&B91OJ!\0?F"\J4&4%JP?WOR!7E_R_M*,DILX& EM2"4 M2F!"H$!,%(*S((7>.\:#^4B$30X"SX7W8]!@A-(@@V4F22_HL"F+C] ]+71/ MA$"Z'T%8PK,S:I)N)XY&VWA0E@M=BB6Z7%RF1>=ZS\6V[I9DWJ!=@I6#TH+] MFRL<&U]@K&F46T7H/E"/JQP!)*(*06G!_DA$2$3H<>AQ#Z%G #UE7/;'7'BC MN7"GB2O_,Q!,3'W/0+D1LO>@&)/$,I<9V^OWTX98I;0#J6,HK^$27- "1/*: M.4J=\>YF+OQQ_->F6U^42^E>+!_'..NOP5Y''58X $E&% MH+1@?\R%-IH+M9%*17D F9, $1T'RU@&:J,6/FHED]L[*BAZIXSAX&-B(+@H MK['10,A:J>BI)F9OX#WF0C'$55EC_'XI.-88CU"B;VN,)\O+;5A+?Z15F'6I MPT:RE@0C=FR,R_XH&!L5C$9$GK708'+4()B@X(RE0(U,R?"4H_ W!6.D1M"4 M-2B>,PA"BW2D,0#E/"F;3!9D;_-\&]2?=MTFQ1\VJ]GBY4[W[0;@;Q\\VP;\ M[L>K@!^_ ,\LP8(T0 >3Q"D%IP?[-*=[Q\3"N,='C1H, $E&%H+1@?R0B)"+TN(H\ MKG($D(@J!*4%^V-FL]',IM24&Y8"..LY""+Z(Q4"!:\$SYPR%HT>HM@:,YL8 ML![T>.9C!+HV:J?[*.$6(4V6N9_/?+'LOTN)$--)?S&Y?),4)W_VJ\FW5_?2 M[N=_W&KE%NMNXA;QS>O>_&TZ6:1U_W[[+YN]^;2P[,J+OUZEN5N7#[ATJ_7K MB;LHEKOEE?\;S_2YE59XL(938R G72@B> ;.<0Z!,I&Y)ZK\_V@]/.^HY\VM M]:3'>A"&L5-)R*TD,VY'O._!-]C@6N6:"[N_QF5_7',U2HZ*,)*4-V"R$2", MS6#*R@N2=403SU04].#]"N6;;!_JOK!'P4[+M4P-'^P@' Q3386IRA% ]JX0 ME!;LC^S=*'MGHLN:5D@@PM'"Q"&!4;(_A\Y%+Y6V(J4AV/LN2]O_M\MO[#A^ MF/4LTCC&JR9*#9#9T5/&Y2G([*=.6@NN68A 528@,O-@4EFF#X8$KB$QJ$-DF,/U_:FY%^3^S ME)ECU>0>*+W)!IN6BE%K%/T>."I_]*K[I^6J?,QB$C:K55J$UY-UB0S=?'O0 MQ@>Z+MS;Z(+3]%N2B=A@-R[[8[[BY)$31U.@QXT& 22B"D%IP?Y(1$A$Z''H M<0^A5!@]95SV;\Y3D)O0X\;L<94C@$14(2@MV+^]3=WQ,='7."_JUKWIR 7U MY1_0HF^C(5: YY1#HLFR*(Q-3MS7.U#O>BWH787^7@17[S; ME'JWO_TLK<_R"_?'W3>PN_(!Y;>/#RW$F85'V?<\WCU_WT%:*'Y0_*#XJ5?\ MX"H<5^'H<4A$8X$%W:)JM\!5.*["3[L*-UDQG2TX2S,(K0)8ZQV03*-6PG#O MU1 5XK@*;S1(CV\5_A".'AC/S7#BJ/CKHN R+V\;)R_=;#$I@=&]AQSV$FG3TE''9OSE/06Y"CQNSQU6. !)1A:"T8/_V=L-Q&WF[ MC>Q)#$'8!(F$_H2DE,$Z)\ IH[V,1JNT=Z;\D,7<[[9Q_KZL'(W[^1O)']H^YQE%D&-?&AP#2?86@M&!_7'>>G*YQ MW8D>-QH$D(@J!*4%^^.ZL]%UIU#<4:H99*XL"$48^+)\!$N\#3;0R)D[9/DR MKCLQKN$([)-C.;YP5@+ 9%[B!+:)MZ0+!VW\\.79:?7.4/)R/>F6\UF"SA]PGWNBA0F/*I/>!S3@Z]_6($#7;D"5ZX< 61"9,*:W0>9$)D0F; ) M5QZ?BR(Y(CG6[%%(CDB.2(Y-N'+E"" 3(A/6[#[(A,B$R(1-N'+E"" 3(A/6 M[#Z'9T(<%(J#0@>HM%,B",P\M9F#MT7[",,B6%+DDU#)99DE\ZR3)/GJ?+=;KP:37A9#IAA#$< M@]Z2IAZT$>S]$,T>L3Y&Q^7&SQ.JZLI:8>^.U0AU-0K2K2!EG+K 8P++C 41 MG05ON($B4ITC3%IA]@0II3%G80)D:A0(0BAXPC7$$(ARUB3G]4U!^OS58X M"H91"X:J%W/_NP[)CHJC?<4A6$@YV !&10F"RE1^"%%< $S9H20RAC M1](@2HFIX1:%" H1S'R,&194':@Z'H#J&)]LP!JFCU1_1\MY"AXTCP%$(!:< M"[873YP:Z4B,Y*9XRM([3GT$)T,"X4@13YII(%$*H8UV1/$AQ=-="ID$4:B@ MD #N6P&.$@PE&$HPE& HP5""'5N".:Z()-)"T)05.:4(N!@"&"=9$D0D'NA- M":833X[J!);P?M]-9S!%QX'5VJHD6*(J'E^"\:G1F,A"$D 9AC(,91C*L,9E M&.J7G7[Q.@G/,C#'#(CD+3C!>=$O+&?6'^+CU?X1L5IQP2EPT:>0=*)%R6@" M6E&5/?$Y)GJD_3>FR%01AK*ES?VW-TULY=^NF&W[ZVT&^M-G1Q5Z;%% V4'- M5I-UWM$ VN?N]CD*JU RI)6?IS1Q(2PORM=X/5N\G"R6Z_(NZV4)[VX3R\7% MGCZ*G;O=;]LV8-?_.<\6;A%F;EZ^?OG#17G#[M&'<@TU?N_)-8JIZ<:Z3U@: MU# #NMU5/$"_^X"9U8W[[_QME_>E>YEVL@5<+E_V.S?_CWO=??_5Y-O1WZE( M$ =O4!_V-GW\[-F/_W/V;#IY^NS)HTI#9B.F?O*699]<9]GG;[EU.R+@VCIL M-V/6?C_9+<@0G4.B\_5L,5F?+S>=6\1N.DE_A-3/1.G;;2?NHGR1=?<-(G!0 M!'Y](TB_&4QD'O2":Y68]UK;R8,S]S9%\/;NW"5?^LLIBY+OR/?;1V'N7B\W MZ_)N?Z3X_>Z=*=F:\.H%Y2Z8N\LN?=>E2[W-.'G'-_K2]Y ^DH:ZNX!$1_-//^<0S]"-JN+WVSQ>_(WTDV1VN M_1//4(^(-95^K#Y_WO5=PU]7L=IYH&NP1@+G'7&Q7.Q6F'7,DO^Q M[#!E@?$8XW$5L& \?NCQ^(>49V&&60L,R55NP")0IPC2%[,8YPF#="U!>F^T MS2D\^6XW!<;HZFIIAAJH7#"H";R!!F*?U+'_ZN9N$S%PY*"W8_V#'K>.\^,5)Y\7;9(5UQD/B*8,@AH)1 MW$(F5MNHB(^&WYP73S-)/ED)A!("0NH QEL'BG/FK)%)-THEZ*[48A.H/"\X\+A -GG*H0/%@3 M+0@F%%A.)9"8G?8YNJ3)3>$0HV>2Q*(S@DA%;'@%GC(&6HA^VRBHR/.Q:CJ$ MF#*-A1UCV.DYU$3;Z[9ENZ\^7&/.E6%[ [YY\PJQ'%\TVL8#\*X_G3XL+R[3 MHG.]Y];1/%VYZXY&)WXN+!A/Q])Y_IDR[PB8-)+EV@WO%\<:WH\>5[7'58X M$E&%H+1@?R0B)"+TN(H\KG($D(@J!*4%^V/BN]'$M[9",TH96-D7_DD6P%.O M05LEC7?2"^YO)KYY"IJ:+$$*XD%0&L FXX&F$*2P-O.H;B:^'\=_;;KU1;F4 M[L7RW0GM_=GL3Q=70[6WLPVVN; GUU)AOZ3?-[.NF.YY6KV:A?1S^9;+^$L* MRY>+[;O\T\TW:9 T.IM:-=BF.X:XID)EQ%'E+"^W82W]D59AUJ7['H^';6=5"D9LSQB7_5$P-BH80W8N)I5Z MA6A V$3 "DK "QUTC%93;_;:S2WG5&8'24H&0I4?1N3R:J62SUY13\D'N\:> M=MTFQ1\VJ]GBY4[W[9X%SZH"#$OK#:,08N M)0.,"B]=H)ZHO?%E]RG&OF4]N=T\^/1R\MX["@H'E&#$&B$"2.05@M*"_7%% M>7(BQA4E>MQH$$ BJA"4%NR/1(1$A!Y7D<=5C@ 2486@M&!_3&TVFMK,DE!G M- 5'F>]KJP,8Z0ED9;BVD5LGPA"UU9C:Q(B%LY>Q5/H.M\E/RU7YF,4D;%:K MM BO)^N56W3S;:/%Y,]^-?GVZA;:_71ONS9P.'-+$A%[4\9E?\Q5G#QR8A\X M>MQH$$ BJA"4%NR/1(1$A!Y7D<=5C@ 2486@M&!_)"(D(O2XBCRN<@20B"H$ MI07[M[=[.SXF^OH-!>$F]-XF-'6*!A$(V.QY?V*O :_ZLWNUTTQE0Z+8F]= MM0?&Z@!")@V>" +>9B()+[\Z=G,3^FQ]GE;]W*Y5.D^+;O8J/5V$Y47Z MQ[+KKG:=GEQM.KWH]YQV%_EX$5^\VX%Z-R3L65J?Y1?NC[OO5'?E \IO']VR MICC;ZRB;G,>[Y[_!?4D4/^,$I07[XRK\Y*R/JW#TN-$@@$14(2@MV!]7X:=G M(ER%?V3,=O"T=.7B?4G!W"L<1 MW37=#">.BK\N"B[S\K9Q,B^A:%("HWOE9G/GYPE*K("NQ),/%*!W*6Q6L_4, MQWFWI:^QXV=<]L=$S\E#*#;+H\>-!@$DH@I!:<'^2$1(1.AQ%7EP MD2=0V?B4)-%:R$,6H+_;>OK[NCT\[ MS.8WDS@T[2'L?J/^0?U3/R@MV!\7XB-!@$DH@I!:<'^N! _/1/A M0OSVA;CF6FDE&01G6%F("PHNV S.D\QM\DFXO9,6AZQ!QX7X^./T^!;B./Z\ MIIOAQ(&QA))M_3E.#6A)* _:!^3+L]/JG:'DY7K2+>>S.'G_3JXBG)( %YD#[4@*-&A)61ZBVP&5$RJG#X7\7]W<+4)YG>LFRSSY;[<*YQ-.IQ-&&,6Q$RWIZ8?41=:" M_=OK]D7AN!..T3!#M8"H!0.A10"GN ##?) T"6>INRD<5?:.A>P@9DE J$#! M2%ETI*0B6^Z2,7O"\?FY6Z7N;+/NUF[1M\.^)QZ[[:/75>/39S]]5"UR,V6< M3:4PV-B*(0E+2VM&"CVE44]!\CXM>0>39 A>0&(J@[#<@V54 )6>4A)HU)D/ M0M[K9?CW>5GYI57WX^^;V?KUW5,_'^5PY&Z,2,C=-2.%GM*HIR!WGWCAG805 M1%E05"@0)%@PRBF(E%OC^H(7MSY1Q9MG:OYO9+=,A=RD?B1!LKX.("&J9 M3P1(\ F$TA&<.1MMX -YU*9;HHS%(YS(/I#KZW(&0KGZ12I%9'N);Y#(HF0 M'( S;4%X[L P[8%+3[S@R4J=;B:^'\=_;;KU1;F4[L7R<8RS_AK<_&1QU6. !)1A:"T8'_,A3::"Q6:2$YT7\:K% CE'=A^RDKP/CI*LY/" M[^5"O95:L@34]/U 5"=P@6<@3@6JG0G)8BX40]PX"HK?K_O&@N(12O1M0?%D M>;D-:^F/M JS+G5U-))5[KBC$8S8GC$N^Z-@;%0PDA1X47P$4I0>1,BBB#]* MP$FNA4]<2[770%XTI(F&4%":,A#$,#!.%<%H= J&Z.RL^V#7V-.NVZ3XPV8U M6[S!7PXQ<.S#=L:HC$=C*,5^-# &F\0E!:L#]N0)R< MAK]P P(]KBF/JQP!)*(*06G!_KB>;'4]R2(A/DJ0-"D0T65Y''58X $E&%H+1@?TQM-IK:M-0HR6(&&Y(&P8@"+UD& M)Y/G.1"CR=[)4?>IK<;4)D8LG+V,I=)WN$WZ*.$6(4V6N9^]?+'LOTM?/7V9 M5I,_^]7DVZM;:/?SQXO+^?)U2I-=B?7/FU4X=UV:_#PO1MA_^N75XSC)N24] MB8TLX[(_ZLE&]61.UEI9]*0R12"*$!DX%XM C%09;D0T?F]NV>"EUV\H8?ND M-X30\T'WA?77:JKE8,>E8\QJ*F95C@!2>86@M&!_W*,X.17C_!?TN-$@@$14 M(2@MV!_7E(VN*0E)F1/#P3KE0'BIP&@3@ LO,HW>)>T.77Y]ZY)RD'T*2@VN M*C%JC0\!)/,*06G!_KBJ/#D9XZH2/6XT"" 150A*"_9'(D(B0H^KR.,J1P") MJ$)06K _IC<;36]J9Z@F+H%GWH (3H/ES *3E#MB&&-9'KH$&].;&+5P8C66 M85^[37Y:KLK'+"9ALUJE17@]6:_CT.M6Y*)V/ MI:>+L+Q(_UAVW=6NTY.K3:<7_9[3[B(?+^*+=SM0[\YJ?I;69_F%^^/N.]5= M^8#RV\>WK'%NV%$V.8]WSW^#^Y(H?L8)2@OVQU7XR5D?5^'H<:-! (FH0E!: ML#^NPD_/1+@*_\BT"V&IIU*457B2(%0.8$(BP$/63-.DG=Q;A=^G'!Q7X8T& MZ?&MPG'\=TTWPXFCXJ^+@LN\O&V;.SQ.46 %=B21 MQU6. !)1A:"T8'\D(B0B]+B*/*YR!)"(*@2E!?NWM_6->\;;/6,?LS*.<_ ^ M.A!,1+"^_-#&.F*-TT3X0U9NO]NS^?MR'F>+EW]SLT6_D7RV>/YV6^;Q:M:5 MAZ[/'OO\7>./;!9S/)D/X]H($4"ZKQ"4%NR/Z\Z3TS6N.]'C1H, $E&%H+1@ M?UQW-KKNC"X*8D4 Q80&04(HRT>9P!$7RU^X52D=LE89UYT8UW"X]O!9P^X3YW10H3 M'M4G/([IP=?E5H$#7;D"5ZX< 61"9,*:W0>9$)D0F; )5QZ?BR(Y(CG6[%%( MCDB.2(Y-N'+E"" 3(A/6[#[(A,B$R(1-N'+E"" 3(A/6[#Z'9T*<"HI300>H MM,M$NTR)!$.S!T&= AU=(7$G/$A2O*<_,EH(K3X0D8S"* M4:VEO5EI]RRMWXT!'7:8)Z=39D65$SU;$S[C&P&*R@F5$RJGFG!"Y30>S8#* MZ7;E9"VEW 4/VLM>!3$-AL@,R>5$J:6,B3Q$CP(J)U1.+0U/'ZZ)H0V8/QG< M_'(>#X7\7]W<+4)YG>LFRSSYOYM%FG RG3#"*(X[;TE.8P_8N.R/O:V-ZD9F M&$LB:5"<91!2""BJT(%.23CFC#!4W]2-GG@N>3]3*4L)@E$.CF@*T3$K&5-" M9W93-SX_=ZO4G6W6W=HM^A[6][1CMWWTNFA\^NRGCXM%,^6L2#O*L"T50]+X M$$"FKA"4%NR/3-TH4T?GJ8V! C69]7MCLK!NLF"4#C8*[ZRV@S#U>AG^?5Y6 M>6G5_?C[9K9^/X^+7<+44C8,P_"V-COM.2R MRB8>7%_4(G+(T;J]R<6%H2.3 IS@Y37,!G"62E":)VNYUD'E(W&WI&:J"1(X MAJ41(H!L72$H+=B_/;8>']UB2*!R0>52/R@M MV!^5R^DY&Y7+[^D2[9+*U&8PRC(0 MR45PED10).4<8M]9%(^M7!CC4RX4RA>4+RA?4+[4 $H+]F]/OB#O;WG?N! = M%12,+Y0OM$I@8F)0I "GT5@3_5[&PD5BRY\C"*DE"*L4&"X)*&IU].4!%?21 MMDF8E5/.,5LQAK"$YV34)-U.'(VV\0"\ZU(LT>7B,BTZUWLNMG"W)/,&[0BL M')06[-]!>ESE"" 150A*"_9'(D(B0H]#CWL(+0/H*>.R M/^;"&\V%1YFC\II!2EZ"T)R"L=9"D(JQ+(T,?*\Q/[.0=2 *I%811+01;+8! M3/+"1^MS#NIF+OQQ_->F6U^42^E>+!_'..NOP7S,C:M2]+C1((!$5"$H+=@?B0B)"#VN(H^K' $D MH@I!:<'^F MM-!@SG1U$K9(TDEHN]OJ!,!>*(:[*&N/W2\&QQGB$$GU;8SQ97F[#6OHCK<*L M2QTVDK4D&+%C8USV1\'8J&!4)B:A'(&0F021M (;8@ GN6&4.1G9WCF2AI"H ME%3 N"^"T7 &7KD,O@A)2Z413LD/-I(][;I-BC]L5K/%RYWNVPV[WSYXM@WX MW8]7 3]^X=A[H:?68$,YQJL1(H T7B$H+=@?-R!.3L-?N &!'H<>A_79Z"GH M*;C$K([;;EEB)AH35PX,=Q:$2!FL9PJHL%$SF9*->[-*[E.??(2@MV+\YR3L^(L9%)GK<:!! (JH0E!;LCT2$1(0> M5Y''58X $E&%H+1@?TQM-IK:E()H2;@!&K4 06("QVD$$J*56C(AF1FBW!I3 MFQBQ<$(S5D_?X3;Y:;DJ'[.8A,UJE1;A]62]0HDP M>LJX[-^-V>,J1P")J$)06K!_>QNZXV.BK]]0$.Y+[^]+>ZZ,T0FT MDWW+#1=@6#00> R>1*V]VSL2(?J4O"_/S(XH$-EZ<)%GB-2YG%V0RKF;^])G MZ_.TZJ=[K=)Y6G2S5^GI(BPOTC^677>U$?7D:A_J1;\-M;O(QXOXXMVFU+M1 M8L_2^BR_<'_OPHVT)NAD@8F^TIO3!-YG!4QIDR05 M1A(^1'4XKL(;#=+C6X7C(.^:;H831\5?%P67>7G;.)F74#0I@=&]AQ8_:XRA% (JH0E!;LC[OAIV]VH_Z^G,?9XN7?W&S1;Y&? M+9Z_W7!ZO)IUY:'K0]8.LQ^N<;+:0]@/1_F#\J=^4%JP/Z[#3\[[N Y'CQL- M DA$%8+2@OUQ'7YZ)L)U^.WK<"J4D+0LIVET 00)$2RG"A2/5F8:N-9[Z_ A MJ])Q'3[Z,#V^=3B.2*_I9CAQ7"R19%N0CF,$6M+)@S8&^?+LM'IG*'FYGG3+ M^2Q.WK^3*P>O!9P^X3YW10H30-4G@([IP=?U6H$#7;D"5ZX< 61"9,*:W0>9 M$)D0F; )5QZ?BR(Y(CG6[%%(CDB.2(Y-N'+E"" 3(A/6[#[(A,B$R(1-N'+E M"" 3(A/6[#Z'9T(LV<.2O0%*]H()1C!#(>2<0)#HP# 9((5DN#2":[\W2%8' MP9CA!(PB$H15"GQQ(,B38@>>_RJFTILHAL*T)G_%5 MYZ%R0N6$RJDFG% YC4_G,=#(?]7-W>+4%[GNLDR3YZGRW6Z\&DU MX60Z8811G#S1DJ8>M)/L_1#-'K$^1L?EQL\3JNK*6H/OCM4(=34*TEWWK2$^ M*45!.EW$)6$:?!8,K,\R>6LRY^ZF(!52"J:H .<(*Z]1$GP4&20QU">NB//A MIB!]?NY6J3O;K+NU6_1=MN^)TF[[Z'4U^O393Q]7H6;*=3'L<$KTN&%N=%KT M <2[RA% P3!JP5#U8NY_UR'947&TKS@(ISEJRL$4X0$BR ">9@^&JT =DU0J M.HCB6"_#O\_+,CBMNA]_W\S6K^^>!_NH\$#!@8+CU+.7L*VF*N="#8(:!#7( M>#0(E\1*G3Q([04(Q12X: 5X3A@U4=H0_4T-XHV2AD@.+E@*@AH#3@4"HN@/ M99-G/MHC:1#)^%1(%"(H1##S,6I84'6@ZG@ JF-\L@%KF&X73]8ZH:0DD(11 M("01X%@10CKX(H],])KN57]['J(-K@BN+!,(9R@820TH8Q)A0CGM]ZJ_OT0\ MW6G4JD0!A?$?CTE!!88*#!48*K"ZM M6%%M28)4)#GJ&-%&'5N!,6FF5@B484@"*,-0 MAJ$,0QG6M@Q#_;+5+U)(K8/RD+PH6H2Q )Y3 UE;3RFCB7AY4[]DZ\IWR *( M(;Z\1D>P65-@EFE!F DE3!UI^XTI,16ZSI-ZVI,M1Z>W-SULY=^NF&W[ZVT& M^M-G1Q7Z109Z%^@^0Q90=E##H7W&;I^C\ HE0UKY>4H3%\+RHGR-U[/%R\EB MN2[OLEZ6 .\VL5Q<[ FDV+G;_;;M W;]G_-LX19AYN;EZY<_7)0W[!Y=B]WW MQ^OJ1D+ /@"8OF'A\[?]P9?N9=HQ'KA:5'Z'C?R>^7JVF*S/ MEYO.+6+W#=KZH+;^]8WN^@9][TONAW]MNO4LO_Y,I2$/+C2VB^$W5W/]*%BW M62_?Y!WZZRMJ_#OR_?;I,'>OEYMU>?L_4OQ^]U&4;(UZ]8)R7\S=99>^Z]*E M6Y58_L8\V_S9[KV_NCE1YM6LF_G9?+9^_=V;UW]@L,SNXS1]Q*WXT_9;?2 G M_S5 78[7^S+?YR/@>O;W!CCZ^9[]3ZHT,OU/. MRAP^9W6OE(,9[4[-0!MH1P#F'NNU8\)20.@?_Z^OU%>GW&&YT[#$S_(Y?2J? M.X)FTD/>(,^*12;_7?[SO)O\6&P9_^Q7DV__\MX\K1HWY>XP6&]T]\XG L.@ MN']ZZP'Y%_D7^?=(_,N0?Q\F_S+"&/)K%?'X2/Q:;SP^ C#WB,?'A 7C,<;C M6D8'8SP^^7KG,\>%#W6@!(X+'[S2[NPRK=RZK]'IZR1?S=:SU'V'Q^Z,J]S_ M[NP\,$0X(VTLA_ @4F-!JB)<,.RA,XW;F1"I4VO_H19_#U3['[8#[%E:3^;+ MKJMC85\YO'5XYK%[UBH'!;MV#TF".!(%1Z(,T%+L)34\20/>) '"N?);DAP$ MU4)R3AAC::^EV"43.*/@J-#E-;8_C%-)L$9F2E0@-!WS8$U:A*E4=4Y#P1"- MHTU0^J!?U>17*'U0^J#T^>DW5:2-ZV6,X+I('\M8?SB2!&.Y\"1[;\+>@4K] M(4OE?PD,LP1$#!9\5@:BXRX:H:B1>]/@#BA]+)M:R5#Y-!:A#WQ$..[Y5QRK M'L>^D7'7F;U>3E:I/!1F\S197"4$^[_VO_?MZ9--W]@]6TR66"LP?OV,FV8C MVXK!33-$"L,>ACUT)D2J2J0.52MPW>)L9Y#AEA'79V2P:]:N*X".;V7Q0RH? M&F9NFP)QBSAQ%\L"Q/^W_4,=.<&*O+IRTL1,SD#9S"KLWUZJ''/,N^UU(I.S MVH.268.(*8(S@8/ADB?F@W(T#[&]?CVVE]_GJ?_E\2(^OA;B!YGA3:=2*TPX M8Y@:'P+(WA6"TH+]D;T;9>_$9':.$1!9.Q#!:7#"<.#!\V28YYJI(7:(C\C> MBM=Y>BN&J>-T>&/F9H29F\_GO19G%=N-M\.C"U.#YWK M!\VFL%EM]W]Q^[Q!^-P?PJ8S,"&# M3-$FK<00*9VW0?^Z"CS+/UR%_Z[HPY]7Z6*VN>B>+EZEJYJA8>L+A25#J46, M7TW%K\H10%JO$)06[(^TWBBM4V*M<9& 5C:!R$F",2Z XUYQP;7GB0R1ZZF! MUBT?K%L2X]E%48%9%V]D(CJGR0UGE+'$D&#U$FN?YN5NEO_91_)L&M5J^WTQ@N=J4Z>;(-W;#, ML.G2Q'5=6F.!3E-"$#/AX[(_"L%&A:#05(5((R@211&"-(%7VH.W2DC#O'#[ M<[WND[EY>S[//U)1@[_TW_R/28;#;Y.=5NG2S.$F[ M1,%NO;!N"5!9M(Z#L1:/F+95'NC1V[SP;VTT58]2GO']+NWT\75P3V0\JIT%6\2G@_ M7L2SGL2V"?'/:$7]R#8V,SA8XD&<6H6J!E5-_:"T8']4-:?G:'R;-M^6K9\O%%5L-F=TCA=GSZ%V4,RICZ06G!_LT5 M[HR/O__/__J#$2J^1R:KS^.P *LF57+Z@W*V0Y0GE^YU?RP.[DBVI%P>4D:\ M!?MC N;T$1$3,!\YWI&F*+4-$*7JSWBT!BQW'#B)7F;CF$KV, F8-SSU\XZF MAIWNKS6.",$<#"H95#)5@-*"_=M3,B@!=C-&M(F2)P/,1@M""0/>2 7,94,3 M(\!#<56M)T6&.?USV1T77 MJ*(SA.7_G[UW;X[;QO9%_[^?@N6]YYRDJJ$0($@"3B95BNW,]KD9VQ4[^^S[ MUQ2(A\1)J]E#=LO6?/H+@.R76I)EB2V![)6]DVEU\XF%M=9OO4E.&$I3;-$9 M90IQDW"4Y,3H%*M< 1)E#.L/ MVGNDVIM(G4C!"2IB3A'EE".KC1.4YX1PH313;*_TO3=_S$.U]\^8@8(>@B2" M7"%PR:RWR;KMIOMD#['^)D8?D^"% M["$ -*$JU"'SU1C6?WR !I! V](HT7%,BP)IKC2B:*L.AP3NBC?EO3FS0% -PID%^46#M]?>[S09ARRCD2*_7J,#A3U:UYN%2N>+ MJ*FFI8IVMW;@Q!L#G;["/O>E%"#)\"7US4@R+73"-68(9C%5^P%Y KUK%T3>43,(,BWZ%G;9O9CCP M5*\>;L!3P=#IV?$4Y"I!KE(/?B6C5)RG&4:I81A1E1I4Q(E!22Z9X"DO>-9+ M-9Q5?:^LYOM05Y>ETNJ7JS^L"MR*5)ZN]5_/V4I\@O,P1\F-#5M#AA/ JE#5 M-<"J8= )8-5P 7 JMMA%6?2=1G(4:$QMQ"I2! 7%BR9)(GM_U$<.XCT^#+% MYX)5>3[)&0=8!;#J"4??]>?@' >9ORKYBFJJ#D7YM[-+W5QS7;Z$9+)A@6Q+ M!/?[7U]8&W\@#1B>*XX8$-6 4D I$'L@]H"9@%*A4>HI\AW((?,=".0[]+9- M/BQK>2X:>V)EHGGMLAT65Y&8J4C_:UG.+^Q1X)8?ENJ$>KXC#&QW644?.I.I56,]7Z0Z>L M/DS%;'$Z4V]6^JJ7LI?,N!3EU,VH0U9.H,:*$'NV7-;07V9TH!BZSP]K_0$4/[^L!%!\.RC. M4A;G!34HRZ1 %&<)$CQ)DFL7ZOZH]58']<*Z[4N M^D'&-)LD66]NOF.2O,,#QX!H -&$3Y0QK#\@FN?7Y8!H;D_KZZD MUJJ)3%U=1-[%=Z/C#SW:\0?1\"!A\C'%9L:P_J-+;Q^>S'QD'T?@N%%Q7. 4 M $44(%'&L/[C\]> HZ/-S4YRY[,P*&-QBF@L*6))7""-:1XSP1G5>YWC'N3H MZ$R/7ZWEX?P:[\T3>#KR"6<,\IH&(+(@+0G<%+>X*2QS=W(!LI2."B/"$(L M!/,8AU@ YGSFX%I,L5(Q0S+G"E&L,6*I2%&6&I.P3 F<]]*M>!MS_GVM13[4 M>MY%W4YGZI683IN[P&@_(;>43K(L"S+D-K9.>T<@(@.G " ,0!@ALP\@C+$C M#"+B#&>4H92*Q"*,0J)"X@29G%$<$XQ)L3=G\[%>K>=%&!F9Q'%O$Q( 8(0D M(9\BAP=&P ]$X*VGC\V[;N%1<15]UXTB^][^N]_0%W)XQ@1:86A& "(9AF8 M:.U]V@0F:9'D"M'"XE6*.46CD^OM6K+_I9+[J)U<4IE:!@!H@!4!O M!TB4,:P_Z.V1ZFVFDSSC-$$XRZW>9I@C'N<2I4P+HI(XX[KW.I##Z6W7MA54 M]Q!D%+0S 1?.+2XLLZ(HZ1U%);;2V)(OP@3IL^M75O M]8X@E@;AIX%4FY'Y:5RJ3=DT2S&3?DK.=K;-)'*/9^R[:15]%G4M9HLF$C.U M.FKU':3CC DA@LM\6.L/"'&D"#')4R[R-$.&8XEH(C$2)+4OE1*=Y8P+G&5] M^W/>=KK@O?F_G7#O!RF2>,+SWCK#@H@:E8@*G *@N0,DRAC6?W25)BGHHY^Z/9>^]]:3\7"GC@7]>(*$E7&!(_ QSRL]0?' MQD@=&R;1(J.8(U%(@2A-4R2$MC);\1@+3O(,/RI11FE M;GZMZD_G>N/I>.750AL;JW6K.%;>#]?9WO_75L_TAD"'#<(9PCD< R>43^T=N QE@7B6$D04 MQCI-6,YX_'C73C=V<,=U#W) :<7D13-N?,[ M^4'347$5F1L&P$+D;4PP_"G'<@,,#R9"-V(8#OC5X]'M*"Q>N.551L?.JWQR]4?C59O9^O1X:=KQ=%3.QHR M8?U58#VE^!LU_N.KA0.X MZ.&B)EH1*0BB&;$@D20)8CC!*!%I&A.>4YP5?7B='%9T_[[92/G?UP+>_7 Z M4[M?;!WYP;Y8I58JY'6G0-Y\D=.ELE#3?C@7LS/]NUCH-\9HN>C'0.D ""! (DRAO4?'Q(8GBJ'-+ [_%^<%(:(#&7:#6C7+$'"V$\DD;G& MQG"6D3[\7Z$"FL;N<_OI;F3#V83E86:9!2["(6GL\;$(<+ =@/:MG'#-IW0G M/:+:BH^H_=Q$U1,XVR#6&R3$AM+Q8:T_0.SG%Z< L6^'V'$69R(G AFF-*+, M*,02DR"++SG%,LTQ3?KP&;8J[;W9AL/O9X\"WOWBZ#!#TH%+Z.$A:$ ^@'S" M)\H8UA^0S_/K?$ ^=S@7J2*ID#&B,E:(4D.12 Q!F2R8UDP)QGD?SL7@D4]O MOL-CDM##0SZ0G!>([["HINI0E'\%.7@C!<>6".[WO[X@+X82!7ZNME@!40TH M!90"L0=B#Y@)*!4:I2"9(!"#X+#&X"_:ON/,M9&I3#3WR4K@&!^6$@RG!A+* MOX-QH$/Y]^@]U/9IDD3E*!5:(9KR&(G,&!1GB:9<9#3-]N9]4Y/2E B%<$H3 M1)EFB$LC$%F4*D@:6S!")=6(BB)#!28$ MY90J0S.9J21 8$$R-DFS,"/<@"R"<6!!1#M@&?9FIA[MNH+X39 (\X ][%,8/.+?K/,#CP_L0&F!J^B+_%_U5H@A6C*"L2Y\MB"2IRD:&X MR+$Q.3-IIJ[#U$SD64)=TQLJ+4S--48\SF.49S@S15P8BVT#A*D83S+>6V/E MIQ6K %3#BXD'3@$ * !0 * 0!DX0#$TB96*-4ID6B"JA=TR(L4H%:8P3!DN M]_UHA@O[#H:BF,7V')(KQ'U/&TYR&A,FK9@*#Z!D?)*Q,)O, #X)R)$&F6#! MEH9\7,[G4^W&'8III,I&3JMF66OG6O/U(F9:?8[*62L$+'._A"RQ82'9^Z=* M!U/*>]P)N$,JN@9*@=@+DRP@]H"9@%*!VP408 _8N?'*3QX6I7(>@$ALL+U!1I K1G.>HD$J@3,M"&)GJ0K#'](P4L]D7 M[_/^8'72KU5]VFJDMYU">CO[=*[_OM%&[\UO3A?]ME)%O3B\DTE,PAP7 _[N M$#4@ ),@R0+ !( ) )-C 2:&RHPD5%B0D<2(,@=1,LT1(\P8GA*1J+UX_+>T M= P!F'"> 2P9)RR!,'P@[K9#AN'?53/DX^WE[%(W"]>7Q75G-*M9ZY%8#UN' M"/S L"N$H@86X(!0%% *Q!Z(/6 FH%20E(((?" FP6'=&1^6M3P7C1OM:*)Y M7 M\N M87!ZJ;*Q;+6S@&^K&NM?EDNWE6+_T\OG'^\%V\WQA"$'ZFW M&W (X!# (8!# (>,"X=DJ=:"4HHP5P6B.,>($R(0$TG.E39%QG$?)P81!,AD2B,"TZE!19&QX5*'UV/L3+LWG=VW2MGUFU*,DY;F^ZW MC4G73V"*]Q:8 C02%AJ!G*NC< C][NZ!*H.6C8Y$T^A%$U7%0MB%\LX@_46> MB]F9]DU1H-O)B$$LQ#./!L0.,)X)7J$G\@I!8"XL' 8*%10J*%10J. 5&I=7 M*.4\+E*:(Q9+BJ@V&1(%8XC)+"TR+&2V/];K(0E"WL![;_YH]*FS[MYWMMW; MV9O.LONUJM_/=2U<$?X!.G40/(D9A;2A<:(32!LZ"B_1JVK6+.JE9UV[F&A> M5V>U;NYP%=D3A2O7N["'7K;MMXR_M[,/G>EWHR/ID[?ZWFZ,OM.5S?>K-?E^:RV^?C*/ MXDE.(?EHI'AEY5:R_^L:^_B/MRW07[Y9'N%'+= _E\VB-%??B"C2@R[' M]+X^&Q7R#M?0NN"_L:5ZZ4<%8M[%46E97O8JGLP[FF MB&Z=F_934TU+)=S779]?,;6O;[]PFJ(Y63Z.V[5R>]B(7#+;4W&;R(_L>B^L=:,/]C6S#_8R68ATZ8=RM5 M]&JM@%ZU[WF3EAGU%OVXUJ*!;\*!K_MW?ZR0S?>!+O0#G)U/H'94 M>;EO2S[LOFM7R+OEA?U"=IX0C$U&F.1(QWF,J.$:<<4$,H7.-,]-+JCLH^_? M+\O&4JMI7NM&UN7<.1U.9^H7T93->_.AUHU=!>&^_63O\\NTDG^^B.RA8NZV M1KW4=UCZ(6R5P7$D/HG>UV=B5O[;KWIO-L1!'WK;@KAY.]"3-$GNWA#94WDV M!FA G,YF^DLUL[AL)D\FD62G\A3X+W^FG MJN=5O3KXM9Z*SZ+6[O/?12W/(Q)C?-+'#CV B3N>+;I%OC;8SG^TV^6\FDZO M4/79I50URZ(I[2:I[8[M-G3T2UDUTFXM:6]X:M>BMLLBH@^+J^BWA5IO](]; M9_J][IJIUZ5>V&^B:7G1N6:ZO7-M0]A'R?QN497=<>6T_79]LW;C;>[@;S!M MJDC/SBP?^8.=&O1;R5]&7^IIU79OWTQU1+UR:PE+?NQ]_*?RTM13=5G6&HT/N_ "C50_M[2Y>[ MZ?[C8>]D6Z=&YU:U%%K/W$"W:GIIY8 5.'9I[#T=J\]U[8)Y3H?>0SA,O-_8 M11Q=@[I.3T>+VIJZ]K?STNMB>\FFLF)Q.O%7JD79^,/;AIC.]E_)%S]!XLO< M_8]]9%?GO+[3KAIU+V$/M*O@)*RR.K5QTRCNTBN7/M\WFT\-%^I2\*74=)/+%BEA#[+L(" -]R;WFQG'H1 MK+2Q8M=+Q:?R51QXX_SG3>_QV)L-9;0!*.$2HUHKC'BSN[-,YR9(BZ,TGBO$$2W ?LWPN+!V5ES MNMESK]LM=VM@/ML)S*?V>RO9[*<[(_0T3D[XK0'Z@6_IR%Y@>HN]^32OTZO3 M9BR2QDEJ+Z#7']SDH$N[B9TQYKYLSJU&0 M=7W2C1[W7%(3MD0C;)(]IRC*. M5(8EHB+)$<=IC@11F4P()U+MN0D?(FS=>&SW[YO-]CN=J8]N\WVR>^_M9NO= M7^C>5627\9-T[+)VD D"X#PYL//$@_;SLEE4M;,2K+EA[)LX/X03ZQMPOCBW MKWAV[HV6LFF6OA#-BOWF7-3MQ#EW0JV5UA=^F)R]F\_OJDN+JI9^\5)]'X6_9^EO3G&*VB_;1U):TDX5Y\SBBXMXHKF4[MTWNK9>83M M:T[<75'W,I]%78N5#NN.6GWGW3X?N@M_6%UX$EDB62O+7GDY[5P[,[UPKB"I MM?*W$W/[UQ-75[ MT1J8D)-L[%K#6M\N4;^:W1GXU>696OO )@USC7PBW!,:W> MY9)_:NF=]5L^"OLH]@+^0MT!3LJ(10L\[6GG[J)E$S5+X^PK=^"65V)+-KF0 M@3W/M5=;>+DQLWLHPB2R;+XX=[^[-&KW[-N2J_5E?$N&7?3WS2.[U_1/7/E- M6\Z6VGTNW?"0;W5\W/S\C;;RTS[ E19UL^/._6$G@FO_5N7E$\6)N5&%8BE' MFHD3[T>$'0"T:KBT>\&*[=-V>*DEZ@=+-+L[ MFKXCQN#^OE4X$,_"VR3R.WZ+2-&&2M&*3&'YQ^^%06]FJP?=[Q:V*I21 M,C<9DE);MI*8(<8R@W):R#BWYI)5F#VRU37FN6K_VS<#]1\,&%3*Q?U#+S?R M$H1C#F\#[:3?/RCKWH(4J]M]Y,:^A O!KD=KU\HC#9_"T&8D..O*_N+B&&HU M?=LCJMK"AG(^;<.Z#@#\,?,/XO,26P/E;Z>G']I(C;4Z[&;R-E:]G'8PH]9G MSA?MX42+;:*/;UZYKT6M//)Q"83EQ=9+V,>U.,K^=I]D!0SV]B/WVBV;JA!3 MOTV:V_L MGHGE03.U9H3K[1,)Y3:\/W7E?.C&BMEGL9*CW:/V%#>>T&=3;9\PTU(WC4LH ML5;(O-4CD1%E;<]?CVI[:1 9V*;<2+R[X6ZG5 W1D MV;J\O9U8;Y/68-S\6,Y::]LME&.>=6NDUE1;UT?=L<5N)$2MV]!P=^I-N[M[ M\,9O*I^/L[NS;EF-AS),[=]F3;0VRJ^L5/>F8B? 5[>TCUWHSN!TK]C=T]F% M[A9N*[RV%VIOT?G/G,KP9N7L:K7,2S?=>CCMOYIA.>5ECV-WX<3S=G%?+J7)+5VOAMY$]YY_+ M6>N5\FIYBS'^=Q-MW>0KE]X>]WYL7_T>CWYHW% \[9VEPS4-8>&'6ZN.]#_0/WZQB($[!L]H&/)9OCZ#7A MPC+^'Y@<=S.O!6^C]>,1[%A-; _HN2^[C0#%M_"P?7N[L6_1#DX@^7P]BZF] M#'?6FU5#%F6[2-66Y]OJ]@OQI]7N*PYI3;RF65[,5X$WJPV%,0XFMJC Z11G M0%XX^[$-1+6#1]RI6U-GVPS!LG'1,Z?Z?8#,6YS>>7_+.>U=G/);X9#;P.WN MXZS\_I%:>G2Z^;'+-O0@X[WS$5I5=E:Y;SVNWHD$Z$LQ7?IU<.'$]:I,.I7K M3UHN/'A:)6+;)70X-W)G^F?>2DR91,M&F^74'GRYJBVH'7ZSA/%IC98B\Q:* MVQO4_AGL>Q957;6#WT)@[48%AXGG\K%TMN&K<4@/?)5I1MFMH+> M.[?98,=K(OW&\&6(Q-W1R/8E]!"T#O%9?*\3#.X%BAC5ODWN9F\4A8\2I M(*C0!,;O"(?-G%+:W;M4&<4CI[@73H#!)-W M1!GN];U[I7=&N=)6@?I:MW/)U.V\C) MJOZ[BXUT'I%:S)HV$70[J*B=KV*VJA"7VXP2A!>?)8JF6@AD,L40S0J&6"$2 M1 H1)X9K+8SN18#;I3V=J6N5';];L]0^BUV=FW]O)?TA!3PX[V^<6F/)X'I@ M6'9XB$6R]IYI+U4<_'J+DSM)U,WK>O7/IW[?;ZLY;ES=K:QY^NE M@"?MKMCZYEK&0K/V3K?.V%;PV?OI*_L<]9]ZX;/TK[_LNI M?F]N5F/VFUU-]\GE\'VC 0.;_O&2=%,.XKNCNXC09>EEEDNNJBP$G9;K")_T M2O#&6NCZ&@.M0V%.]':9(?=)J.EB?,WR8IVA5+DH5!=^\QEH*W':G%MD&]U] M\=O2[%X.2DT_>\?S]I^?VCW2/53W*@[PO72-QU;#"MQCV@WU,O[1'XZFXJI: M+NQ-OFCU8WM#''MLVIU@>6,JYHU^V;3Q9+U:)3^NH[WVB\U3;,^'O"R;LATP M^G)UE9U#M^T[_X]UP-=;CE4'*2I-F]CL3N;>YS'#^A..6;?_)^ M+W_"^?U>[1L>."7L$9=<#_7<(]V*8]J]>QO1PAI3_A0S:A[B0CTL_]]!>B!/ MF.2QQ'!'_?4%>?&TI-H=6!.?N'DU7AO?/B=JM:+!D'@DH:(=Z^6GHHY^^-F9 M,#>.-7HFQO[*;MD?;C2\;1.>; #1'31Y0'2#Z-XN@EA+;@R2^W@E]X'LJ+[F MA%JZ!$71IXI"'=A#=SV>],UMKRD3>!(SK3F:$49;[-#6,98@6.D9(T2PBV_Z5[W:,>VCZTES') M:1[?;T8R2+4[YQX'9_(?&4@("M<#FX#R!^5_=,H_([+019(B7B0*4*6[O&RD*G=@!@_Z>V>X!L3W ME,$*^)LQ)3-,)HH0)&6<(2JR%!69$"B)%8\QC1.=9GTYE+93N1>O1%V[KK'_ M[6H5>D&;!-N59JQ?Q/F4(G __AD2'QVW+ R=$D/S3P&T.&IV F@Q?FAA7:\_?]AVA17>6NO "#Q ,??JML&N(05X0F?LH0%5"#D,DPX0!QTML"QD MI@TC!>(Q$XABK1#+6(H,(53D>9&:?*\9P4-]5C=T(3B0ZRI+>W9=@>0:I>0* MG1*@X ,FSHCH I^M I>X81FN10HCI5THZXI8D9@E"NJL"9$JG@OR_FAGJ.G M4? YG3":@'X?G.""9*AC]/10,Z511'"M6),STX5?:;6+9"[[$DS@A$)\$R7=\@&-H_B8 $D?- M3@ DC@!(L#BG><%1HCA!%"842+2WC*WOC8C;?>+ MK2/?^@E,Y>SL==G,JT9,_V:7?F[/L']WD[ZU>K\>>==3 AB>9#S(5EGW95" MW@$FPPP$%PW-AP=X!_ .X!W .U_#.RE6%#-<(,$RAB@6&G%C8J2HTA;XX(+F MO26R#0KOY-DD[KN@$N!.F'!GU]-H_W(#WFX;U?Q< YRE237.$XU8GKG>>EEF M.36C*-6D&&S>1 MN!3EU(^&M&H%62VEO3/:33^6HJ[+=ORQO8Q5,,XUO1F$[,Y6VMVHG/G)H6[> MYW)NE;1[3ONYFZ<\M]) ^V'.[I.;;GI1*3UM_$3>IK3O*^S_:NEF0/M)]MM# MI=CI-T;N;ISLAJOZ8[BV^O7]LG[=:N\L-3 M[?)V-/&C-/TJ+>W9]F56AU=KT+ >5WR+-SRDC1GUP?PP0_B>T]BUXU$W'7OB M]I6P/"EJRTK3*[?92ONM8Y8;F/\ZP[CM-Z_<#4J[\TM[\;)VW'42_5K5][F MW;=V49 82"W][/=NP+>_UII[C(6[5=VT9SGV.A>S,[V>#^YXQDJ?U?3B]A'M>ERY M^VMVGE]_*1LWJ/[.E; '6R$2S:=BYE^HT=/I[GM4_J"R ML6+(KM.T_%-;8B_L$D2S:N%^^ES:4PJ[#B[R:.^_OHR_X=V4M,NDW1O[0=06 MVE^MY*U],XOS_^U'/3>+=G/Y-]2E?^[U*O@GTXO)SD-OIK#?=!UWRF=[F-U] MUD;X/',/O*U_[%K;(]P3G;$DNBB7+1D\+K-3])VU[_&+),'O->I):G;JIUF=->_SH)^MK=] M5;<[MM].[#[E[@I;;JZZU;JP(N["S!671.20O_D)[TW?M-LPZ[&6AINVVRCFJB9:^G &BK= M\F]@FV6T\TI91EQ1UGYW$Z@9H#J^97\_[NU"V@ [:KYY/*,^EY."Z3P5+#6H MX!(C2A."6*$I,KDR2I*")+IXM)/B_UIK2H!CXMD=$RLZC-05$8ST6ZVSU^%" M2@=NG/_ 60W-"ATJ>XE+JP@N'6!M+=ZR]16X8RQ,M<#3(@C+&JUJ4=K*#N51 M_*Y:B9R;H%E!'7%FS?'62MFRB39@TZV'L8OI4)KK.U9=6'P>?=Y^XO;F:,M> MWWX.CYT^ZP[PU9W0$ZH%D-90LF:20LYD%W.W'R,/M9JE!X(K_XH#7LVR^*>6 M"X67N_K)3SID^W++NU?5.VID\+M&19R^5%LW"WZA[4KKW3 MR/9:LG5-[+M.5N]^#WELO]1?O*1_L+#J'U@]W:SA [,-CK=WU:+UT;RJW%(ZF\%^\L4'WN/\:SFSLLQYGSXN[!?WBR, .1Y* MCN_^F(FED.9$#AV6W->+AK16>QSFE6"*+9:RU(@1%3*8%RHC, MF:*Q3'3\&&MEJPI*BUJZ'(?7^E)/J[ECO3>M]=9:,=>,EVB=UG"ZN.^3_@.' M9/,\(?Q^8K-G14V/$;?H&74$_4H@*=CWZB6J!';NVJV-LY@T*5M;-KO(]^UOWAG(7>3>3BF*TIZ .E6Q?M#+@;++9*+=TE M[ 4]+OAJZ#.8!82XYZ%7^'6[O=8;LG-$1M^5WSM3WP5QG.WK/ZKEHBF5 M"T75EZ74W>:T=G$E2X\[?=&D'B_.R5F@NZL655[ NJ2^JZC,Q*_\MNOABZWXOSUI7RN;) M:@>;F](![-;1,7-1'K%V8;B8EWNT^C8F=PF$EYU39G;SZQ7Z7$R-?R7[3NLG MM-1;.J_$LG9KTZZN!?GM8NP]HTLN<1_LTKA'^*Z\_#Z:BJ*JQ:*JKWS@=5IV M;[$^UD4-U&VT/_W>QZCLMZV3PYTYUW53S69ZBFH]]41>G_==N4K7M(Q0R3]1 M&[W8OL3W]AU_^=Y'].3NR4Z2V7==N:_:173[I?0G=N_TZONU)WQ;(((@ T'V M-5W;"2?GEVSWG \OKS3I2?1!7+42XT(HW0:4K="(G-!8A5&=N[/>%BY> +A? MSO1,U]ZU*)W3T(>L7%;$%K>?1*?JTCLOYZL[N3U_'['ADS:TT5[E"^][=<[1 M-?.TGL[5MVT0?/]5??Y&Q[,;26D/LBSM\J'M(@R2C6YVL8;+7-XD[+79BG7GH5VH$J MH_6UQ*;-HKEOV\!&Y!!69$EKGWF]&JMLI>,E/=Q8\*%]F_]46W$VS=9[-VX#8K!^XZ&+8;YW(9;BXJYFAI M7\3^KGQRV@KQ63ANK";1/K15Z,5GE\_LG[?+&VNIT*WD-7.S*=TBMCG"4L_= MDVL^#5"9/X'MDADK*8X2ISA%55"!F5&K_S+1,69Y2VHOO\>.YY=)? M').^V@+@[SW13F?J[7A+R=,IVB84.!.'NH&> M$#YU.2%='<@M-G?D\Q+.MOTA^F(^K:X\L+#R":W^[#R.5;WOZE@V3J.*[=SA M-NVPPQQ=0O3*RO#)KJO$B)V'Z0!S]P;V*O;-(O%9 MU*K9RQ/=/;#-6U:N;J'U(OE$G?9-Q#K=IWTH#Z;&ZJ((*>USFXG/VHPIJ>N% M<,![O:6V@&O'#SO[KRL?:?= FXG>.>ZV$>]V"<6LVN5%GWF\FYQNI4DYW8/- M9Y6S7KROH*X*#U+MOBFTWZ$NS=^EJ5%;!& ME"VC?/8)5\5V.0#LS*>H?;Q-BVS\9_<7-ITPLQ:P7+9"_EO$7B?(R&S^"]U9,.LJ6K6*_[")+G2MCK"(DF%WXNJLV M7K'Y=KGQ-@;;8O!6,HBF65YTR&H-S?ZY5&<. 6X#P Z?K6YP;[0S\=+#PT3W MB%M_MFK5%UE'EY736JYL>!+59?,G,JXL>5V+X=BK==67SF=E/UR5>JIV?3 [ ML-S^:W2Y6-9M$9Q]P*NHDG)9C\G;?GBW2<8*SI5KLR>+'%$2&\0UYD@0K&B, M5<%TVH?;Y(VHW=YM/NC:>U &4VLR7A?).[V(?G/EEI8FD2=*=+JP%I]5\1Z* M^KQ7S^<>O%A X9S)X$ 9ZO8ZL#C[Q0)%Z0KGNC)Z5R/O-Y6XMJFVE4>WJ1RJ MV$*SQ56K!U:Z:'W1^URJ"P^W+ZT5$A;9N'E1V&=R[@;W6$WG0ME8[2[M M9B':&IY5 M@:^Y06+BT7;4*9ZGI<7.M H,KITAMF-U__)#K=]8E\%FT+@MVV M ]$*:;>W]A&\QN5OVZ;GZ;4S*&JJ/#EI]A*'Z*(PR#*@^@NJC(R0'5!\%7GVD M=6ZR6'&$K=F*J"FL*1LSA3*-8YQD.B9$]V'*6B9T6[K%@+^7S9^O?%,:]RE< M,_9Q+1.^R77YQ(;=#CDUT(MHV!=3>!W:"PW"9> ML]7!ROD(;R[?\1.*?!S]IE%%S8T])F]IMK ]S&C@\-B__'CB$]] 6V]3GNNI M=QN=8"K=MZ[!F6NM M=G-EQ1"WW=]]IJY/G!S/[BOTM-27JQXENXFBN\G-]=9/3LJY-YUTF9[K'-5) MY (W%R[OMG$?NY8?ZFIF/TH]K$;:XXTAK"@5=:2* M-K2*=HDU4B@6C"1^.XM.EVD/T;^+R]LK<%PJ>MF57GYWA<^ON]"Y-]]7!9V MJUEY1_,8D?C[KBO!JAE8BT3^2ZLSM\775[?7[$IA+$)X8_?_XNI_-]'[S_:/ MME78YKH,IXC&WP]LV6];Y'8%U(_1=ZO]=&VCK0X8R?M^?W*=DURC^/G4-6)K M5D4J*PG8)N/._+P1%TO9LI!:B^1L62J/%&M]4;G-M0Y%&ST6] MRJ'5%X56RN>3K3>TT:)-B5CG 9Z[9,1UZ?-7GVAEF]U$K@-!BC0W69KE!I$D MHX@RKA'G(D,QCDD>&R$(V_/;4&&R)),*6;C!$>W M\3WIWLZVX41I8=9\JC=??7010)?,]L?<>5D[M;8[V::HJJD6LPYE#'Q#B_8- MM\N-=G#E*+C6\^R*7]MPI0M,MGG:3[C5& RDJ1*%API M0QBBJ3"(94HCF1AEP5+.\BSI(\QEG^INQPNX7\)QO[SMC/RO>5\@:W-H.^H) M*^94I=LF!YW_N^O#8W^I5_NL.W(Y6S_V"Y4:-?6 MQ5ZM,&R<0^_6$95;Y5SK.M/MTK#N*=NQF*XWF[6.?/UT*Y2[,8^K.E+A3]:N MV>-Z.L;5*J(^;VTKU\BRCBZ<^U&X#FT+<::K9=/=Y"3ZO^=NXF>73^\=G7MW MWWE"/TIBJ]G AB7;8(>IW#PS[W;=''9>6FU0RW.7C>X+%I=E<[[5H6=K7=WB MW[#0J[K'=NSH0I]5]7K.E8V27-N9%1?Z7'_=T MBUW2^514>I'+F5]0O]9WWO>Z2+YCV;=7,T])1K(L)Q@G++::H8OM$+(.W6QM MC]VG&M"2W]_T^,TW,,/16R\&;F3H@-_S5G[_8]8V5+,BS)W@NL&T4Y!]U,EC M^E80MV6V[4P\WUC8"?QF6^+[@A[ILJ'*KE*H+2#WTQU=1;&/@Z[ZKFU)[*Z[ MW%KTM%C\NO\$1!"((!!!TXB,302U&1=^_N]U$;09T[@2ORNXNVH)O 705D6: M^U!TLI[BYKM%3=L1Q+/57Y.VL=>R78*R1W%+-[G8Y9>NIK7M71FD5KA; M"Z160%(K&9O4^N,&(_QV">3;ZCA(U,&>;:-TUW3WDNT&7T WAG'=O]9;N;5V M,^'7AJZ38N5B*=86\KK[DIM.W=C'62RF>C/:NC.QNQ[H5W<]OW,'W NQ0;N? M ^RV]S,_^-SU!W:$]DVX=GLC=\39I(QM/.,=4O>SS;>A^F)K$YY\+>WE0;6! MM\7YI5:828WR@KHX/^%(9"9'/"$Z944J4R5ZZZ1:+U^+*>D)S?!?_!LNU!T'6@IF M]SB,GW"'^/NZ''9K\M6CLA-.:6]7Z_71V$D>[J,E,0OST?(3%F=\ZY_T@9>V M?]0WL4DGEMJ@],W\<;/^)&DZ6?WK-*9EU[87S,NV(XS[XF8]ZO/@I9AV$JV5 M=#?)N-MD[DJ8>>G&[B-SXP/TTOB*U&4';O-PRPYX&F(%1)P'*,11DP;X:$#$ M"H@X ^ C2PAWS%]?8/KB:>G4@='UVJ7S1>2SEJ-=NW%PS/<$.6*][I*/>K[0 MOJ5D$E\K(GEV9O[*)MF^G:7.$'=+./( X.QX:0MJ&$@#FCP>L?P/:(P-@^S7Z)@"^CU,$G%ZX',-_:]6*@%=5LQ@P]P]NNP0F M#P"A!4L:$-7'+JK_5E=-TXKI/V:6E-.-V/XO>]MR=M;^\3=1SAH0XB#$08B' M1AH0XB#$[R?$W3PQ#5(!( U+\V*7XZ=E9K<_$0K?">M/A @3V,0KL MKT0NNV3=;PI=QOF$T-B2ASQN-UB"W)N2]\MU[E^\#ZZI35L+\?(1S-X7>;]1 M?S\7A9\WF_V9B?-0P?H4Q'J09!TWN4(BSQ!XZ?YH^'!\M=G&P9#.U[*$3CN@ M%] +!"$(0F LH!?0"P0A"$)@+* 7T L$(0A"8"R@US#H=8#P2U_!N&,-OQRX ME]*K:U/-'Q.*>:94"M"1 ZK@A% ,\-( >.G9$I, OPR+L8!>PZ)72-0!00B, M-1K& GH-BUXA40<$(3#6:!@+Z#4L>H5$'1"$P%BC82R@5V"AF-U0VS8!NJOU M%YW9[G"/M]8^,-DZP(#-WZN9OEI-S3'VR1]3V@Q9#0&+XZ,OGAD@=W8C H$E M@27=&\VJ 9/F >SWA)SVG^'PV "![F.I,D#1W(V!^[5VHP;7(ZXT(\QPD2-B M#$:TD"D2#&?($)TQI6.%B_3Z'#B:%HHE.$%:J!31)%6(Y4(CR7(N,R:R1.[- M@3M=S4S\M:H_BJE^K8O%1S=$S,\:6_>.=%TC_>"W%]%R5K8W_.,??WQ\;6UM MN^_L!9,7D=*RM"O5_/4%LG\9MVR+O[XHO]@E7%ZH:M']_N)G@NW:,[8:+K9Z M]9^?D'4&+0%'HX< ) 1,G$&S"("$\8*$ 2KY=KPG_1$T'&BX(=$!-%RPI $- M!QH.--Q@V72(4LI0D9(8 MF4+RA-K_%)0?PM&[5_4"685Q$96S2]TL M+J#6>L3H$6JMCYE<(9%G"+P$">6#3%"&A'*@%PA"$(3 6" (@5X@"$$0 F.! M( 1Z@2 $00B,!8)P0/2"6FL(V]S8'+>ZN-"U+,4TFHNYKL/)1 B)NX>@2*'2 M>IR5U@18$E@2TE!"H<+X4"KDSW7Y1B%TLF$D132Z$!^@8H/ECC M(B%087PJ?H J&HK @/N&2 =04,&29C14 45@(+Z;J69P):^P98VB4AUG,4H MS2A&%(L4B0P3I/,X89G*C4GQ$]C24BXOEE.QT.IO==4T?\PL0TV=L7 M;>UE_4E\Z<7 QG$,UO4HRW._!P\\H)_!\]AHJ# ^] .HH4,-6R0+S5(J^]OE5WZ MF:MMCXKJ<9,I(/$X8&AX]/7M ^3-Q^=+ 4N.B"7O1#V%/5K7F]5*YXNHJ::E MBG;W=.@D' VUOL)*]Z476']#D-0W6W^8\TQG@B.N58:H$@*QQ/XG*;A(>$H9 MS_9\Q@PK5N!<(<:MV4BE2A"7*44Z29*8Q5 [;0.,E(+(T+?>2(JIP@SFF+0UC*6%IH?0C8;#G45UD,K$' *H!5 *L 5CEBK#) K!%:0S50M.'*WOVY?I[]\\S+AL4$(RP_ZBYPNU8.7 M"9/>UVDT[;[P=J>O]18]7Z>=SL69;J4&$L:^\DLQ_2RNFA]?1#^$LVN?CAI% M-54'H\7INW=O_N?]NTGT]MVKDVVY#^OGL@%R',[5]\=,+)5] O5]B*O\$)5(#@PG'J\3PUBG MPT*'%XI9ZCO2VE M)Y3G?_%O>(L!T#W?29QG]SB.G_"8]'@][%;EJT?E)]90Z^UJ_3X;.V%I'F_^ M"?!*1F.!P M&LA\Y* 35(<9#B M(,6#(PU(\6.7XJ=G9[4^$PO="NM?15E'SIFJ06 ?H\"&YN/!-1\_;,6);SK^ M,IP"WM I/.YR^ONG#0RE9OJHZ142=8; 3/>'P\!8H=$.Z 7T D$(@A 8"^@% M] )!"((0& OH!?0"00B"$!@+Z#4,>AT@_M)7-.Y8XR\'[K_V2C3GD?[7LKP4 M4]=GZC&QF&?*I0 =^;PEG"!G!T"OD*@S!&9ZMM0D8*QA,1;0:UCT"HDZ( B! ML4;#6$"O8=$K).J ( 3&&@UC ;V&1:^0J ."$!AK-(P%] HL%K,;:]LF0'>U M_L(SVVWN\=;:!R9;!QBQ^7LUTU>1?=<_]2(R]LD?4]P,:0T!B^/#A<:_J2[Q M*8@UFGE6O^E+/8T>TW@76')$+'GG2,/020-C7\<+=!]+E0&*YIN'N69$9C3A M&B6Q*1"E,4-%FB=(L0*G:<$+H?=&V?.X8 57]LA$"41-9A!+)4:8ZR+112S3 M./W&4?:K[I&N;^0OHBG[&>J:TPF.PYWI&A*7A#.@%3 "8(3!D 8PPG@QP@!U M_/_ZCR\DQO1'T'"@X89$!]!PP9(&-!QH.-!P@V7?T0A1T' !$V?0+ (:;KP: M#OR\G9\W5S$U&2T0C],$49$2Q+B.D8B5L?LCX47*#N'GW?AX=SV^X-]]?L$W MFL0>*+(.6B)]/*_J!;+ZXB(J9Y>Z65Q J?6(P6,@TW*?+V_GJ,D5$GF&P$N0 M3C[(]&1()P=Z@2 $00B,!8(0Z 6"$ 0A,!8(0J 7"$(0A,!8( @'1"^HM(:P MS8V]<:N+"UW+4DRCN9CK.IQ$A)"X>PB*%.JLQUEG38 E@24A#244*HP/I4+Z MW*I,FJ94%SE#*SBK"@0(R9!*BVP2;B1A4Z> MP):6,<8<(S1)/U-1JBHGK4R8 ME(BFTMK%&4Z0(%F,P);N/24*+&A(B0*$ P@G3-*,A@KC0SB M#%;)TDR9/.,8$244HH7FB',AD4F8X3K&G.?Q(9#!05.B*)OD/ 9L,"BY!6VB MPH1]SRVW_E;9I9^YD1Z/SHF";/F H2&TB1H>;T*;*&#)^Z*>PAZMZ\UJI?-% MU%334D6[>SIT$HZ&6E]AI?O2"ZR_(4CJFZV_6!I:*)(B3DV*J*(*B<(42.5$ M2A[3K#![.5:%277&TAAAP7)$>9$B1F*!5&QB)GB.8U=>&T".59),6,#3&[_" M7]LFI]T)(!B#$8RATP$P!F",4*AUO!AC@!@AM+Y7H"$'RM:ATP$T)&C(4*@% M&G) &A*RS.[R)B0RR8C ##&""T0SC1%+.4-*IH927> B,T_@3>@[RRS@UM6C M0TCC34L#B 40"R 60"P(=#P'-$E5PEF::V0DL=!$"H-$S#EBBB?<<,59Q@\! M30Z:YI8DDSP-MROHZ,#):/+B^LK_O9X$%R+1!BC"/E4+,8U$T^@%= ;*>*$ M%/RCIE=(U#D^9OH&V$).B,,MJEI:4#

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end